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Second messenger 3′, 5′-cyclic adenosine monophosphate (cAMP) is a 
master regulator of numerous cellular processes like learning and memory, 
endocrine functions, transcriptional regulation, etc. This necessitates an absolute 
control and regulation of its levels in the cytoplasm. Stimulated adenylyl cyclases 
synthesize cAMP from ATP, which then binds to its receptors and mediates a 
specific response to the stimulus. Phosphodiesterases (PDEs) keep cAMP levels 
in check by hydrolyzing them and hence act in cAMP signal termination. It is to 
be noted that many copies of cAMP receptors are present in the cell and cAMP 
stays bound to them unless targeted specifically. For my thesis, I focus on the 
primary receptor of cAMP – regulatory subunit of cAMP-dependent protein kinase 
A (PKAR), to which cAMP binds extremely tightly (KD ~ nM) at the cyclic 
nucleotide binding sites (CNBs). Cyclic AMP does not readily dissociate from 
PKAR and thus does not allow easy reassociation with PKA C-subunit, which 
constitutes the termination phase of cAMP signaling. Maintaining an inactivated 
state of PKA C-subunit is as important for cellular functions as its cytoplasmic 
activity is. A possible role of PDEs has been shown to mediate cAMP hydrolysis 
and hence facilitate termination. PDE actions lead to uneven distribution of cAMP 
in the cytoplasm, called as cAMP compartmentalization. As multiple primary 
messengers can stimulate various such cAMP microdomains, an understanding of 
the cell’s robust desensitization and consequent signal adaptation to varying 
threshold levels is essential. 
An understanding of protein-ligand interactions, such as PKAR-cAMP 
interactions, and the accompanying changes in real-time requires the use of a 
combination of dynamic and functional studies. In this dissertation, I have used 
 xi 
 
amide hydrogen-deuterium exchange mass spectrometry (HDXMS), which 
detects conformational changes in a protein as it interacts with another protein or 
ligand; and fluorescence polarization spectroscopy that reports on the ligand, as it 
toggles from or to the protein(s).  
For the first part of my research, I probe how PDEs mediate direct 
interactions with PKA R-subunit by monitoring the time-dependent release of 
cAMP from PKAR (Chapter 1). Two model systems were used: a higher 
eukaryote mammalian cAMP-PKAR-PDE8 signaling module, and a lower 
eukaryote Dictyostelium discoideum cAMP-PKAR-RegA signaling module. Real-
time monitoring reactions revealed that PDEs manifest release of cAMP from R-
subunit directly into its own catalytic site. Time-dependent appearance of 
characteristic bimodal distribution profiles of peptides spanning cAMP binding 
regions reveal different conformations of PKAR only in the presence of PDE. 
Further, fluorescence polarization assay showed dissociation of PDE-susceptible 
cAMP analog from R-subunit when complexed with PDE. 
Consequently, this leads to the important question - how this happens? 
Firstly, HDXMS experiments on R-subunit from D. discoideum (RD) with 
phosphodiesterase RegA (Chapter 2), showed that binding of RegA induced 
cAMP release directly from CNB:B site and via allosteric relays from CNB:A site. 
This transition from cAMP-bound to cAMP-free conformation occurs only when 
RD directly interacts with RegA. Importantly, these results suggest that cAMP 
dissociation occurs via a substrate channeling mechanism. This leads to depletion 
of the cAMP pool, and therefore in termination of cAMP signaling. 
Such regulation of termination of cAMP signaling was also observed from 
elaborate studies I carried out for the mammalian R-subunit (RIα), as it interacts 
 xii 
 
with phosphodiesterase PDE8 (Chapter 3). The PDE8:RIα complex was observed 
to be formed at limited cAMP levels and more stably at high cAMP 
concentrations. Through various structure-function-dynamic approaches, it was 
observed that the two cAMP interacting sites (CNB sites and catalytic pocket) are 
coupled by the formation of ‘substrate channel’. PDE8:RIα complex showed 
enhanced enzymatic activity for a rapid cAMP turnover. This complex acts in 
unison as a regulatory complex to maintain dynamic levels of cAMP, especially 
post-hormonal stimulation state of the cell. 
Upon further investigations, I discovered that cAMP hydrolysis product 
AMP binds to RIα (Chapter 4) and induces conformational changes similar to that 
observed with cAMP. Most importantly, PDE8 was not only capable of binding to 
AMP-saturated RIα but also that the conformational changes accompanying the 
complexation facilitated AMP release from RIα, making it completely ligand-free.  
In the last part, the similarities and differences of PDE:PKAR complexes 
from D. discoideum and mammalian systems were compared (Chapter 5), to 
understand the cAMP release mechanisms in detail. Comparison of the data 
showed that the RegA:RD complex differed to PDE8:RIα complex in terms of 
stability, the time required for cAMP dissociation and hydrolysis, and the interface 
of interaction. While RegA bound to RD primarily at CNB:B site, PDE8 bound to 
RIα at both CNB sites. In both complexes, conformational dynamics and allostery 
were prominent in mediating cAMP release from R-subunits via a ‘substrate 
channeling’ mechanism. It is noteworthy to mention that while PDE8:RIα 
complex operates at a faster rate and helps in robust desensitization and signal 
adaptation, the RegA:RD complex is precisely activated only at high 
concentrations of cAMP in Dictyostelium cells. 
 xiii 
 
This study uniquely highlights the active role of PDEs in accelerating the 
cAMP hydrolysis and in promoting cAMP signal termination. The substrate 
channeling mechanism shown here is first of its kind in ‘signaling’ pathways that 
regulates the cAMP-PKA signaling at a finer level, rather than just passively 
degrading cAMP. Furthermore, preliminary studies suggest that PDE:PKAR 
complex acts as a sensitive fluorescence polarization tool that helps in rapid 
screening of potential inhibitors (Chapter 6).  Biological implications of this study 
are also discussed (Conclusion & Future Prospects) with key ideas for expanding 
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One of the major hallmarks of functioning of any cell is its ability to respond to 
different environmental cues efficiently. In order to achieve this, different cells utilize 
different modules to regulate the specific and selective response to various stimuli. 
External chemical and physical stimuli are sensed by different membrane receptors, which 
often are G-protein coupled receptors (Gilman 1987). These seven-transmembrane helices 
containing heterotrimeric proteins are associated with three cytoplasmic subunits 
responsible for functioning within the cytoplasm (Selbie and Hill 1998). Extracellular first 
messengers like small molecules, ligands and hormones bind to or associate with these 
membrane receptors and induce structural/conformational or functional changes, which 
then get relayed to bound subunits and thereby transducing the extracellular stimulus to 
inside of the cell (Jalink and Moolenaar 2010, Wright, Schobesberger et al. 2015). Of the 
three subunits, G alpha subunit (Gαs) gets dissociated to migrate and bind to downstream 
targets for initiating the response (Hanoune and Defer 2001). 
In such signal transduction processes, small molecules mediate the response by 
diffusing across the cytoplasm and binding to their target proteins. These small molecules 
are called as second messengers, such as cyclic nucleotides and ions (Newton, Bootman 
et al. 2016). One of the most important and widely characterized second messengers is 3′, 
5′ - cyclic adenosine monophosphate (cAMP) (Sutherland 1950, Rich and Karpen 2002, 
Sassone-Corsi 2012). Hormonal stimulation leads to activation of adenylyl cyclases 
through the Gαs subunit, which then catalyzes the conversion of ATP to cAMP. This leads 
to the generation of large pools of cAMP in the cytoplasm. Subsequently, cAMP translates 
this extracellular stimulus to the cytoplasm by binding to one of its different targets and 
regulates a plethora of cellular processes involved in cell growth and development, like 
neuronal signaling, endocrine functions, cardiovascular functions etc. (Spiegel, Shenker 




Dynamic levels of cyclic AMP orchestrate different signaling pathways 
A very important consideration in this context are the levels of cAMP generated 
and its distribution within the cytoplasm. For efficiency and proper regulation of myriad 
effects of cAMP, its precise control of production, detection and subsequent degradation 
is critical. Differential activation of adenylyl cyclases (slow turnover, (Sunahara, 
Dessauer et al. 1996)) and phosphodiesterases PDEs (rapid degradation, (Rocque, Holmes 
et al. 1997) results in dynamic levels of cAMP. Importantly, certain studies have reported 
that cAMP degradation is never saturated in unstimulated conditions or during activation 
(Feinstein, Zhu et al. 2012, Conti, Mika et al. 2014). The levels and distribution of cAMP 
generated largely depends on the stimulus and receptor activated. Different types of 
stimuli are associated with different types of membrane receptors, thereby necessitating a 
multidimensional regulation of cAMP signaling. For a pre-stimulated cell, re-stimulation 
by same/similar first messengers may only lead to small changes in the cellular levels of 
cAMP and hence not result in a proportional response (Johnston and Watts 2003). Such 
fine control is important to prevent an exaggerated response from a single cell, rather than 
the whole tissue/organ (Houslay 1998) and is often associated with molecular adaptation. 
In literature, reduced activity of cAMP-dependent protein kinase A (PKA) under 
sustained high levels of cAMP within the cytoplasm and alternative regulatory 
mechanisms have been well documented (Mendelson, Dufau et al. 1975, Hemmings 1986, 
Leiser, Fleischer et al. 1986, Chneiweiss, Cordier et al. 1991, Ni, Ganesan et al. 2011). 
Regulation of PKA activity by cAMP levels to generate a specific response is essential to 
control the signaling output by cellular and nuclear targets of PKA. 
Stimulation of the same cell by a different stimulus may initiate another signaling 
pathway, which may or may not be related to the already initiated response. 
Discrimination of such stimuli is critical for appropriate sensitization and robustness by 
the cell (Blüthgen and Legewie 2013). Positive feedback mechanisms amplify the signal 
while negative feedback regulation attenuates it. This not only changes steady-state 
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responses but mainly allows cAMP level fluctuations. Thus, a steady-state system 
becomes unstable and elevates to another stable state (with a higher threshold for cAMP 
levels) and therefore oscillates in dynamic levels. Sustained stimulation enables 
reconfiguration of the intracellular machinery to reset its basal activity to a higher 
threshold, and the cell undergoes ‘bistability’ state: stable at low cAMP levels (pre-
stimulated state) and also stable at high cAMP levels (sustained stimulation state) 
(Shepherd  and Kahn 1999, Teruel and Meyer 2002, Giri, Mutalik et al. 2004, Hayer and 
Bhalla 2005). This ability of intracellular molecular machinery to reset its basal levels is 
called adaptation and is very important at different cellular levels. For example, in social 
amoeba Dictyostelium, oscillating levels of cAMP helps in the diversity of chemotactic 
responsiveness of the cell population (Tyson and Murray 1989, Wang, Bergmann et al. 
2012, Nakajima, Ishihara et al. 2014). Therefore, adaptation to a particular stimulus 
locally ensures sensitization of neighboring cells and such control is imparted by 
molecular adaptation and alteration in protein(s)-ligand interactions (Dinauer, Steck et al. 
1980, Houslay 1998, Kim, Heslop-Harrison et al. 2010, Yuan, Branch et al. 2012). In 
cAMP signaling pathway, adaptation of cells to different levels of cAMP is known to 
maintain optimal responses by preventing unstimulated activation and by regulated 
deactivation mechanisms mediated by various macromolecular assemblies in different 
cAMP compartments. 
Compartmentalization of cyclic nucleotides govern selectivity and sensitivity 
Equally important to the dynamic levels of cAMP in the cytoplasm is their 
temporal and spatial distribution, which largely moderates the type of response manifested 
by a cell. In cells, uneven clustering of cAMP occurs localizing them to specific subsets 
of cytoplasm and such ‘pools’ of cAMP are called as cAMP microdomains (Lefkimmiatis 
and Zaccolo 2014). One of the critical components that cause the formation of such 
‘clouds’ of cAMP are their degrading enzymes phosphodiesterases (Conti and Beavo 
2007, Lomas and Zaccolo 2014). Being a pleiotropic second messenger, cAMP generates 
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several functional responses for various extracellular stimuli with high fidelity and 
specificity through these spatial segregations. Many studies have reported the existence 
of cAMP microdomains in different types of cells and their importance in independent 
signal pathways. Collectively, regulation of this multidimensional cAMP signaling 
pathway is through compartmentalization of cAMP in different parts of the cell, defined 
by different constituents or multi-protein complexes, including the cAMP-producing 
adenylyl cyclases, cAMP-degrading phosphodiesterases and cAMP receptors like protein 
kinase A scaffolded to anchoring proteins (Bauman, Michel et al. 2007).  
Microdomains at different locations have been shown to play critical roles in 
various processes such as beta-adrenergic receptor signaling (Fischmeister, Castro et al. 
2006, Rababa'h, Craft et al. 2013, Zoccarato, Surdo et al. 2015). A coordinated 
communication between different components of cAMP microdomains has been 
implicated in localized cAMP signaling in cardiac cells, rapid activity at Z-bands of 
cardiomyocytes, modulating L-type calcium channels activity by cAMP pulses at plasma 
membrane etc. Any kind of dysregulation of such compartmentalized signaling has been 
shown to be associated with pathophysiological processes and implicated in diseases such 
as cardiomyopathy, susceptibility to stroke, chronic obstructive pulmonary disorder 
(COPD), cancer and neurodegenerative disorders (Goraya, Masada et al. 2004, 
Fischmeister, Castro et al. 2006, Stangherlin and Zaccolo 2012, McCormick and Baillie 
2014, Fields, Koschinski et al. 2015, Ellisdon and Halls 2016). Hence, these segregated 
cAMP microdomains and PDEs have been targeted to synthesize drugs, small molecule 
therapeutics, and inhibitors. Moreover, targeting signalosomes or protein-protein 
complexes have also been implicated for better and potent molecules for specific 
inhibition (Arora, Sinha et al. 2013, Maurice, Ke et al. 2014, Ahmad, Murata et al. 2015, 
Wright, Schobesberger et al. 2015). These signalosomes consist of cAMP-receptor 
Protein Kinase A, phosphodiesterases and A-kinase anchoring proteins which result in 
response to stimuli. 
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Biochemistry and components of cAMP-PKA signaling pathway 
Protein Kinase A: primary target of cyclic AMP 
Cyclic AMP binds to a module/domain conserved from prokaryotes to eukaryotes 
(Berman, Ten Eyck et al. 2005). Main effectors of cAMP signaling in bacteria are 
catabolite activated protein (CAP) (Mitra, Zubay et al. 1975), while in mammals the main 
targets of cAMP (Fig. i) are cAMP-dependent protein kinase A ‘PKA’, (Taylor, Buechler 
et al. 1990), exchange protein activated by cAMP ‘Epac’ (Bos 2003), cyclic-nucleotide 
gated channels ‘CNG’ (Finn, Grunwald et al. 1996), and newly discovered targets Popeye-
domain-containing ‘Popdc’ proteins (Simrick, Schindler et al. 2013).  
The cAMP-dependent protein kinase A (PKA) is the most important cAMP-
receptor as it phosphorylates numerous cytoplasmic and nuclear targets. PKA holoenzyme 
(Fig. ii) is a heterotetramer of two copies of catalytic (PKA-C) subunits and a dimer of 
regulatory (PKA-R) subunit (Potter and Taylor 1979). High-resolution crystal structure 
of the PKA holoenzyme with monomers of C- and R- subunits (PDB: 2QCS, (Kim, Xuong 
et al. 2005, Kim, Cheng et al. 2007), its individual components PKA C- subunit [PDB ID: 
1ATP (Karlsson, Zheng et al. 1993)] and PKA R- subunit [PDB ID: 1RGS, (Su, Dostmann 
et al. 1995)] in different stable-conformations have been characterised (Fig. ii). In the 
absence of cAMP, PKA C- and R-subunits have a high affinity of association KD ~ 10 nM 
(Bubis and Taylor 1985). Two molecules of cAMP bind to each regulatory subunit and 
induce conformational changes, leading to dissociation of PKA C- and R-subunits, and 




Figure i: The cAMP-PKA signaling pathway. Stimulation of GPCRs by hormones activates 
adenylyl cyclases to synthesize cyclic AMP from ATP. A cAMP flux is generated, which then 
binds to one of its three targets, PKA (R2C2), Epac, CNG or Popdc proteins depending on 
subcellular location and type of extracellular stimulus. PKA R-subunit (dark blue) is often found 
associated to AKAPs (light blue). Cyclic AMP binding dissociates PKA C-subunit (red) and the 
activated C-subunit phosphorylates downstream targets. Phosphodiesterases (green) are enzymes 
that catalyze the hydrolysis of cAMP to 5’-AMP. 
 
 
In the presence of substrate, PKA-C subunit dissociates from cAMP-bound 
regulatory subunit and gets activated to phosphorylate serine/threonine residues of its 
target proteins that are involved in multiple signaling and metabolic pathways, which 
regulate cell growth and morphology (Taylor, Buechler et al. 1990, Kandel 2001, Shabb 
2001). The regulatory subunit functions to regulate the catalytic subunit activity in 






Figure ii: Activation of Protein Kinase A subunits by cAMP. To a PKA holoenzyme (2QCS, 
complex of monomers of R and C- subunits), binding of cAMP molecules to PKA Regulatory 
subunit (lime green, cAMP-bound RIα, PDB ID: 1RGS) activates PKA Catalytic subunit (olive, 
PDB ID: 1ATP), and dissociates it in the presence of its substrate (orange). This dissociation of 
activated C-subunit and cAMP-bound RIα constitutes the activation phase of cAMP signaling. 
 
PKA Regulatory subunit: central feature of cAMP pathway 
PKA regulatory subunit exists in four isoforms (RIα, RIβ, RIIα, RIIβ) which are 
distributed unequally in different types of cells and are functionally non-redundant 
(Taylor, Buechler et al. 1990, Skalhegg and Tasken 2000). The four isoforms of regulatory 
subunit have conserved amino acid sequence (Appendix –A1) and each subunit is a 
modular peptide comprising (Fig. iii A, B) of (i) a N-terminal dimerization/docking 
domain, (ii) an unstructured flexible region encompassing the PKA C-subunit and 
pseudosubstrate binding sites (pink), followed by (iii) two tandem cyclic nucleotide 
binding domains (CNB:A and CNB:B, blue and green respectively) (Ogreid and 
Doskeland 1981, Ogreid and Doskeland 1981) connected by (iv) αB:C helix (red). Cyclic 
nucleotide-binding domains (both A and B) are critical in determining the function of R-
subunit and numerous studies (X-ray crystallography, NMR, SAXS, molecular dynamic 
simulations, HDXMS) have been carried out to understand the binding kinetics of cAMP 
molecules to PKA R-subunit. One molecule of cAMP binds to CNB:B site followed by 
cooperative binding of the second cAMP molecule to the CNB:A site. While both sites 
bind to cAMP with very high-affinity, the CNB:B site has higher affinity than the CNB:A 
site. CNB:A site has a faster rate of exchange for cAMP and CNB:B site shows slow 
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exchange (Ogreid, Ekanger et al. 1989). The cyclic nucleotide binding domain is 
composed of α-helices and β-sheets that sandwich the central cAMP binding pocket called 
phosphate-binding cassette (PBC). Cyclic AMP binds in the PBC (Su, Dostmann et al. 
1995) by a framework of hydrogen bonds (Arg 209, Ala 210, Asp 170), electrostatic (Glu 
200, Arg 209) and stacking (Trp 260) interactions, which are mediated between cAMP 
and the amino acid residues of PBC (inset Fig. iii B). Although the binding sites are 
conserved across all isoforms, the binding affinities to cAMP differ for each isoform, for 
example, RIα has a very high affinity to cAMP with a dissociation constant KD ~ 2 nM 
(Ogreid, Ekanger et al. 1989).  
High-resolution crystal structures of the PKA holoenzyme for different isoforms 
of R-subunit with the C-subunit revealed a distinction between the quaternary structures 
of the four isoforms. Two defined conformations of R-subunit are known, inactive PKA 
C-subunit bound, cAMP-free conformation (H-form, Fig. iii C) and a kinase-free 
functional cAMP-bound conformation (B-form, Fig. iii D). While the H-form is present 
as inactive PKA holoenzyme and prevents unstimulated PKA C-subunit activity, the B-
form or cAMP-bound form imparts specificity to the cAMP signaling pathway by 
interacting with other proteins and forming multi-protein complexes. These higher order 
interactions of R-subunit are modulated by a class of proteins called A-kinase anchoring 
protein (AKAPs) scaffolds (Wong and Scott 2004, Dodge-Kafka, Bauman et al. 2008). In 
addition, isoform diversity and their AKAP diversity plays a large part in the specificity 
and subcellular localization of the cAMP-PKA signaling pathway. Regulatory subunits 
bind to different AKAPs via their dimerization/docking and unstructured regions and 





Figure iii. Mammalian Protein Kinase A Regulatory subunit: Structure and domain 
organization. (A) Schematic of domain organization PKA regulatory subunits showing the 
dimerization/docking (D/D) domain and two tandem cyclic nucleotide binding domains. Full-
length R subunit is a dimer. (B) Crystal structure of full-length PKA RIα is shown with one 
monomer (left) in surface representation highlighting the different domains: D/D domain in pink, 
CNB:A in blue, inter-domain linker in red, and CNB:B in green. Other monomer (right) is shown 
in cartoon, with the phosphate-binding cassette residues and cAMP interactions zoomed-in inset. 
Two defined conformations of RIα – cAMP-free ‘H-form’ (C) and cAMP-bound ‘B-form’ (D) are 
shown. Cyclic AMP molecules are shown as yellow sticks. 
 
AKAPs thus play a significant role in specificity and versatility of the cAMP-PKA 
signaling pathway to a range of stimuli, viz. membrane (smAKAP-PKA-RIα (Burgers, 
Ma et al. 2012)), mitochondria (S-AKAP84, PKA RIIα and RIIβ (Lin, Moss et al. 1995)), 
endoplasmic reticulum (dAKAP-PKA RIα (Ma and Taylor 2008)), and nucleus 
(AKAP7γ-PKA RI (Brown, August et al. 2003).  
PKA R-subunit has been shown to be phosphorylated by cyclin-dependent 
kinases CDK2/cyclin E complex, to regulate cell cycle, proliferation and indirectly 
promote apoptosis (Gupte, Traganos et al. 2006). The importance of the regulatory 
subunits arises from independent mutational studies, which show that aberrant R-subunits 
cause uncontrolled transcription of specific genes, onset of various diseases like Carney 
complex disease (Miller 2002, Bruystens, Wu et al. 2014), systemic lupus erythematosus 
(Kammer, Khan et al. 1996), sporadic tumours, acrodysostosis, and pseudo-
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hypoparathyroidism (Elli, Bordogna et al. 2016). Moreover, knockout studies in mice 
report that prkar1a-/- strains are embryonically lethal due to failure in cardiac 
morphogenesis (Amieux and McKnight 2002). This information stresses the unique 
nature of RIα in regulating PKA C-subunit activity effectively and thus stresses the 
importance of RIα in tissue distribution and localization, anchoring and regulation. Hence, 
RIα isoform was chosen as a representative PKA R-subunit for our studies. 
Regulatory subunit from Dictyostelium discoideum 
 The second messenger cyclic AMP signaling is conserved across all organisms 
like protozoa, metazoa, including fungi and slime molds, having a critical role in 
developmental processes of the cell (Berman, Ten Eyck et al. 2005). As described above, 
even in the slime mold Dictyostelium discoideum, cAMP binds to its protein kinase A 
holoenzyme and induces conformational changes to dissociate the catalytic and regulatory 
subunits (Mutzel, Lacombe et al. 1987). However, unlike mammals, this lower eukaryote 
PKA holoenzyme is a simple model system with single copies of catalytic and regulatory 
subunits. Active catalytic subunit then phosphorylates different targets involved in 
different stages of the life cycle of slime mold (Williams, Harwood et al. 1993). It has 
been reported that uncontrolled activity of catalytic subunit induces premature 
differentiation to result in sporulation (Simon, Pelegrini et al. 1992). The regulatory 
subunit lacks the N-terminal dimerization domain and exists as a monomer (Leichtling, 
Majerfeld et al. 1982) with similar specificity and binding of cAMP in cyclic nucleotide 
binding domains (Fig. iv A). Just like mammalian PKA R-subunits, regulatory subunits 
from D. discoideum, (henceforth referred as ‘RD’) regulate the activity of catalytic subunit 
and also play an important role in the regulation of sorocarp development and stalk cell 
differentiation (Hopper, Anjard et al. 1993, Mann and Firtel 1993). Mutational and 
knockout studies in D. discoideum have shown unrestrained activity of catalytic subunit 





Figure iv: Domain organization of PKA R-subunit and phosphodiesterase RegA from D. 
discoideum. Schematic diagram of domain organization of PKA R-subunit (A) and 
phosphodiesterase RegA (B) from D. discoideum are shown. PKA R-subunit exists as a monomer 
(327 amino acid residues) with docking/phosphorylation domain and two tandem conserved cyclic 
nucleotide binding domains (CNB:A, CNB:B). A class III cAMP-specific phosphodiesterase, 
RegA (793 amino acid residues), is a hybrid of two-component like proteins and enzymes, having 
response-regulatory and catalytic domains respectively. 
 
Phosphodiesterases: regulators of cyclic nucleotides in cells 
Phosphodiesterases are a class of enzymes that catalyze the hydrolysis of cyclic 
nucleotides and thereby play an important role in different signaling pathways. In 
mammals, 21 different genes code for cyclic nucleotide phosphodiesterases (PDEs) 
superfamily, which comprises of 11 different members (PDE1-PDE11) with each having 
multiple isoforms and their splice variants, totaling to about 100 different isoforms. Each 
PDE member is different from other in terms of their amino acid sequences, substrate 
preferences, biochemical properties, regulation and tissue distribution (Thompson 1991, 
Conti and Beavo 2007, Francis, Blount et al. 2011). These are widely distributed – 
spatially (located in different tissues and domains) and temporally (different stages of cell 
growth and development) and are therefore non-redundant (Beavo 1995). Specificity to 
one or both substrates classifies them into three types: cyclic AMP-specific (4, 7 and 8), 
cyclic GMP-specific (5, 6 and 9) and dual specificity PDEs (1, 2, 3, 10 and 11).  
 Structurally, each PDE member has a unique molecular architecture at N-
terminus (Appendix – A2) but a conserved catalytic domain towards the C-terminus. 
Different domains in the PDE isoforms are responsible for the wide functioning and 
regulation of their activity. Activation of PDEs occurs through calcium and calmodulin 
binding [PDE1, (Goraya, Masada et al. 2004)], cGMP binding [PDE2, (Martinez, Beavo 
et al. 2002)], [PDE9, (Fisher, Smith et al. 1998)], phosphorylation (Beltman, Sonnenburg 
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et al. 1993) by protein kinases like PKA, PKB, and/or ERK [PDE3, PDE4, PDE7 (Sette 
and Conti 1996, Heikaus, Pandit et al. 2009)], cGMP and PKG [PDE5, (Francis, Bessay 
et al. 2002)], transducin-binding [PDE6, (Paglia, Mou et al. 2002)], kinase activation of 
PAS domains [PDE8, (Brown, Lee et al. 2012)], cAMP-binding [PDE10, (Gross-
Langenhoff, Hofbauer et al. 2006, Jager, Russwurm et al. 2012)], cAMP/cGMP regulation 
of GAF domain activation [PDE11, (Wayman, Phillips et al. 2005)]. The conserved 
catalytic domain is responsible for hydrolysis of cAMP and cGMP to 5′-AMP and 5′-
GMP respectively.  
High-resolution crystal structures of the catalytic domain (Fig. v) of PDEs have 
been solved (Wang, Robinson et al. 2007, Wang, Yan et al. 2008, Russwurm, Schlicker 
et al. 2011) which show three major helical subdomains: N-terminal cyclin fold (salmon, 
Fig. v A), followed by a linker region (olive, Fig. v A) and C-terminal helical bundle 
(blue, Fig. v A). At their interface, a hydrophobic pocket is buried which encompasses: a 
metal binding site (M-site) that harbours two divalent cations, zinc and 
magnesium/manganese which form coordination sphere with two water molecules and 
specific amino acid residues (three histidines, one aspartate) in the surrounding core Q-
pocket; a set of hydrophobic residues near the surface that recognise the specific substrate 






Figure v: Phosphodiesterases: cAMP-degrading machinery. Representative crystal structure of 
the catalytic domain of phosphodiesterases (PDE8A, PDB ID 3ECM). (A) Monomer of PDE8A 
catalytic domain in surface representation showing different regions: N-terminal cyclin fold in 
salmon, linker-region in olive and C-terminal helical bundle in blue are highlighted. (B) Cartoon 
form of a monomer of PDE8A catalytic domain highlighting the major cAMP binding sites: H-
loop (purple), M-site (red circle) with Zn+2 and Mg+2 ions as brown and pink spheres respectively, 
Q-pocket (residues shown as red sticks), M-loop (green) and lid-region (blue circle) are mapped. 
 
As cyclic nucleotides are essential second messengers, their hydrolysing enzymes 
PDEs also play a critical role in most of the associated signaling pathways and cellular 
processes like cardiac functioning, smooth muscle activity, adrenogenesis etc. Moreover, 
as most of these processes are prone to diseases, PDEs have become one of the major 
targets for manufacturing drugs to restore normal cell functioning. In this regard, certain 
isozyme- and isoform-specific inhibitors are known which mainly disrupt their catalytic 
activity by binding to the catalytic site or an allosteric site. Furthermore, the activity of 
certain PDEs is known to be regulated by their binding to scaffold proteins AKAPs. Many 
PDE-AKAP macromolecular complexes, for example, PDE4D with AKAP18 (Witczak, 
Skalhegg et al. 1999, McSorley, Stefan et al. 2006, Rababa'h, Craft et al. 2013) have been 
discovered to play an important role in feedback inhibition mechanisms. 
Phosphodiesterases from lower eukaryotes 
Mammalian PDEs have a conserved catalytic domain across all members of 
eukaryotes and the mechanism of hydrolysis of 3′, 5′- cyclic phosphodiester bond falls 
 14 
 
under the first category of the different classes of catalytic domains for cyclic nucleotides 
(Bader, Kortholt et al. 2007). First class, class I domain, is present in members of protozoa 
and metazoa while the second class (class II) is found in amoebae, fungi, and slime molds. 
So far, a third class (III) of catalytic domains (β-lactamase type) is only found in 
Dictyostelium discoideum and bears resemblance with PDE8 family of mammalian 
phosphodiesterases (Mutzel, Lacombe et al. 1987, Thomason, Traynor et al. 1998). 
Currently, four PDEs are known to be expressed in D. discoideum: DdPDE1 (ecto-PDE), 
DdPDE2 (RegA), DdPDE3 (cGMP-specific) and DdPDE4, all of which have critical roles 
during different stages of the slime mould’s life cycle (Wu, Franke et al. 1995, Palsson 
2009, Schwebs, Nguyen et al. 2014).  
The dominantly expressed intracellular form in D. discoideum is DdPDE2, 
henceforth referred to as ‘RegA’ and is regulated by multiple mechanisms. Uniquely, it 
has two-component signal transduction like mechanism, wherein activation of RegA 
occurs via phosphorylation of its Asp212 by a relay cascade (Shaulsky, Fuller et al. 1998, 
Thomason, Traynor et al. 1998). RegA is a hybrid of bacteria-like receiver domain (N-
terminus) and mammalian type catalytic domain (Fig. iv B). Mammalian PDE8 has high 
homology to RegA, thus PDE8 also contains similar receiver and PAS domains 
(Appendix – A3). Both PDEs are therefore supposed to be activated in a similar manner, 
by phosphorylation of their receiver domains. The catalytic domain of RegA is similar to 
that of mammalian PDEs, with specific amino acid residues involved in coordination with 
divalent metal and nucleotide binding residues being highly conserved. In starving 
conditions D. discoideum initiates sporulation in multicellular fruiting bodies for 
encystation by cAMP-activated PKA (Schwebs, Nguyen et al. 2014). However, RegA 
regulates cAMP levels and therefore has been reported to control PKA-mediated 
differentiation of pre-stalk and spore cells and regulate encystation and prevent cyst 
germination (Mann and Firtel 1993). Knockout studies have shown that loss of RegA 
phosphodiesterase from the social amoeba results in accelerated sporulation, a feature 
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similar to that observed by increased PKA C-subunit activity or by the lack of PKA R-
subunit (Schwebs, Nguyen et al. 2014). Moreover, it has been previously shown that 
RegA gets activated by direct interactions with PKA R-subunit and therefore it was 
selected as a potential target for detecting cAMP dissociation (Shaulsky, Fuller et al. 
1998) from PKA R-subunit for signal termination. 
Termination phase of cAMP-PKA signaling pathway: ‘Beginning the end’ 
 Constant fluctuations in cAMP levels govern most of its activities via a complex 
network of signaling pathways. An increase or decrease in the dynamic levels of cAMP 
should, therefore, be regulated to prevent any malfunctioning of the cell. Several 
mechanisms have been discovered which maintain cAMP homeostasis by controlling the 
intensity, duration of response and spatial propagation of the cAMP signals by employing 
multiple feedback mechanisms (Conti and Beavo 2007). Maintaining a balance of cAMP 
levels is critical for restricting the unregulated activity of cAMP-related pathways and 
thus necessitates their termination and robust desensitization (Kitano 2004, Moorthy, Gao 
et al. 2011).  
In cAMP-PKA signaling pathway, activation of PKA occurs when cAMP binds 
to PKA R-subunit and dissociates PKA C-subunit (left to right, Fig. vi), which then 
phosphorylates various targets (Taylor, Zhang et al. 2013). Under low concentrations of 
cAMP or in the presence of cAMP-free R-subunit, the C-subunit gets re-associated with 
R-subunit forming an inactive Protein Kinase A (Ogreid and Doskeland 1983). This 
constitutes the termination phase of cAMP-PKA signaling pathway (right to left, Fig. vi), 
wherein the activity of PKA C-subunit is abated by binding to PKA R-subunit. This 
reversibility of PKA from active state to inactive state is critical for regulating its activity, 
as it is essential for the cells to return back to resting state (basal cAMP levels) after 
transient increase in cAMP levels to stimulated state (Kopperud, Christensen et al. 2002) 
(Kopperud, Krakstad et al. 2003). Many studies have reported abnormalities in cAMP-
PKA pathway due to the uncontrolled activity of C-subunit (Miller 2002, Taylor, Zhang 
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et al. 2013, Berthon, Szarek et al. 2015). Constitutively active PKA C-subunit has been 
shown to cause multiple diseases like endocrine Carney complex syndrome (Veugelers, 
Wilkes et al. 2004), Adrenal Cushing’s syndrome, McCune-Albright syndrome (Salpea 
and Stratakis 2014), tumorigenesis (adrenocortical tumors) etc. Mutational and knockout 
(haploinsufficiency) studies of PKA R-subunit have shown an overall increase in PKA C-
subunit activity and thus enhanced cAMP signaling (Amieux and McKnight 2002). 
Moreover, dysfunctional or lack of R-subunits also cause diseases (Carney complex 
syndrome) and may even be lethal. In D. discoideum, loss of regulatory subunit leads to 
unregulated C-subunit which results in behavioral defects, disrupted motility and 
chemotaxis (Simon, Pelegrini et al. 1992, Hopper, Anjard et al. 1993, Williams, Harwood 
et al. 1993, Mann, Brown et al. 1997). 
 
Figure vi: Inactive and active forms of the PKA holoenzyme complex. The inactive form of PKA 
holoenzyme comprises of a dimer of the regulatory subunit (blue) and two catalytic subunits 
(salmon). cAMP (pink) activates PKA holoenzyme (forward reaction) by dissociating the R- and 
C-subunits and forming cAMP-bound R-subunit (right) and substrate-bound active C-subunit. The 
activity of active form is terminated by the release of cAMP from PKA R-subunit and its 
reassociation with C-subunit (reverse reaction). This image was adapted and modified from David 
Goodsell, PDB’s molecule of the month (http://pdb101.rcsb.org/motm/152). 
 
One of the direct mechanisms of cAMP signal termination is to inactivate its main 
receptor PKA holoenzyme. However, the reassociation of active C- and cAMP-bound R- 
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subunits does not occur readily in cells. As mentioned before, cAMP binds to regulatory 
subunit with very high affinity (KD ~ nM) and does not dissociate easily, even after 
dialyzing the protein for five days. Unbinding of cAMP from R-subunits is very important 
for PKA holoenzyme reformation, as C-subunit does not form a stable complex with R-
subunit in the presence of high amounts of cAMP. The current assumption of competitive 
displacement of bound cAMP by C-subunit (Ogreid and Doskeland 1983, Ogreid, 
Ekanger et al. 1989), followed by PDE-mediated passive hydrolysis of displaced cAMP 
is insufficient to account for the rapid hydrolysis of cAMP observed under a broad range 
of cAMP concentrations (Houslay 2010). Moreover, at physiological cAMP 
concentrations activation of C-subunit is achieved upon substrate-mediated dissociation 
from R:cAMP:C ternary complex, subsequently resulting in the phosphorylation of 
numerous cytoplasmic and nuclear targets (Kopperud, Christensen et al. 2002, Viste, 
Kopperud et al. 2005). Therefore, this mechanism of inactivation would only contribute 
minimally and thus warrants alternative path for subduing the cAMP signal.  
 Another direct mechanism of terminating the cAMP-PKA signaling is by 
hydrolysis of cAMP itself to decrease the overall cAMP levels in the cytoplasm. Although 
cAMP-degrading phosphodiesterases efficiently hydrolyse cAMP to 5′-AMP and keep 
cAMP levels in check, this does not inactivate the cAMP-PKA signaling pathway as the 
C- and R- subunits still remain dissociated. Passive hydrolysis of unbound freely diffusing 
cAMP by PDEs in different subsets of the cytoplasm does not reflect cAMP 
concentrations at other locations, like cAMP bound to receptors or in other microdomains 
where elevated and concentrated cAMP levels persist. Previous studies from our lab have 
reported a novel role of phosphodiesterases in removing cAMP-bound to the R-subunits 
(Moorthy, Gao et al. 2011, Krishnamurthy, Moorthy et al. 2013, Krishnamurthy, Moorthy 
et al. 2014). This active hydrolysis of cAMP by removal from its receptors offers a rapid 
mechanism of cAMP turnover to reset the cytoplasm for a new cycle of activation and 
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inactivation. This important role of phosphodiesterases in cAMP-PKA signal termination 
thus needs to be characterized in detail.  
 With this relevant information, and uncharacterized termination phase of cAMP-
PKA signaling in different cellular contexts, and a keen interest to understand the 
mechanism of molecular functioning through protein-ligand interaction, in this 
dissertation, I will be discussing my results in pursuit of the description of a novel and 
active role of PDE in facilitating cAMP signal termination by directly interacting with 
PKA R-subunit. To understand this, I have chosen cAMP-PKA signaling components 
from two model systems – (a) higher eukaryotic mammalian, and (b) lower eukaryote 
Dictyostelium discoideum for further studies. Following are the objectives of my graduate 
research. 
Objectives 
1. To monitor PDE-mediated dissociation of cAMP from R-subunits: Extending 
the active-site coupling model by capturing the transitional states of PDE8:RIα 
and RegA:RD 
 
2. To identify dynamics of RegA:RD complex by unraveling their interaction 
interface and differentiating the effects of cAMP and PDE on RD 
 
3. To describe the structure-function-dynamic mechanisms of PDE8:RIα 
interactions in terminating the cAMP-PKA signaling pathway, using 
biochemical tools 
 
4. To study the effects of PDE and dynamic cAMP levels in cAMP signal 
termination and uncover role of 5′-AMP in PDE:PKAR interactions 
 
5. To compare mechanism of cAMP release and hydrolysis between the two model 




Amide Hydrogen-Deuterium Exchange Mass Spectrometry determines conformational 
dynamics of proteins 
Deconstructing this name says it all, that this method relies on the exchange of 
labile amide hydrogen atoms of a macromolecule by ‘heavy’ isotope of hydrogen 
deuterium, followed by identification of the magnitude of this exchange by proteolysis 
coupled to mass spectrometry. This method has been established as a powerful technique 
to determine the conformational changes of proteins (and associated macromolecules) 
between different conditions (Katta and Chait 1991, Clarke and Itzhaki 1998). Hydrogen-
deuterium exchange mass spectrometry, or HDXMS in short, has been used to monitor 
the changes in hydrogen-bonding, protein dynamics, solvent accessibility and other 
structural changes induced during protein-protein or protein-ligand interactions 
(Hoofnagle, Resing et al. 2003, Marcsisin and Engen 2010). Protein’s function is 
dependent on protein’s structure and this HDXMS tool is capable of identifying proteins’ 
conformational dynamics. 
As proteins are dynamic, the backbone, as well as their side chains, undergo 
constant structural alterations. These changes are accompanied by exchanging of labile 
hydrogens with hydrogens from the solvent surrounding it. While hydrogens at functional 
groups of amino acids are extremely fast (~101-103 sec-1) to be detected by most 
techniques, hydrogen atoms at backbone amides undergo slower exchange (milliseconds-





Figure vii: Principle of amide hydrogen - deuterium exchange. A model peptide is shown with 
labile backbone amide hydrogens in red (rate of exchange ranges from milliseconds – days) and 
hydrogens on functional groups in blue (rate of exchange is extremely fast) for a protonated protein. 
Replacing the water in solution by deuterium oxide (D2O) enables the exchange of these hydrogens 
with deuterium atoms (peptide on right), where the backbone amide deuterium atoms exchanged 
to the peptide are shown in green. The peptide was drawn using ChemDraw 15.1 (Perkin Elmer, 
MA). 
 
 HDXMS is based on this theory that the labile backbone amide hydrogens are 
exchanged with deuterium atoms from the solvent and the extent of deuteration is 
dependent on various intrinsic and extrinsic factors. The number of deuterons 
incorporated in the protein, i.e. mass shifts can then be quantified at a protein-level (global 
exchange) or at a peptide-level (residue-specific local exchange) using liquid 
chromatography-mass spectrometry. Besides conformational changes and protein 
flexibility, factors like temperature, pH, deuterium labeling times, and its 
microenvironment play an important role in determining the deuterium exchange kinetics 
of the proteins (Englander and Kallenbach 1983, Zhang and Smith 1993). 
The rate and amount of deuterium exchange are influenced by hydrogen-bonding 
network in proteins which can be tempered by surrounding ligands and/or proteins. 
Importantly, the rates of exchange are also governed by local unfolding and refolding 
events occurring during the labeling reaction. Based on Linderstrøm-Lang’s model 
(Benson and Linderstrom-Lang 1959), differences between the rate of exchange (kch) and 
 21 
 
the rates of opening (kop) or closing (kcl) direct two modes of deuterium exchange kinetics 
– EX1 and EX2 (Englander, Downer et al. 1972, Konermann, Rodriguez et al. 2014). 
 
Figure viii: Two modes of exchange kinetics in HDXMS. Proteins can exist as folded or unfolded 
states in solution. The rates of the opening (kop) and closing (kcl) govern the rates of exchange (kch). 
In EX1 kinetics kch >> kcl, hence two populations co-exist together as shown by blue and red 
isotopic distributions in the left panel. With time, lower exchanging population morphs into higher 
exchanging population. For EX2 kinetics, kcl >> kch indicating refolding of protein is faster than 
the rate of exchange and this averages across the peptide giving a binomial isotopic distribution of 
one population time (green spectra, right panel). 
 
 In EX1 regime (Fig. viii, left panel), rate of hydrogen-deuterium exchange is 
greater than the rate of closing (kch >> kcl), and hence the protein samples a more open 
conformation. These short-lived partial unfolded intermediates or fully unfolded protein 
states are uncommon during a typical H-to-D exchange reaction and are often 
characterised by bimodal distributions of the mass spectra showing coexistence of 
unlabeled and labeled populations in different ratios (Cliff, Higgins et al. 2004, Ferraro, 
Lazo et al. 2004). With increase in labeling time, the rate of closing become faster than 
rate of exchange resulting in unimodal binomial distribution. In the EX2 scenario (Fig. 
viii, right panels), the rate of opening limits the exchange and the equilibrium constant (kcl 
>> kch), where multiple opening and closing events occur before the actual H-to-D 
exchange. This bimolecular exchange reaction is characterised by binomial isotopic 
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distributions of mass spectra, which give a read out of the free energy of structural opening 
or protection at specific regions. EX2 regimes are pH-dependent and thus more prevalent 
in physiological conditions than the EX1 regime. Many groups have applied HDXMS to 
study the folding and unfolding of proteins that have provided valuable information 
(Clarke and Itzhaki 1998, Englander 2000, Englander, Mayne et al. 2016). The terms 
‘closing’ or ‘protection’ indicate restricted solvent accessibility to that particular region 
of protein due to stable hydrogen bonding or compact structure; while ‘opening’ or 
‘deprotection’ indicate disruption of hydrogen-bond and increased solvent accessibility in 
that particular region.  
Hydrogen-deuterium exchange is a solution-based technique, where H-to-D 
exchange reaction is initiated by diluting a protonated protein in an exchange buffer whose 
water molecules are replaced by heavy water (deuterium oxide, D2O). The exchange 
reactions can either be base-catalysed (OH-) or acid-catalysed (H3O+) (Berger and 
Linderstrom-Lang 1957). Time-dependent hydrogen-deuterium exchange is quenched by 
diluting the final pH to 2-3 (pHread ~ 2.5) and lowering of temperature to 0 °C (Englander, 
Downer et al. 1972, Dempsey 2001). A mass of 1 dalton gets increased for each hydrogen-
deuterium exchanged by the peptide. Total number of deuterons incorporated are then 
quantified by mass spectrometry and calculated as an average increase in mass of peptide 
or protein. This increase in mass is compared with undeuterated peptides and determined 
by the distribution of the isotopic envelope (Fig. viii) of the peptide mass spectra. A time-
course of hydrogen-deuterium exchange reactions under different perturbations of protein 
is carried out and analyzed. Relative deuterium exchange and a comparison of deuterium 
exchange between different states (Houde, Berkowitz et al. , Wales, Eggertson et al. 2013) 
is then compared and regions with significant differences are analysed and represented as 





Figure ix: A difference plot compares deuterium exchange levels between two conditions of a 
protein. A plot of differences in number of deuterons (Y-axis) exchanged by protein in condition 
B, (such as ligand-bound) relative to protein in condition A is compared for pepsin fragment 
peptides (represented by each colored circle) across most regions of the protein (N- to C- terminus 
left to right) at different hydrogen-deuterium exchange labeling times, x (red), y (green) and z 
(blue), usually in minutes scale. A significant threshold of ± 0.5 Da is considered and represented 
by red-dashed line. Positive differences indicate increased exchange in protein in condition B, 
while negative differences indicate increased exchange in protein in condition A. This plot gives a 
sense of relative dynamics of regions of proteins between two conditions. 
 
The difference plots are particularly useful in comparing two states of the protein, 
as the regions where differences exist and their magnitudes can be identified easily. 
Importantly, minor errors in handling, temperature or back-exchange apply similarly to 
two test states and get canceled out. Therefore, sites of binding (orthosteric) and allosteric 
sites can be identified which are helpful in providing sensitive information. Recent 
advancements in the field of mass spectrometry (and HDXMS) have enabled monitoring 
rapid changes in proteins with minimum loss of information. A combination of protein 
digestion patterns, high-end liquid chromatography columns (UPLC) and high-resolution 
high-sensitivity mass spectrometers have resulted in unraveling important information of 
small proteins (peptides) to large protein assemblies (viruses). These offer biological 
insights that have wide implications such as drug discovery (Pirrone, Iacob et al. 2015, 




Chapter 1.  
 
Monitoring the release of  cyclic AMP from  
PKA R-subunit by PDE: active-site coupling 





The main intracellular target of cAMP inside eukaryotic cells is Protein Kinase A 
(PKA), wherein cAMP binding leads to dissociation of regulatory and catalytic subunits 
and activates the C-subunit (Taylor, Buechler et al. 1990).  An increase in cAMP flux 
manifests dynamic levels, contributing partially in regulating PKA activation. These 
fluctuating levels of cAMP in the cytoplasm are governed by differential activation of 
adenylyl cyclases (synthesis of cAMP from ATP) and phosphodiesterases (hydrolysis of 
cAMP to 5′-AMP). Phosphodiesterases (PDEs), with their cAMP hydrolytic activity, have 
been shown to lead to a non-uniform distribution of cAMP inside cells and generate 
functional cAMP-compartments, referred to as cAMP microdomains (Conti, Mika et al. 
2014). Different PDE members have been discovered to localize cAMP microdomains in 
different parts of the cell. These microdomains often comprise of one of the cAMP-
receptors, which activate the downstream targets and responsible for a specific process in 
cellular functioning. Different PDE enzymes and different isoforms of PKA play an 
essential role in specificity and duration of the response of cAMP signaling (Conti and 
Beavo 2007). 
Along with other signaling proteins, the functional module of each cAMP 
compartment is a macromolecular assembly of cAMP-receptor PKA anchored to A-
kinase anchoring proteins (AKAPs) and cAMP-degrading PDE (Rababa'h, Singh et al. 
2015). Over 50 AKAPs have been discovered that not only bind to different isoforms of 
R-subunit but also bind to PDEs, such as mAKAP-PKAR-PDE4D signalosome complex 
localized near the nuclear envelope of cardiac myocytes (Bauman, Michel et al. 2007). 
Tethering of different signaling proteins by AKAPs brings them closer to each other and 
thus regulates fine-tuning of cAMP signaling response. Besides, certain AKAP-
independent colocalization of PKA and PDEs have been characterized. Subcellular 
colocalization of PDEs and PKAs have discrete effects on cell and are complementary in 
action. Studies have shown activation of different PDEs by PKA C-subunits and R-
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subunits independently (Heikaus, Pandit et al. 2009), and in social amoebae direct 
interactions between R-subunit and its phosphodiesterase RegA have also been 
discovered (Shaulsky, Fuller et al. 1998). 
The termination of cAMP signaling requires the generation of cAMP-free R-
subunit and previously an active role of PDEs have been highlighted in this regard 
(Moorthy, Gao et al. 2011). Direct interactions between D. discoideum phosphodiesterase 
RegA and PKA R-subunit were reported to activate phosphodiesterase activity (Shaulsky, 
Fuller et al. 1998, Krishnamurthy, Moorthy et al. 2013). Previous studies from our 
laboratory have shown increased RegA activity, during interaction with a deletion 
construct of mammalian PKA-RI  and facilitates cAMP dissociation. In mammals, 11 
PDEs are known and by sequence homology search, PDE8 followed by PDE9 were found 
to be closest homologs. Further, preliminary results using a cGMP-specific (PDE5), dual-
specificity PDE (PDE2), and two cAMP-specific (PDE8, PDE9) were tested for 
dissociation of cAMP bound to RI . Amongst them, PDE8 was successful in mediating 
cAMP release from the deletion construct of PKA-RI  (Krishnamurthy, Moorthy et al. 
2014). Hence, it is essential to study how these interactions (between PKA R-subunit and 
PDEs) succeed in dissociating cAMP bound to its receptors. A passive role of PDEs in 
cAMP signal termination by degradation of free diffusing cAMP molecules in cytoplasm 
has been characterized (Conti and Beavo 2007), but the dissociation and degradation of 
cAMP buffered by binding sites of receptors, and therefore in cAMP signal termination 
remains elusive. 
In this first chapter of this thesis, I monitor the release of cAMP tightly bound to 
PKA R-subunit by phosphodiesterase. To probe this, I have used a combination of amide 
hydrogen-deuterium exchange mass spectrometry for obtaining conformational dynamics 
of the proteins (Hoofnagle, Resing et al. 2003) and fluorescence polarization spectroscopy 
for monitoring the ligand mobility. This chapter describes the interaction between PKA 
R-subunits and PDEs, using the two model systems – (a) mammalian PKA-RI  and PDE8 
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and (b) D. discoideum PKA RD and RegA phosphodiesterase. By this combinatorial 
approach, we observed that PDEs mediate direct structural and functional interactions 
with R-subunit and enable cAMP release from R-subunit into its own active site. 
Following tables compare the binding affinities of cAMP with the two different R-
subunits and the catalytic properties of phosphodiesterases. 
 
Table 1.1: Dissociation constant values for affinity of cAMP to the two binding sites of 
PKA R-subunits from mammals and D. discoideum. 
  
R:cAMP affinity 
PKA Regulatory subunit KD for A:site KD for B:site 
RIα (mammalian) ~ 2 nM a ~ 1 nM a 
RD (D. discoideum) ~ 3 nM b ~ 1 µM * 
    a(Doskeland and Ogreid 1981); b(De Gunzburg, Part et al. 1984); *Chapter 2 
Table 1.2: Kinetic constants for enzyme turnover rate (kcat) and substrate affinity (KM) for 
phosphodiesterases from mammals and D. discoideum. 
Phosphodiesterase kcat KM 
PDE8A1 (mammalian) a ~ 4 s-1 ~ 1.8 µM 
RegA (D. discoideum) ~ 4.45 min-1 c ~ 5 µM b 
     a(Wang, Yan et al. 2008); b(Bosgraaf, Russcher et al. 2002, Moorthy, Gao et al. 2011) 
1.2 MATERIALS & METHODS 
1.2.1 Reagents 
Chemically ultra-competent Escherichia coli BL 21 (DE3) bacterial strains used 
for protein expression were obtained from Life Technologies (Carlsbad, CA). TALON® 
cobalt resin for his-tagged affinity purification was from ClonTech (Mountain View, CA) 
while BioGel HTP hydroxyapatite beads from BioRad laboratories (Hercules, CA) and 
Glutathione-sepharose beads were from GE Healthcare life sciences (Marlborough, MA). 
Fluorescent analog of cAMP: 2′-fluo-AHC-cAMP (2′- (6- [Fluoresceinyl] 
aminohexylcarbamoyl) adenosine- 3', 5'- cyclic monophosphate) was acquired from 
Biolog Life Science Institute (Bremen, Germany). LC/MS grade acetonitrile, methanol, 
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and water were from Fisher Scientific (Waltham, MA); and trifluoro acetic acid (TFA), 
sequence analysis grade from Fluka BioChemika (Buchs, Switzerland). Deuterium oxide 
was from Cambridge Isotope Laboratories (Tewksbury, MA). All other reagents and 
chemicals were research grade and obtained from Sigma-Aldrich (St. Louis, MO). 
1.2.2 Expression and purification of RIα 
Full-length construct of bovine PKA regulatory subunit (PRKAR1A, UniProt ID: 
P00514) was cloned into pRSETa bacterial expression vector encoding ampicillin 
resistance gene and then transformed into E. coli BL21 (DE3) strain for protein expression 
and purification. Large volumes of bacterial culture induced by IPTG (500 µM) were 
grown overnight at 291 K in shaker incubator with constant shaking (180 rpm). Harvested 
bacterial pellet (10 g) was resuspended in lysis buffer (20 mM Tris-Cl pH 7.5, 150 mM 
NaCl, 5 mM β-ME) supplemented with protease inhibitor cocktail tablets and subjected 
to lysis by sonication for 20 min. Lysate was centrifuged at 17000 g for 30 min and the 
supernatant was incubated with pre-equilibrated TALON® cobalt resin for 3 h at 277 K 
with gentle shaking. Non-specific proteins bound to the resin were washed away with 
wash buffer (lysis buffer + 5 mM Imidazole) and RIα was eluted with elution buffer (lysis 
buffer + 250 mM Imidazole pH 7.5). Eluate fractions were subjected to further 
purification by size-exclusion chromatography using HiLoad 16/60 superdexTM 200 prep 
grade column with lysis buffer on AKTATM FPLC system (GE Healthcare, Marlborough, 
MA). The quality of the purified RIα was analyzed using denaturing SDS-PAG 
electrophoresis and quantified by Bradford colorimetric assay. During the bacterial 
growth, owing to the high-affinity interactions cAMP molecules bind to the over-
expressed regulatory subunit RIα and stay bound to it, even after purification procedure. 
1.2.3 Expression and purification of PDE8AC 
Catalytic domain of human PDE8A1 (UniProt ID: O60658) spanning residues 
472-829 was cloned into pETDuet-1 plasmid previously. Expression and purification of 
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catalytic fragment of PDE8A (Yan, Wang et al. 2009) was carried out by culturing the 
transformed E. coli BL21 (DE3) competent cells in super broth medium (25 g tryptone, 
15 g yeast extract, 5 g of sodium chloride), induced by IPTG (500 µM) and grown 
overnight (16 h) at 291 K with constant shaking. Harvested bacterial cell pellet was 
resuspended in lysis buffer (20 mM Tris pH 7.5, 100 mM NaCl, 5 mM β-ME) 
supplemented with protease inhibitor cocktail. It was then subjected to sonication for 20 
minutes and the lysate was centrifuged at 17000 g for 30 min to collect the inclusion body 
pellet. This pellet was then resolubilized in buffer (0.1 M Tris pH 8.0, 6 M Guanidinium 
Hydrochloride) and incubated at room temperature for 12 h on a rocker. Debris and 
membranous particles were cleared from unfolded proteins by centrifugation at 13000 g 
for 15 min. This supernatant was incubated with equilibrated TALON® resin for 3 h at 
277 K with constant stirring. Unbound proteins were collected and the resin was washed 
with 10 times bed volume wash buffer (0.1 M Tris-Cl pH 8.0, 8 M Urea) and 6x-histidine 
tagged denatured PDE8AC was eluted with elution buffer (0.1 M Tris pH 8.0, 0.5 M 
imidazole, 0.5 M arginine, 6 M urea).  
The concentration of above eluate was checked by Bradford assay and ~30 mg of 
unfolded PDE8AC was refolded in 1-litre buffer (0.5M Tris pH 7.0, 0.7 M L-Arginine, 
30% glycerol, 10 mM NaCl, 1 mM KCl, 10 mM DTT, 20 mM MgCl2, 20 mM MnCl2, 20 
µM ZnSO4) and incubated at 277 K undisturbed. After 3-4 days, soaked Bio-gel HTP 
hydroxyapatite beads were added to this solution and stirred for 1 h at 277 K for binding. 
Using a filter paper, beads were collected from solution and washed with wash buffer (20 
mM Tris-Cl pH 7.0, 100 mM NaCl) and the protein was eluted with HTP-elution buffer 
(50 mM Tris-Cl pH 7.0, 500 mM KH2PO4, 5 mM β -ME) and checked for purity by 
denaturing gel electrophoresis. Refolded PDE8AC protein was subjected to dialysis in 
dialysis buffer (20 mM Tris pH 7.5, 50 mM NaCl, 5 mM β-ME) with buffer changes after 
1, 3 and 12 h. Dialysed protein sample was further purified by ion-exchange 
chromatography (MonoQ 5/50 GL column) eluting with gradient of 0.1 M – 2 M NaCl in 
buffer (50 mM Tris-Cl pH 7.5, 5 mM MgCl2, 5 mM β-ME). Elution fractions were 
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collected and subjected to size-exclusion chromatography (HiLoad 16/60 Superdex 200 
pg column) on AKTATM FPLC system (GE Healthcare, Marlborough, MA).  
The quality of the purified PDE8AC fractions was determined by denaturing SDS-
PAG electrophoresis and quantified by Bradford colorimetric assay. The activity of 
refolded PDE8AC protein was checked by phosphodiesterase assay using BioMol 
malachite green phosphate assay kit (BioAssay systems, Hayward, CA). It was previously 
shown that deletion construct of PDE8A1 spanning the catalytic domain is functional like 
its full-length construct and does not require any modification for enzymatic activation 
(Wang, Yan et al. 2008, Yan, Wang et al. 2009, Krishnamurthy, Moorthy et al. 2014) . 
1.2.4 Expression and purification of RD 
 Full-length construct of cAMP-dependent protein kinase A regulatory subunit 
(RD) from Dictyostelium discoideum (UniProt ID: P05987) was first sub-cloned into 
IPTG-inducible bacterial expression pET28a plasmid and transformed into E.coli BL21 
(DE3) for protein expression and purification. Harvested bacterial cell pellet (15g) was 
resuspended in lysis buffer (20 mM Tris-Cl pH 7.5, 100 mM NaCl, 5 mM β-ME) and 
subjected to lysis by sonication for 20 min. Lysate was centrifuged at 17000 g for 30 min 
and supernatant was then incubated with pre-equilibrated TALON® cobalt metal affinity 
chromatography resin for 3 h with gentle stirring at 277 K. Non-specific proteins bound 
to resin were washed away with wash buffer (lysis buffer + 10 mM imidazole) and RD 
was then eluted in lysis buffer containing 300 mM imidazole. Eluate was subsequently 
subjected to size exclusion chromatography on a HiLoad Superdex S-200 column using 
AKTATM FPLC (GE life sciences) as a finishing step. Purity of the purified RD was 
confirmed by SDS-PAGE and quantified by Bradford colorimetric method. We factored 
that cAMP in E. coli would bind to RD during growth and expression, but would dissociate 




1.2.5 Expression and purification of RegAC 
Deletion construct spanning the catalytic domain of cAMP-specific 
phosphodiesterase (385-780, henceforth referred to as ‘RegAC’) from Dictyostelium 
discoideum (UniProt ID: Q23917) was first sub-cloned into IPTG-inducible bacterial 
expression pGEX-4T plasmid and transformed into E.coli BL21 (DE3) for protein 
expression and purification (Moorthy, Gao et al. 2011). Harvested bacterial cell pellet 
(15g) was resuspended in lysis buffer (20 mM Tris pH 7.5, 150 mM NaCl, 5 mM MgCl2, 
5 mM β-ME) complemented with protease inhibitor cocktail tablet and subjected to lysis 
by sonication for 20 min. Lysate was centrifuged at 17000 g for 30 min and supernatant 
was then incubated with pre-equilibrated glutathione sepharose (GST) 4B resin (GE Life 
sciences, Marlborough, MA) for 3 h with gentle shaking at 277 K. Non-specific protein 
bound to resin were washed away with lysis buffer and RegAC was eluted with elution 
buffer (lysis buffer + 10 mM reduced glutathione). Eluate was subsequently subjected to 
size exclusion chromatography on a HiLoad Superdex S-200 column using AKTATM-
FPLC (GE life sciences) as a finishing step. Purity of the purified RegAC was confirmed 
by SDS-PAGE and subsequently quantified by Bradford colorimetric method. Active 
RegAC was confirmed by phosphodiesterase assay using BioMol malachite green 
phosphate assay kit (BioAssay systems, Hayward, CA). 
1.2.6 Amide hydrogen-deuterium exchange mass spectrometry 
(i) To monitor cAMP release from mammalian PKA R-subunit (RIα) 
In order to monitor the dynamics of RIα and PDE8AC-dependent cAMP 
dissociation, amide hydrogen-deuterium exchange mass spectrometry (HDXMS) 
experiments were performed which provides a near amino acid resolution of the 
conformational dynamics of the proteins in the complex. In the first set of experiments 
intrinsic dynamics and deuterium uptake profile of purified RIα (1.5 µM) was carried out 
without addition of any external cAMP. During the bacterial, cAMP binds to RIα and 
stays bound to it even after the purification process. To map the effects of PDE8AC on 
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RIα, saturating concentrations of PDE8AC (4.5 µM) to RIα (1.5 µM) were maintained in 
30 µl reaction volumes. To monitor the protein-protein interaction from initial time, both 
proteins were mixed together with deuterated buffer (final concentration 90%) for varied 
labeling times – 0.5, 1, 5, 10, 30, 60 and 100 minutes. In parallel, to map the effects of 
complexation on PDE8AC, HDXMS experiments for free PDE8AC (1.5 µM) and with 
three times excess RIα (4.5 µM) were carried out, all other conditions being same. Each 
hydrogen-deuterium exchange reaction was done at room temperature and in triplicates. 
After the stipulated time, the exchange reactions were quenched to final pH ~ 2.5 using 
20 µl of trifluoro acetic acid solution. 
(ii) To monitor cAMP dissociation from slime mold’s PKA R-subunit (RD) 
Previously, RegA mediated dissociation of cAMP from RIα were carried out 
(Krishnamurthy, Moorthy et al. 2013). Likewise, cAMP dissociation from RD was tested 
with a deletion construct spanning the catalytic domain of phosphodiesterase RegA. In 
this set of HDXMS experiments, deuterium labeling experiments were carried out in 40 
µl reaction volumes with 90% D2O final concentration. Conformational dynamic profiles 
of apo RD (5 µM) and with excess cAMP (330 µM) were initially obtained as control 
experiments. Next, excess RegAC (10 µM) was added to each condition of RD (apo and 
cAMP-excess states) with simultaneous addition of the deuterated buffer (99.9% D2O, 20 
mM Tris-Cl pH 7.2, 100 mM NaCl, 1 mM MgCl2, 10 µM ZnSO4, 5 mM β-ME) to capture 
the conformational changes on RD. Similarly, parallel HDXMS experiments were carried 
out to observe conformational dynamics of RegAC, where excess cAMP-saturated RD was 
incubated with RegAC followed by deuteration reactions. Deuterium exchange reactions 
were performed in triplicates, at room temperature for various time points – 0.5, 1, 2, 5, 
10, 30, 60 and 100 min and quenched with 10 µl of chilled 0.1% TFA.  
(iii) Protein digestion by pepsin followed by UPLC-MS 
Total volume of 50 µl quenched protein samples (pH ~ 2.5) were serially injected 
to nano-ultra performance liquid chromatography (nano-UPLC) sample manager (Wu, 
Engen et al. 2006) and subjected to cleavage into proteolytic fragments by immobilized 
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pepsin column (Poroszyme, ABI, Foster City, CA) with continuous flow of 0.1% formic 
acid in LC-MS grade water (pH 2.5, 0.1% formic acid) at 100 l/min flow rate. Peptic 
peptides were then trapped on to VanGuard reverse-phase 2.1 x 5mm C-18 trap 
(ACQUITY BEH, Waters, Milford, MA) liquid chromatography column. Peptides were 
eluted using 8-40% gradient of acetonitrile in 0.1% formic acid (pH 2.5) at 40 l/min flow 
rate, pumped by nano-ACQUITY binary solvent manager (Wales, Fadgen et al. 2008). 
For PDE8AC:RIα experimental sets, the chromatographic column was coupled to 
SYNAPT G2-Si mass spectrometer, while for RegAC:RD complex the LC was coupled to 
SYNAPT G1 mass spectrometer (Waters, Milford, MA); acquired in MSE mode to detect 
the peptides and measure their masses. Mass spectrometer was continuously calibrated 
with 200 fmol/l of Glu-fibrinopeptide B (Glu-Fib) standard at a flow rate of 5 l/min. 
(iv) Peptide identification and analysis for HDXMS experiments 
The digested peptides from undeuterated controls were then identified using 
Protein Lynx Global Server (PLGS v3.0) software (Waters, Milford, MA). Peptides were 
matched and identified from primary sequence database of the individual proteins and 
considered only if they appeared twice amongst the triplicates with a minimum of four 
fragment ion digests. The peptides identified from undeuterated controls were then used 
to map the deuteration profiles of all other deuterated samples using DynamX v2.0 
(Waters, Milford, MA). Each peptide was then analyzed at every time point in different 
reaction states and peptides with non-overlapping spectra and high signal-to-noise ratio 
only were considered for quantitative analysis and data interpretation. Isotopic envelope 
of each peptide reflected by its centroid mass was then compared with centroid value of 
the undeuterated sample and a ± 0.5 Da difference was considered significant (Houde, 
Berkowitz et al.). All values reported are not corrected for back-exchange factor and each 





1.2.7 Fluorescence Polarization Spectroscopy of RegA:RD 
To monitor the release of cAMP from RD by direct interactions with RegA, 
fluorescence polarization assay (Huang, Zhang et al. 2002, Rossi and Taylor 2011) was 
performed using phosphodiesterase susceptible fluorescent analog of cAMP – 2′-fluo-
AHC-cAMP (2'- (6- [Fluoresceinyl] aminohexylcarbamoyl) adenosine- 3', 5'- cyclic 
monophosphate). Excess of 2′-fluo-cAMP (2 mM) was added to purified RD and incubated 
for 24 h at 277 K with constant slow mixing and later removed by gel filtration 
chromatography HiLoad 16/60 Superdex 200 pg on AKTATM FPLC system. Fluorescence 
polarization (FP) assays were performed in 96-well opaque black plates from Greiner Bio-
One (Frickenhausen, Germany) using Synergy 4 multi-detection microplate reader 
(BioTek, Winooski, VT) operated in FP mode. Excitation and emission wavelengths used 
were 485 nm and 524 nm respectively, with 20 nM bandwidth. All FP experiments were 
done for 2′-fluo-cAMP saturated RD, henceforth referred as 2′-fluo-cAMP:RD (5 µM) at 
298 K. For the first set of experiments, cAMP (330 µM) and RegA (5 µM) were added 
separately to 2′-fluo-cAMP:RD at t = 0 min and t = 20 min as indicated in different sample 
sets and FP readings were collected every two minutes for total time of 100 min. Control 
polarization values of 2′-fluo-cAMP (2 µM) and RegA (5 µM) were also monitored to get 
a reference baseline. All experiments were performed in biological and technical 
triplicates and an average of these was used to plot the graphs using GraphPad Prism 5.0 
(San Diego, CA). 
1.3 RESULTS 
1.3.1 Real-time reaction monitoring of RIα and PDE8 shows cAMP release from both 
CNB domains 
Direct interactions between a deletion construct of mammalian PKA R-subunit 
(RIαAB) and PDE8 have been reported to facilitate cAMP dissociation from the CNB 
domains via proximity of the active sites of the two proteins (Krishnamurthy, Moorthy et 
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al. 2014). However, an end-state of the reaction was reported without describing the 
details or the mechanism of cAMP release. To describe the process of interaction and 
release of cAMP, a real-time measurement of the protein dynamics in the complex was 
necessary. In order to investigate this process, HDXMS experiments were performed for 
purified RIα, with and without a large excess of cAMP added externally and for 
PDE8AC:RIα complex for different labeling times. As RIα binds tightly with cAMP, its 
CNB sites get loaded cAMP during the bacterial growth and remain bound even after the 
purification process. The complex formation was initiated by adding PDE8AC to purified 
RIα (without any external cAMP) simultaneously with deuterium buffer and the reaction 
was then monitored for different hydrogen-deuterium labeling times.  
Peptides specific to the cAMP binding regions of both CNB domains of RIα 
(Anand, Hughes et al. 2002, Badireddy, Yunfeng et al. 2011) are only represented in this 
section. While cAMP binding loci in purified RIα and excess cAMP-RIα states showed 
inherent deuteration to some extent, addition of PDE8AC exhibited drastic increases in 
deuterium uptake of the same regions as shown by the deuterium uptake plots in Fig. 1.1 
(A and B). Upon closer examination of PDE8AC:RIα complex spectra, peptides spanning 
cAMP binding pockets exhibited a bimodal pattern of the mass spectra (Fig. 1.1C, D) at 
lower labeling times. Bimodal distributions are characteristic of EX1 regimes of 
hydrogen-deuterium exchange kinetics of slow protein unfolding and refolding within the 
time scale of this experiment (Weis, Wales et al. 2006); or denote that a particular peptide 
may simultaneously exist in two or more different conformations (Wang, Morgan et al. 
2012) simultaneously. For PDE8AC:RIα binary complex, we observed bimodal 
distributions of mass spectra at shorter labeling times, which can be attributed to the low-
exchanging ligand-bound and high-exchanging ligand-free conformations of these 
peptides.  
At lower exchange times complex formation occurs, which induces 
conformational changes in RIα, therefore representing only the initiation of the reaction 
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and hence the cAMP-bound conformation appears to be the dominant (blue shaded area, 
Fig. 1.1C, D) population. With time progression, the effects of PDE8AC interaction 
facilitate dissociation of cAMP from RIα. By 30 minutes, the bimodal profiles diminished 
leading to unimodal binomial distribution of high-exchanging cAMP-free conformation 
only, as observed in Fig. 1.1C, D (green shaded area) indicating dissociation of all cAMP 
from RIα. These results are also evident from the centroid shifts observed between these  
 
Figure 1.1: Real-time reaction monitoring of PDE8 mediated cAMP dissociation from RIα. (A, 
B) Kinetic plots from HDXMS results depicting the deuterium uptake by peptides spanning 
CNB:A (203-218) and CNB:B (329-337) at different deuterium labeling times for RIα (●), cAMP-
saturated RIα (▲) and PDE8AC:RIα (■) states. An average of three independent deuterium 
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exchange experiments with standard deviations are indicated. Plots were generated using 
GraphPad Prism 5.0. (C, D) Mass spectra of two representative peptides from CNB:A (C) and 
CNB:B (D) domains at different labeling times are stacked over each other. Each panel consists of 
isotopic distribution profiles from RIα and PDE8AC:RIα. In PDE8AC:RIα complex, initial labeling 
reactions are dominated by a lower-exchanging population of RIα (blue shaded area) and longer 
labeling times are dominated by a higher-exchanging population of RIα (green curved area). Mass 
shifts between different states at different times are indicated by centroids, represented by red 
triangles. Mass spectra of undeuterated controls are also shown. Spectral plots were generated from 
DynamX v2.0 (Waters, Milford, MA). 
 
 
states, reflecting the different conformations. Conclusively, cAMP gets released from 
both the binding pockets of R-subunit only in the presence of PDE8AC. 
Similarly, HDXMS experiments were also carried out to map simultaneous 
changes on PDE8AC protein of the PDE8AC:RIα binary complex. As described in the 
methods section an excess of RIα was used to maintain all PDE8AC in the complex form. 
Peptides spanning the substrate recognition and hydrolysis sites (Russwurm, Schlicker et 
al. 2011) were specifically analyzed to probe the dynamics of the active complex. A 
comparison of deuterium exchange kinetics between the free- and bound- states of 
PDE8AC is summarized as a difference plot in Fig.1.2. Consistent with our expectations, 
the catalytic core (H-loop, blue box) showed an initial decrease in deuterium exchange in 
PDE8AC, corresponding to complexation with RIα. With reaction progression these 
peptides of H-loop showed increased deuterium uptake at later stages, indicating that 
cAMP was hydrolysed.  Inversely, the cAMP binding residues (pink box) of PDE8AC 
showed an initial increase, followed by a progressive decrease in deuterium uptake, 




Figure 1.2 HDXMS results showing complementary changes on PDE8 during reaction-
monitoring. Difference plot showing differences in average number of deuterons (Y-axis) 
exchanged between PDE8AC:RIα complex relative to free PDE8AC protein with pepsin fragments 
listed from N- to C- terminus for the deletion construct of PDE8A. The catalytic site (H-loop) is 
highlighted in blue, sites with PKAR interaction in green and the substrate binding and recognition 
sites in pink. Positive differences indicate increased dynamics and negative differences indicate 
protection in PDE8AC:RIα complex. Deuterium labeling time for every peptide is depicted and 
colored according to key and gray area represents the standard deviations between the three 
deuterium exchange experiments. Plots were generated using DynamX 2.0 software (Waters, 
Milford, MA). 
 
Further, the regions of PDE8AC known to interact with RIα showed decreased 
deuterium exchange in the complex state (green box, Fig. 1.2), throughout the labeling 
times, inferring that a stable complex was formed between the two proteins. Together, 
these observations confirm the interactions within the ternary complex and indicate the 
translocation of cAMP molecules from RIα to PDE8AC. Most importantly, the changes 
observed in PDE8AC are complementary to the concurrent changes observed in RIα for 
different times. These simultaneous changes on both proteins and cAMP translocation 
from RIα to PDE8 can only occur when the cAMP-binding sites of RIα and catalytic sites 
of PDE8 are coupled, as proposed previously via a ‘substrate channeling’ model 
(Krishnamurthy, Moorthy et al. 2014). 
1.3.2 Dynamic interactions between RD and RegAC mediate cAMP release 
 Alike mammalian cAMP signaling, generating cAMP-free RD is very important 
to inactivation of PKA C-subunit for normal growth and development of D. discoideum 
cells. To probe the role of RegA phosphodiesterase, we first monitored the dissociation 
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of cAMP from RD by complexing it with RegAC and measuring the hydrogen-deuterium 
exchange as the reaction progresses. Time-dependent dynamics of cAMP binding regions 
of RD, under different experimental conditions: apo RD, RD:cAMP and RegAC:RD:cAMP 
were compared. Peptides spanning both the CNB domains were considered, and at all 
labeling times apo RD showed most deuterium exchange when compared to cAMP-
saturated RD state, as shown in Fig. 1.3 A, B. Although cAMP is removed from RD during 
the in vitro protein purification process, physiologically high concentration of cAMP 
exists intracellularly that does not dissociate easily from RD. In the presence of cAMP, RD 
showed decreased dynamics even after 100 min of deuterium exchange. Notably, like the 
cytoplasmic state of RD, there was no intrinsic dissociation of cAMP from RD as evident 
from the decreased deuterium exchange in cAMP binding regions (open circle plot, Fig. 
1.3A, B) throughout the various labeling times. Our current findings, therefore are 
consistent with cAMP binding induced rigid conformation of both the CNB domains in 





Figure 1.3: Real-time reaction monitoring of RegA mediated cAMP release from RD by 
HDXMS. (A, B) HDXMS kinetic plots showing number of deuterons exchanged by peptides 
spanning CNB:A (residues 138-150) and CNB:B (266-274) at different deuterium labeling times, 
in a semi-logarithmic plot. Deuterium uptake plots for apo RD (○), RD:cAMP (●), RegAC:RD (□), 
RegAC:RD:cAMP (◼) are shown as indicated in the key. Each value is an average of three 
independent deuterium exchange experiments with standard deviations also shown. (C, D) Mass 
spectra for the two representative peptides of CNB:A (C) and CNB:D domains (D) are stacked 
over each other for three deuterium labeling times (1, 10 and 30 min) for apo RD and 
RegAC:RD:cAMP states. Red triangles represent the centroids. Plots were generated from DynamX 
v2.0 (Waters, Milford, MA). 
 
 
Previously, it has been shown that RegA mediates cAMP dissociation from 
mammalian R-subunit (Krishnamurthy, Moorthy et al. 2013) via a two-step process of 
release and hydrolysis. Here, we show RegAC mediated real-time dissociation of cAMP 
from RD of D. discoideum. To monitor the cAMP release and hydrolysis in real-time, 
complexation was initiated simultaneously with deuteration reaction for various labeling 
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times - 0.5, 1, 2, 5, 10, 30, 60, 100 minutes. Compared to the deuterium exchange kinetics 
of cAMP-saturated RD, RegAC:RD:cAMP ternary complex showed decreased exchange at 
10 minutes or lower deuterium labeling times in both CNB:A and CNB:B domains, 
indicating cAMP was still bound to RD (closed squares, Fig. 1.3A, B). However, a gradual 
increase in deuterium exchange was seen for deuteration times longer than 10 minutes. 
Deuterium uptake at these regions of RegAC:RD:cAMP ternary complex was similar to 
apo RD but greater than cAMP-saturated RD. This is evident from the centroids of the 
mass spectra shown for representative peptides from the two CNB domains of RD (Fig. 
1.3C, D) at different labeling times. The increased deuterium exchange for 
RegAC:RD:cAMP ternary complex, therefore indicates that RegAC facilitated the 
dissociation of cAMP from RD.  
Parallel changes on RegAC were also monitored during their reaction progression. 
HDXMS experiments were performed for free RegAC and RegAC:RD complex with and 
without cAMP added externally and the deuterium uptake plots of representative peptides 
are shown in Fig. 1.4. Three peptides were selected to monitor cAMP binding of which 
two peptides - residues 643-651 and 676-693, span the substrate recognition and binding 
 
Figure 1.4: Kinetic plots from RegA indicate cAMP binds to RegA in RegA:RD:cAMP ternary 
complex. Deuterium uptake plots for three representative peptides of RegAC are shown. Two 
peptides spanning residues 643 – 651 and 676 - 693 are involved in substrate recognition and 
binding, while third peptide 717 – 728 spans the lid-region. Plots are shown for free RegAC (△), 
RegAC with cAMP (▲), RegAC:RD complex (○) and RegAC:RD:cAMP ternary complex (●) at 
different labeling times as indicated in semi-logarithmic plots. Each value represents and an 
average of three independent deuterium exchange experiments along with their standard 




sites on RegAC (Thomason, Traynor et al. 1998, Palsson 2009). The third peptide (717-
728) spans the lid-region that covers the active site opening. In these peptides, we 
observed decreased deuterium exchange in RegAC:RD:cAMP ternary complex state when 
compared to free or cAMP-saturated RegAC. While cAMP binding induced no changes 
in free RegAC, it leads to conformational changes in the bound form of RegAC 
(RegAC:RD:cAMP). Along with these, the lid-region forms a part of the interaction-
interface of the complex. For free RegAC, cAMP entry/exit is unobstructed, while in the 
ternary complex RD restricts free entry or exit of ligand to/from the surroundings. Thus, 
decreased deuterium exchange in these regions of RegAC in ternary complex state and not 
in free RegA clearly show that cAMP released from RD gets directly translocated to the 
catalytic site of RegAC. These real-time monitoring experiments of RD and RegAC show 
that RegA mediates dissociation of cAMP from RD by directly interacting with it. 
Together, these results highlight two important points – (i) dissociation of cAMP 
in D. discoideum follows different kinetics of interaction and release, as RegA mediated 
cAMP release was observed only after 10 min and (ii) RegA mediated cAMP release from 
RD and subsequent hydrolysis occurs through a different mechanism, probably consistent 
with the two-step process proposed earlier. 
1.3.3 Fluorescence polarization shows RegA induces cAMP release from RD 
 To confirm this release of cAMP bound to RD via complexation with RegA and 
understand the mechanism, we further performed a biochemical enzyme assay which 
monitors the ligand’s microenvironment. Here, using a fluorescent cAMP analog 2′-fluo-
AHC-cAMP fluorescence polarization spectroscopy was carried out between RegA and 
RD. Fluorescence polarization spectroscopy measures the changes in anisotropy or 
polarization of a fluorescent ligand as it associates/dissociates or toggles from one protein 
to another (Huang, Zhang et al. 2002, Rossi and Taylor 2011). Firstly, within the 
experimental time-scale (100 min), intrinsic dissociation of the ligand was not observed 
for RD saturated with 2′-fluo-cAMP, henceforth referred to as 2′-fluo-cAMP:RD (green 
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plot, Fig. 1.5). When excess non-fluorescent cAMP was added to 2′-fluo-cAMP:RD, we 
observed gradual decrease in polarization values, indicating that cAMP displaces the 
fluorescent analog (light and dark blue plots, Fig. 1.5).  
 
Figure 1.5: Fluorescence polarization of RD shows RegA mediated cAMP release. Fluorescence 
polarization spectroscopy using PDE-hydrolysable analog monitors RegA mediated cAMP release 
and hydrolysis from RD. To 5 µM of 2′-fluo-cAMP saturated RD (●), cAMP (330 µM) was added 
at 0 min (□) and 20 min (■); RegA
C
 (10 µM) was added at 0 min (◆) and 20 min (▲) as indicated 
in the key. Vertical dashed line indicates the addition of different samples to respective reactions 
sets at 20 min. Time plots of polarization were generated using GraphPad Prism 6.0 (San Diego, 




Fluorescent 2′-fluo-AHC-cAMP is a PDE susceptible analog, i.e., the cyclic 
phosphate bond can be hydrolysed by phosphodiesterases, but still retains its fluorescence. 
Hence, RD was saturated with this phosphodiesterase RegA susceptible analog was 
employed to monitor the release of cAMP from RD. Dissociation of cAMP was tested by 
adding RegA at two time points (0 and 20 min) in two different reaction sets. For both 
sample sets, we observed a constant decrease in fluorescence polarization values for 2′-
fluo-cAMP:RD:RegA, as shown in Fig. 1.5 (red and orange plots). Interestingly, the drop 
in the polarization of this sample set differed from the drop in fluorescence polarization 
observed for cAMP-treated 2′-fluo-cAMP:RD. This highlights that RegA-susceptible 
fluorescent cAMP analog is dissociated from RD, but is now translocated to RegA and 
gets hydrolysed to product 2′-fluo-AMP. Therefore, different polarization intensities 
 44 
 
between the end-states of cAMP- treated and RegA- treated 2′-fluo-cAMP:RD confirms 
that cAMP gets dissociated from RD via direct interactions with RegA and gets directly 
translocated to the catalytic site of RegA, by ‘active-site coupling’ model similar to the 
mammalian system. 
1.4 DISCUSSION 
Signal termination of the cAMP-PKA signaling pathway is crucial for restoring 
the cellular balance and ready it for sensitization by subsequent stimuli. Unbinding of 
cAMP from PKA R-subunits is essential for reassociation with PKA C-subunits and we 
have uncovered a novel role of phosphodiesterase in this regard. We have previously 
proposed an active-site coupling model for the interaction between the deletion constructs 
of PKA R-subunits and PDEs that show distinct conformational changes in both PKAR 
and PDE at the end of the reaction. In this section of my study, I have focussed in 
determining the temporal kinetics of cAMP removal from R-subunits by PDEs during 
their interaction. By using two different model systems, we have obtained certain insights 
into the regulatory mechanisms for cAMP-PKA signaling in lower and higher eukaryotes. 
Firstly, I will discuss the results obtained for monitoring the cAMP dissociation in 
mammalian PKA and PDE system, followed by a discussion of mode of cAMP unbinding 
by their homologs from D. discoideum.  
Detailed changes in the cAMP binding pockets of both CNB domains were 
examined during the PDE8AC:RIα interaction by monitoring their real-time reaction 
progression and are compared to the dynamics of free proteins. Intrinsic dissociation of 
cAMP from RIα was not observed as the dynamics of purified and cAMP-excess RIα did 
not differ significantly. However, when PDE8AC was added, the initial dynamic 
equilibrium between RIα and PDE8AC lead to complex formation (discussed in later 
sections), which subsequently induced conformational changes in both the proteins. Much 
higher deuterium uptake in the PDE8AC:RIα complex, for the peptides spanning both 
cAMP binding pockets (A and B) indicate that cAMP gets released from RIα only in the 
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presence of PDE8AC. A possible mechanism to explain these observations is by coupling 
of the cAMP binding site on RIα with the catalytic site of PDE8AC, and the current real-
time assay results are in good agreement with it.  
During the complexation, cAMP removal from RIα is initiated around 5 minutes 
of their incubation and gets completed by 30 minutes. The bimodal distribution of the 
mass spectra of peptides from CNB regions are evidence of this phenomenon. The low-
exchanging cAMP-bound conformation of RIα in complex gets morphed to the high-
exchanging population of cAMP-free conformation. Moreover, slight delay in 
dissociation-hydrolysis kinetics of cAMP was observed between the two cAMP binding 
sites, with CNB:A showing a faster turnover and CNB:B showing a slower turnover rate. 
This difference highlights the asymmetry between the two ‘coupled’-sites between PDE8 
and RIα, suggesting cAMP gets first released from the CNB:A site, followed by release 
from CNB:B site.  
A very important consideration in this interaction is to observe the concomitant 
change in PDE8AC, which would thereby confirm cAMP removal. When the interaction-
interface was mapped for dynamic changes on PDE8AC, significant changes in deuterium 
exchange were observed in peptides spanning cAMP binding regions with residues 
associated with recognition of cAMP initially showing decreased deuterium uptake 
followed by increased uptake at later times. The C-terminus of PDE8AC comprises of lid-
region confirms the substrate as cAMP and then gets swayed away from the opening of 
the catalytic core. Conformational changes in the protein-protein complex then sequester 
cAMP to PDE8’s catalytic site as observed by decreased deuterium uptake by the binding 
residues. Combining the concurrent time-dependent changes in dynamics of cAMP 
binding regions in RIα and PDE8AC, it is safe to conclude that cAMP gets released from 
RIα only during interaction with PDE8AC. As shown in subsequent chapters, excess 
cAMP concentrations are also true to this mechanism, wherein PDE8AC facilitates 
complete removal of cAMP. 
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 Interestingly, the dissociation kinetics of cAMP from R-subunit of D. discoideum 
followed a different tangent. As inferred from the results section, RegAC mediated cAMP 
release from RD is a slower process than the mammalian system. While constant changes 
were observed for PDE8AC:RIα complex highlighting their dynamic interactions from the 
onset of the reaction, a sudden increase in deuterium uptake was seen after 10 min for the 
RegAC:RD complex reaction. These differences are interpreted from their HDXMS 
results, where PDE8AC:RIα complex is characterized by bimodal kinetics, and RegAC:RD 
show unimodal binomial distribution profiles. According to the HDXMS results, for the 
first 10 minutes, RD exists in similar conformations in RegAC:RD:cAMP ternary complex 
and cAMP-saturated RD (no differences in the centroid values). As the reaction progresses 
RegAC mediates cAMP release from RD. This is similar to the effect of RegA activity seen 
in live D. discoideum cells, which take approximately 15 minutes to get desensitized from 
the effect of a stimulus (Tyson and Murray 1989).  
The dissociation of cAMP from RD in the presence of RegA was clearly visible 
from the fluorescence polarization spectroscopy results. No intrinsic dissociation of 
cAMP from RD suggests their high-affinity interactions and thus necessitates a different 
route for cAMP release. It is only upon the addition of RegA, conformational changes are 
induced in cAMP binding regions of RD that lead to dissociation of fluorescent cAMP 
analogs from RD. Furthermore, the fluorescence polarization assay also indicates that the 
dissociated cAMP is directly translocated to the catalytic site of RegA and gets 
hydrolysed. This is consistent with the previously proposed model for RegA mediated 






Phosphodiesterase and cAMP mediate 
allosteric changes in R-subunit, playing a key 
















Results from this chapter have been published 
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2.1 INTRODUCTION 
Signal transduction by cAMP in stimulated cells triggers a myriad of cellular 
responses. In social amoebae Dictyostelium discoideum, cAMP serves a dual role of 
chemoattractant and signaling molecule (intracellular and extracellular) mediating various 
physiological responses during cell growth and development, transforming from 
unicellular to multicellular form in starving conditions (Firtel and Chapman 1990, 
Reymond, Schaap et al. 1995, Mann, Brown et al. 1997). The main receptor of cAMP is 
Protein Kinase A (PKA). 
During the association of cAMP in the binding pockets of R-subunit, 
conformational changes are induced across R-subunit with extensive networking between 
many amino acid residues. Hydrogen-bonding, electrostatic coupling and hydrophobic 
interactions accompanied by structural rearrangements manifest cAMP binding to PKA 
R-subunit and PKA C-subunit release (Mutzel, Lacombe et al. 1987, Anand, Taylor et al. 
2007). This activation (Fig. 2.1 step 1) phase has been very well characterized by multiple 
structural approaches and highlights cooperativity between the two cyclic nucleotide 
binding domains (Kim, Cheng et al. 2007, McNicholl, Das et al. 2010). However, these 
static structural data only capture defined conformational states based on ligand 
occupancy and do not give a complete understanding of such a dynamic process.  
Just as activation, inactivation or dissociation of cAMP from R-subunit requires 
a series of inter-dependent events throughout the R-subunit (Fig. 2.1 steps 3 and 4). A 
reverse sequence of the activating mechanism is plausible to dislodge cAMP from its 
binding site. Though each domain binds cAMP with high affinity, differences between 
the domains CNB:A and CNB:B play an important role. The B-site (CNB:B) has lower 
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affinity but a slow dissociation rate compared to CNB:A, which exchanges cAMP faster 
(Ogreid, Ekanger et al. 1989). While CNB:A is critical for binding to PKA C-subunit, 
CNB:B acts a ‘gate-keeper’ for CNB:A and allows cAMP binding in A-site only if cAMP 
is bound to the B-site (Kim, Cheng et al. 2007). This interdependence of cAMP binding 
domains plays a significant role in activation of PKA holoenzyme by cAMP binding and 
is manifested by allosteric changes across the two domains and thereby leading to 
conformational changes (Taylor, Kim et al. 2005). 
 
 
Figure 2.1: Activation and Termination phases of cAMP-PKA signaling in Dictyostelium. To an 
inactive PKA holoenzyme complex, two molecules of cAMP (red spheres) bind to PKA R-subunit 
(purple) and mediate dissociation of PKA C-subunit (cyan), thereby activating it (1). 
Phosphodiesterases catalyze cAMP hydrolysis, and potential direct interactions with PKA R-
subunit (2) is suspected to mediate cAMP dissociation from PKA R-subunit (3) and this cross-talk 
releases hydrolyzed product 5′-AMP (yellow). The cAMP-free R-subunit is now able to reassociate 
with C-subunit (4) to form PKA holoenzyme and thus terminating the cAMP-PKA signaling 
pathway. The current chapter focusses on interactions between R-subunit and RegA of D. 
discoideum and is highlighted by a red dashed circle. 
 
Furthermore, the cAMP-free state of R-subunit generated by mutagenesis (or as deletion 
constructs) also stresses on this allosteric mechanism. Interestingly, no major structural 
differences were seen in orientations/interactions of amino acid residues in the cAMP 
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binding pockets between cAMP-bound and cAMP-free states (Su, Dostmann et al. 1995). 
Therefore, dissociation of cAMP from R-subunit must involve inverse allosteric 
interactions between the two domains. We have earlier shown that the catalytic domain 
of RegA (RegAC) is sufficient for hydrolysis of cAMP tightly bound to a deletion 
construct of mammalian R-subunit, RIαA (Moorthy, Gao et al. 2011) and the RegAC 
mediated cAMP dissociation (Fig. 2.1 steps 2 and 3) was proposed to undergo two-step 
mechanism (Krishnamurthy, Moorthy et al. 2013). It is well established that PKA R-
subunits are essential in regulating the PKA C-subunit activity, however, the mechanism 
of cAMP release from RD in live cells is yet uncharacterised. Further, how signals in the 
cAMP signaling pathway converge and branch off from a target through alternate 
allosteric pathways is also of enormous interest. 
In this chapter, I monitor the complexation of RD and RegA in the absence and 
presence of cAMP towards describing the mechanism of cAMP release. Amide 
hydrogen/deuterium exchange mass spectrometry (HDXMS) was used to monitor slow 
conformational transitions in RD, using disordered regions as conformational probes and 
fluorescence polarization spectroscopy was used as a reporter of interaction of ligands 
with the proteins and/or complex. 
2.2 MATERIALS AND METHODS 
2.2.1 Materials 
 A plasmid encoding full-length RD with codon optimization for E. coli expression 
was obtained from DNA2.0 (Menlo Park, CA). Chemically competent E. coli BL21 (DE3) 
bacterial strains were from Life Technologies (Carlsbad, CA). TALON Cobalt affinity 
resin for His-tag purification was from Clontech laboratories (Mountain View, CA) and 
Glutathione-sepharose 4B resin was from GE Healthcare life sciences (Marlborough, 
MA). A fluorescent PDE-resistant analog – 8-[fluo]-cAMP (8- (2-[Fluoresceinyl] 
aminoethylthio) adenosine- 3', 5'- cyclic monophosphate) was acquired from Biolog Life 
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Science Institute (Bremen, Germany). LC/MS grade acetonitrile and water were from 
Fisher Scientific (Waltham, MA). Poroszyme immobilized pepsin cartridge was from 
Applied Biosystems (Foster City, CA); Deuterium Oxide (99.9%) was from Cambridge 
Isotope Laboratories (Tewksbury, MA). All other reagents were research grade from 
Sigma-Aldrich (St. Louis, MO).  
2.2.2 Expression and purification of proteins RD and RegAC 
 Full-length construct of cAMP-dependent protein kinase A regulatory subunit 
(RD) and deletion construct of phosphodiesterase RegA from D. discoideum were 
expressed and purified according to protocol described in chapter 1. For purified RD 
protein, we factored that cAMP in E. coli would bind to RD during growth and expression, 
but would dissociate during size exclusion chromatography to generate apo RD (cAMP-
free). The activity of purified RegAC was tested for its activity using phosphodiesterase 
assay kit (BioAssay systems, Hayward, CA). 
2.2.3 Isothermal Titration Calorimetry 
Isothermal titration calorimetry (ITC) measurements were performed to 
determine the dissociation constant of cAMP and RD using a VP-ITC MicroCalorimeter 
(Microcal Inc., Northampton, MA). The cell reservoir was filled with 1.8 ml of 10 µM RD 
protein, reference cell with 1.8 ml of buffer (20 mM Tris-Cl pH 7.5, 100 mM NaCl) and 
syringe with final volume ~400 µl of 200 µM cAMP prepared in the same buffer. Titration 
was started with first injection of 2 µl followed by 39 sequential injections each of 4 µl 
cAMP at intervals of 240 s and set to a stirring speed of 350 rpm. Continuous titrations 
were carried out to determine the enthalpy change during ligand-binding and its 
equilibrium association and dissociation constants. Three independent titration 
experiments were carried out at 298 K with similar results and the values represented were 




2.2.4 Amide hydrogen/deuterium exchange mass spectrometry 
 To test the effects of cAMP binding to free apo RD, deuterium exchange 
experiments were carried out for cAMP-free (apo) RD (4 µM) and cAMP (330 µM). This 
high concentration of cAMP was used to fully saturate the CNB:A site and also the 
CNB:B site which was predicted to bind at lower than µM concentrations of cAMP. To 
capture conformational dynamics of apo RD present as a binary complex with RegAC, 
RegAC (2 µM) was complexed with apo RD (6 µM) in a 1:3 molar ratio. A ternary complex 
of RD, cAMP, and RegAC was obtained by complexing RegAC (2 µM) with apo RD (6 
µM) in the presence of 330 µM cAMP. In each experimental state, complexation was 
initiated by simultaneous addition of the components along with deuterium exchange 
reaction in the presence of the deuterated buffer. 
 The buffer for deuterium exchange was prepared by dehydrating aqueous buffer 
(20 mM Tris-Cl pH 7.5, 100 mM NaCl) in a vacuum evaporation system overnight until 
dry followed by reconstitution in 99.9% D2O to obtain the deuterated buffer (pH 7.5). 
Each reaction was done in triplicates with deuterium exchange carried out for the 
following times: 0.5, 1, 5, 10, 30, 60 and 100 minutes. Hydrogen-deuterium exchange 
reaction was quenched by lowering the pHread to 2.5, using 0.1% trifluoro acetic acid 
solution. Samples were then injected onto a nano-UPLC HDX sample manager (Waters, 
Milford, MA) followed by pepsin digestion and reverse phase liquid chromatography as 
described previously in chapter 1. Peptides showing EX1 kinetics of amide exchange were 
additionally analyzed using GraphPad Prism 6.0 (San Diego, CA). The bimodal 
deconvolutions were carried out by fitting the curves to a sum of the Gaussian equation. 
2.2.5 Fluorescence polarization spectroscopy of RD and RegA with fluorescent analog 
of cAMP 
To determine the role of cAMP in RD and RegA interactions, fluorescence 
polarization assay (Rossi and Taylor 2011) was performed to obtain a ligand-based 
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functional readout of the complex. Fluorescence assays were implemented using a PDE-
resistant analog – 8-[fluo]-cAMP that binds with high affinity to both cAMP-binding sites 
of PKA R-subunit (Ogreid, Ekanger et al. 1989, Rossi and Taylor 2011). Purified full-
length RD was saturated with the 8-[fluo]-cAMP (2 mM) and incubated for 24 h at 277 K 
with constant slow mixing. Unbound ligands were removed by size exclusion 
chromatography using HiLoad 16/60 Superdex 200 pg on AKTATM FPLC system (GE 
Life sciences). Fluorescence polarization (FP) assays were performed in 96-well opaque 
black plates from Greiner Bio-One (Frickenhausen, Germany) using Synergy 4 multi-
detection microplate reader (BioTek, Winooski, VT) operated in FP mode. Excitation and 
emission wavelengths were 485 nm and 524 nm respectively, with a bandwidth of 20 nm 
and instrument G-factor set at 0.87. All FP experiments were carried using the fluorescent 
cAMP-saturated RD (5 µM), henceforth called as 8-[fluo]-cAMP:RD at 298 K. In the first 
set of experiments, cAMP (330 µM) and RegA (10 µM) in 2:1 (RegA:RD) molar ratio 
were added separately to RD saturated with the fluorescent cAMP, at t = 0 min and t = 20 
min as indicated in different sample sets. FP readings were collected at every two minutes 
for a total time of 100 min. Appropriate controls 8-[fluo]-cAMP (2 µM) and RegA (10 
µM) were also monitored to get a reference baseline. All experiments were performed 
thrice in triplicates and the graphs for polarization values versus time were plotted using 
GraphPad Prism 6.0 (San Diego, CA). 
2.3 RESULTS 
2.3.1 Determining binding constants of cAMP to CNB:B domain of RD by Isothermal 
titration calorimetric measurements 
 The binding kinetics and dissociation constant of cAMP with the mammalian R-
subunit have been characterized previously. For the D. discoideum RD, cAMP binds with 
high affinity to the CNB:A site with the dissociation constant in KD ~ nM range (De 
Gunzburg, Part et al. 1984). However, it is known that cAMP binds weakly to the CNB:B 
site of RD. Therefore, I firstly carried out isothermal titration calorimetric experiments to 
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determine the binding affinity of cAMP at CNB:B site of RD. For this, purified RD (10 
µM) was taken in the sample cell and 200 µM cAMP in the syringe. After baseline thermal 
measurements, periodic injections of 4 µl of 200 µM cAMP were titrated and the enthalpy 
change was measured continuously. The ligand-binding reaction was exothermic as seen 
by the spikes in the negative scale of a representative ITC graph in Fig. 2.2. The 
experiment was performed three times and an average value of KD ~ 1 µM for cAMP at 
CNB:B site was calculated using Origin software (MicroCal Inc.) associated with the 
instrument.  
 
Figure 2.2: cAMP binding to RD as determined by ITC.  Top panel depicts the heat (µcal/sec) 
released (and subsequent recovery) upon injection of cAMP with time (min) from the syringe to 
the experimental cell chamber containing apo RD protein. Bottom panel shows the fit of the 
integrated and corrected heat to a binding isotherm (black line). The release of heat with every 
injection is plotted on Y-axis (kcal/mole of cAMP) with increase in cAMP/RD protein molar ratio 




Continuous measurement of heat change inside the sample cell (as compared to 
the reference cell) allowed us to determine the change in enthalpy, ΔH (-53.7 kcal/mol ± 
1.6 kcal/mol), the equilibrium association constant KA (9.92 x105 ± 1.02 x104 M-1) and 
dissociation constant (KD) ~1 µM. Although the change in enthalpy recorded was 
considerably high, it has been shown that in certain cases heat changes measured were in 
higher range owing to the weak affinity between the protein and ligand. This KD of 
micromolar range is quite low as compared to KD values of the CNB:A site or with CNB:B 
values for the mammalian R-subunits. 
2.3.2 Cyclic nucleotide domain B of RD undergoes local unfolding in cAMP-free state 
 Protein Kinase A R-subunit is an intrinsically dynamic protein with a high-
affinity interaction with cAMP (Kd ~ nM). Mammalian (RIα) and lower eukaryote 
Dictyostelium (RD) regulatory subunits share 51% sequence identity and 70% similarity 
by homology (Appendix – A4), and highly similar in binding to cAMP molecules. The 
dynamics of mammalian R-subunit has been very well characterized by various 
experiments (Taylor, Kim et al. 2005, Kornev and Taylor 2015) and explained by a 
conformational selection model (Badireddy, Yunfeng et al. 2011). Hence, we first aimed 
to characterize the intrinsic dynamics of RD protein alone using hydrogen-deuterium 
exchange mass spectrometry. A total of 24 peptides were identified and analyzed, 




Figure 2.3: Sequence coverage of RD. The primary sequence of full-length RD is depicted. The 
blue boxes indicate all peptide fragments spanning regions of the primary sequence obtained from 
our data set analysis.  Approximately 71% sequence coverage was observed. Amino acids labeled 
as ‘X’ are residues spanning peptides omitted from the final list of analyzed peptides. 
 
 
The overall dynamic profile of RD is provided in a relative exchange plot (Fig. 
2.4A), which plots the ratio of average deuterons exchanged to the total number of 
exchangeable amides available for each peptide. The two CNB domains and their 
connecting linker are shown in Fig. 2.4B. Dynamic and intrinsically disordered regions 
of the protein usually have higher accessibility to solvent and thus have higher relative 
deuterium uptake values.  
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Figure 2.4: Apo RD is a dynamic protein with regions that undergo slow structural transitions/ 
local unfolding. (A) Relative deuterium uptake value (Y-axis) for each pepsin digest fragment 
from the N-C terminus (X-axis) of RD is plotted. The relative exchange plot provides a snapshot of 
the overall dynamics of RD for each deuterium labeling time point as depicted in the key. Peptides 
spanning the cAMP binding pocket in CNB:A and B are highlighted in red. Gray area represents 
standard deviations. Plots were generated using DynamX software (v2.0, Waters, MA). (B) 
Peptides showing bimodal characteristics are mapped in red onto the modeled structure of RD. 
CNB:A (1-180) is in yellow and CNB:B (181-327) is in green, inter-domain linker (171-190) is 
highlighted in maroon. (C) Stacked mass spectra of the three peptides exhibiting bimodal 
distributions are shown. Mass spectra are stacked in order of increasing deuterium labeling time 
(Y-axis) as shown. Colored curves are used to represent lower exchanging (blue curve) and higher 
exchanging distributions (orange curve) in the 30 s labeling time of spectra.  
 
 
Upon closer examination, three regions showed a bimodal distribution of their 
mass spectra (Fig. 2.4C), indicative of multiple (two or more) spectral envelopes within 
the same mass spectrum.  Bimodal spectra in HDXMS results can be attributed to EX1 
(Weis, Wales et al. 2006) regime (local unfolding coupled to slow conformational 
changes) or different populations of the protein at a given time (dynamic interconversion 
between different states of the protein) (Wildes and Marqusee 2004). EX1 kinetics may 
provide insights into protein dynamics by serving as conformational probes. Here, mass 
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spectra of peptides at shorter hydrogen-deuterium exchange times exhibited bimodal 
characteristics (Fig. 2.4C), but shifted to unimodal binomial distribution at higher 
exchange times reflecting the EX1 kinetics of the peptides. These peptides spanned loci 
important for RD function, mainly the putative C-helix (171-201) and the conserved 
arginine in CNB:B (266-279). Deconvolution of the bimodal spectral envelopes 
confirmed EX1 kinetics and is interpreted later (Fig. 2.11A). By subtractive analysis of 
continuous peptides (spanning residues 171-201), the region showing bimodal 
distribution was localized to the residues 171-190. To better visualize these results, the 
results were mapped onto the three-dimensional model of RD (Fig. 2.4B). A structural 
model for RD was generated using the structure of a close homolog, PKA-RIα from B. 
taurus (PDB ID: 1RGS (Su, Dostmann et al. 1995)) using SWISS-MODELLER. 
(Deuterium uptake values for RD in different states are listed in Table 2.1 at different 
deuterium labeling times.) 
 
2.3.3 Cyclic AMP binding induces distinct conformational dynamics as represented by 
their bimodal signatures 
 Above results showed the dynamic nature of apo RD and we identified three 
regions undergoing slow conformational changes. Next, we pursued to determine the 
effect of cAMP binding to dynamics of RD, as a whole protein and specifically at the three 
loci by employing HDXMS experiments for RD in the presence of excess cAMP (330 
µM). For RD, the CNB:A site binds cAMP with high affinity of dissociation constant in 
nanomolar range, KD ~3 nM (De Gunzburg, Part et al. 1984) and the affinity for CNB:B 
site was calculated to be ~ 1 µM (Fig. 2.2). These guided us to use high concentrations of 
cAMP (330 µM), to ensure complete ligand saturation of the cAMP binding pocket at 




Table 2.1: Summary of peptide fragments from HDXMS data for apo RD, RD:cAMP, RegAC:RD and RegAC:RD:cAMP. The table summarizes the relative 
deuterium exchange values reported for the 24 peptides obtained in the analysis. A comparison of an absolute number of deuterons exchanged by the peptides 
at two different labeling times 1 min and 30 min are tabulated. 
    
      
No. of deuterons exchanged after 1min  
(Mean ± SD)b 
No. of deuterons exchanged after 30min  
(Mean ± SD)b 
S.No 
































17.04 ± 0.08 
17.51 ± 
0.15 





3 ISSEPLGDKPATPLPNIPKT (2075.138) 2 31-50 14 2.01 ± 0.09 2.47 ± 0.22 2.18 ± 0.02 2.70 ± 0.06 4.79 ± 0.24 5.15 ± 0.18 5.43 ± 0.12 5.88 ± 0.09 
4 EQALSNNIM (1019.483) 3 58-66 8 3.36 ± 0.15 3.48 ± 0.08 3.90 ± 0.06 3.87 ± 0.05 4.42 ± 0.15 4.31 ± 0.12 4.67 ± 0.02 4.66 ± 0.01 
5 EERNVVF (892.452) 2 73-79 6 1.04 ± 0.05 1.22 ± 0.13 1.11 ± 0.06 1.34 ± 0.09 2.75 ± 0.05 2.72 ± 0.11 2.58 ± 0.03 2.75 ± 0.13 
6 LYKAGDIIIKQGDEGD (1734.891) 2 86-101 15 3.18 ± 0.15 2.75 ± 0.06 3.73 ± 0.06 2.87 ± 0.04 4.45 ± 0.19 3.94 ± 0.12 4.79 ± 0.04 4.26 ± 0.06 
7 ALIYGSPRAATVI (1331.768) 2 138-150 11 3.67 ± 0.08 1.76 ± 0.05 4.19 ± 0.12 1.91 ± 0.08 4.88 ± 0.07 3.22 ± 0.13 5.21 ± 0.01 2.99 ± 0.17 
8 WALNGAT (732.367) 2 158-164 6 2.38 ± 0.04 2.12 ± 0.05 2.45 ± 0.02 2.09 ± 0.03 2.65 ± 0.03 2.48 ± 0.03 2.70 ± 0.02 2.49 ± 0.04 




4 183-201 17 6.92 ± 0.23 6.97 ± 0.12 8.22 ± 0.05 8.09 ± 0.10 7.80 ± 0.25 7.44 ± 0.09 9.19 ± 0.05 8.98 ± 0.01 
11 LEKVSIL (801.508) 2 184-190 6 2.60 ± 0.03 2.61 ± 0.06 3.28 ± 0.02 2.95 ± 0.02 3.22 ± 0.06 3.05 ± 0.04 3.62 ± 0.03 3.50 ± 0.01 
12 LEKVSILRHIDKYERVSL (2198.266) 2 184-201 17 6.93 ± 0.11 6.79 ± 0.11 7.97 ± 0.02 7.49 ± 0.08 7.85 ± 0.09 7.51 ± 0.09 8.58 ± 0.03 8.41 ± 0.06 






3 198-227 27 6.60 ± 0.08 6.79 ± 0.10 6.65 ± 0.02 7.27 ± 0.05 9.43 ± 0.11 9.05 ± 0.05 9.84 ± 0.05 9.51 ± 0.05 
15 ADALEPVNF (975.478) 4 202-210 7 3.53 ± 0.04 3.45 ± 0.05 3.02 ± 0.05 2.45 ± 0.01 3.76 ± 0.05 3.57 ± 0.03 3.87 ± 0.01 2.92 ± 0.02 
16 VIVRQGDPGDRF(1358.717) 2 215-226 10 4.39 ± 0.06 4.01 ± 0.09 3.97 ± 0.09 2.76 ± 0.07 4.97 ± 0.09 4.51 ± 0.06 5.55 ± 0.07 3.80 ± 0.04 
17 IVRQGDPGDRF (1259.649) 2 216-226 9 3.92 ± 0.06 3.56 ± 0.07 3.69 ± 0.01 2.62 ± 0.06 4.38 ± 0.06 4.03 ± 0.05 4.68 ± 0.01 3.75 ± 0.03 
18 TQETVPGDHSTSHVVSEL (1922.909) 3 237-254 16 6.37 ± 0.23 7.35 ± 0.15 n/a n/a  7.16 ± 0.02 7.95 ± 0.06 n/a  n/a  
19 LTDRPRAATVTSIG (1457.807) 2 266-279 12 5.89 ± 0.05 4.97 ± 0.19 4.42 ± 0.09 1.98 ± 0.12 6.66 ± 0.15 5.39 ± 0.16 7.46 ± 0.03 3.07 ± 0.16 
20 DRQRFNRLCGPIDQML (1961.98) 3 287-302 15 6.62 ± 0.17 5.62 ± 0.14 n/a 8.25 ± 0.04 7.69 ± 0.18 7.50 ± 0.08 5.64 ± 0.09 7.69 ± 0.15 
21 NRLCGPIDQ (1015.499) 2 292-300 7 3.08 ± 0.06 2.97 ± 0.08 3.28 ± 0.04 2.83 ± 0.06 3.61 ± 0.09 3.47 ± 0.25 3.94 ± 0.05 3.64 ± 0.09 
22 RRNMETYNQF (1358.627) 2 303-312 9 5.13 ± 0.05 4.98 ± 0.06 5.23 ± 0.04 4.93 ± 0.08 5.37 ± 0.09 5.13 ± 0.05 5.53 ± 0.06 5.22 ± 0.07 
23 FLNRPPSSPNL (1241.664) 2 312-322 7 4.06 ± 0.03 4.04 ± 0.03 4.01 ± 0.04 3.95 ± 0.05 4.10 ± 0.04 4.02 ± 0.03 4.06 ± 0.01 3.93 ± 0.06 
24 LNRPPSSPNL (1094.595) 2 313-322 6 3.62 ± 0.05 3.58 ± 0.09 3.65 ± 0.03 3.58 ± 0.03 3.63 ± 0.06 3.56 ± 0.06 3.65 ± 0.05 3.61 ± 0.03 
a Number of maximum available exchangeable amides for each peptide. b Average and standard deviation values calculated from three independent deuterium 




Figure 2.5: Effects of cAMP binding on RD dynamics: A) Difference plot, plotting absolute 
difference in deuterons (Y-axis) between apo RD and RD:cAMP for each pepsin fragment peptide 
listed from the N to C-terminus (X-axis). Negative differences represent a decrease in deuterium 
exchange upon cAMP binding, while positive differences represent an increase in deuterium 
exchange upon cAMP binding. Peptides spanning the cAMP binding pocket in CNB:A and B are 
highlighted in red. Each deuterium labeling time for every peptide is depicted and colored 
according to the key. A difference of ± 0.5 Da is considered significant and is represented by a red 
dashed line and gray area represents standard deviation. Plots were generated using DynamX 
software (Waters, MA). (B) Regions showing significant decreases in deuterium exchange are 
mapped in red onto the modeled structure of RD. The cAMP molecules are represented in the 
structure as yellow sticks, CNB:A (residues 1-180) domain is in yellow and CNB:B domain 
(residues 181- 327) is in green, the N and C termini of the protein and cyclic nucleotide binding 
pockets in A and B domain are labeled. (C) Stacked mass spectra of peptides spanning residues (i) 
138-150 in CNB:A and (ii) 266-279 in CNB:B are shown. Mass spectra compares the ligand-free 
state to the ligand-bound at 5 min deuterium labeling time. The shift in centroids is represented by 
the red double-headed arrows. 
 
 The HDXMS results of cAMP-saturated RD and apo RD were compared as a 
difference plot showing significant differences in deuterium exchange between the two 
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states (Fig. 2.5A). Significant decreases in deuterium exchange were observed for 
peptides located within the cAMP binding pockets of CNB:A and CNB:B at all labeling 
times, clearly showing binding of cAMP to RD at these sites. Another region spanning 
residues 287-302 also showed significant differences at shorter deuterium labeling times, 
but at increased labeling times the difference between apo RD and RD:cAMP was 
negligible. This region is distal to C-terminus of CNB:B and denotes an allosteric effect 
upon ligand binding. These significant differences are mapped onto the modeled structure 
of RD in Fig. 2.5B and representative mass spectra for peptides in CNB:A and CNB:B are 
shown in Fig. 2.5C.  
Of the three peptides showing bimodal kinetics of deuterium exchange in apo RD, 
only one peptide (residues 266-279) at CNB:B showed considerable differences in the 
presence of cAMP. For the entire duration of the experiment, this spectrum exhibited 
bimodal characteristics resulting in a shift of the centroid to the left (Fig. 2.5 C-ii). 
Interestingly, the centroid of the higher exchanging population did not show any shifts, 
but the centroid of the lower exchanging population shifted to the right with increasing 
labeling time (Fig. 2.11B). The spectra for the lower exchanging species is representative 
of EX2 deuterium exchange kinetics seen in stably folded regions (Hoofnagle, Resing et 
al. 2003). In comparison, apo RD showed bimodal distributions at shorter labeling times 
and binomial distribution after 10 min deuterium labeling times (Fig. 2.6). Interestingly, 
the interdomain linker with its characteristic bimodal spectra (Residues 171-190) did not 




Figure 2.6: Comparing dynamics by HDXMS of CNB pockets in cAMP-free (apo) and cAMP 
bound states: A) Stacked mass spectra of a peptide spanning residues 138-150 in CNB:A domain, 
comparing cAMP-free and cAMP bound state, is depicted with increasing deuterium exchange 
labeling time.  Centroids of the spectrum are labeled in black triangles. B) Stacked mass spectra of 
peptide fragment spanning residues 266-279 in CNB:B domain, comparing cAMP-free and cAMP 
bound state, is depicted with increasing deuterium exchange labeling time. Bimodal distributions 
are seen for shorter labeling times (30 s and 1 min) in apo RD.  In the cAMP-bound state, bimodal 
distribution in mass spectra is seen for all deuterium labeling times. Blue triangles indicate centroid 
for the lower exchanging envelope and red triangles indicate centroid for the higher exchanging 
envelope. 
 
2.3.4 RegA:RD  forms transient complex in absence of cAMP 
To terminate the cAMP-PKA signaling, one of the mechanisms is to inactivate 
the PKA catalytic subunit by re-associating to cAMP-free R subunit. How RD goes from 
a cAMP-bound state to a cAMP-free state is yet uncharacterized. Using a non-
hydrolysable cAMP analog, previously we had shown a potential role of 
phosphodiesterase RegA in mediating cAMP release from RIαA through direct 
interactions (Krishnamurthy, Moorthy et al. 2013). Moreover, from the results discussed 
in the first chapter of this thesis, we observed direct interactions between the cAMP 
binding pockets of R-subunit with the active site of PDE. In order to determine these 
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interactions between RD and RegA, we set out to monitor the dynamics of the RegAC:RD 
complex by HDXMS experiments with RD at a 3-fold molar excess to RegAC in the 
absence of excess cAMP. Importantly, complexation was initiated simultaneously with 
deuterium exchange reaction, to better follow steps in complex formation as well as 
dissociation. HDXMS results from the binary complex RegAC:RD were compared with 
apo RD and are represented as a difference plot in Fig. 2.7A. For this set of experiments, 
the rationale behind using excess RD was to maintain all RegAC towards complexation 
and obviate any hydrolysis of cAMP by free RegAC during the reaction. 
 An overall increased dynamics was observed for most regions of RD in the 
presence of RegAC. Although some regions show decreased exchange initially, at longer 
labeling times all regions showed increased deuterium exchange. Different results were 
observed for the two cAMP binding domains. In the binary complex state, multiple 
peptides spanning the CNB:B domain showed decreased deuterium exchange at lower 
time points (0.5 and 1 min), but this trend reversed with the same regions showing 
increased dynamics, reflected by the increase in deuterium exchange. Further, adjoining 
regions to CNB:B also showed a similar trend of initial decrease in deuterium uptake 
compared to apo RD. These results signify formation of RegAC:RD complex with the 
interaction interface at CNB:B of RD. At longer labeling times, the complex dissociates 
as inferred by increased exchange at all regions, including the interaction interface. Whilst 
dissociation of the complex should result in no net differences in deuterium exchange for 
free RD and end-state of binary complex, we observed increased exchange at most loci, 
including CNB:B domain. 
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Figure 2.7: Mapping transient RegAC:RD 
interactions by HDXMS: A) Difference plot, 
plotting difference in deuterons (Y-axis) between 
apo RD and RegAC:RD complex for each pepsin 
fragment peptide listed from the N to C terminus 
(X-axis). Negative differences denote a decrease 
in deuterium exchange, while positive 
differences denote increase in deuterium 
exchange upon RegAC binding. Peptides 
spanning the cAMP binding pocket in CNB:A 
and B are highlighted in red.. Significant 
difference of ±0.5 Da is represented by a red 
dashed line and standard deviation in gray. (B) 
(Top panel) Stacked mass spectra of peptide 266-
279 from CNB-B domain of RD. Bimodal spectra 
from apo RD are compared with that of the 
complex in order of increasing deuterium 
labeling time. (Bottom panel) Deuterium 
exchange plot comparing apo RD and RegAC:RD. 
C) Representative mass spectra and deuterium 
exchange plots for two peptides 171-183 and 
184-201 are shown comparing apo RD and 
RegAC:RD. Semi-log deuterium exchange plots 
are generated with x-axis in the log scale and y-




 In order to understand this association and dissociation of RD and RegAC, peptides 
showing bimodal mass spectra were examined as conformational probes. First, we 
focused on peptide spanning residues 266-279 to determine the degree or disorder in 
CNB:B regions. RegAC binding resulted in significant ordering in early stages of the 
reaction, but as the reaction progressed, the degree of disorder increased towards the end 
of the reaction (100 min). At later stages, the peptide is completely deuterated (relative 
uptake ~ 0.7), suggesting complete disorder in this region (Fig. 2.7B top panel). This 
inversion is better visualized in deuterium uptake plots (Fig. 2.7B, bottom panel, Fig. 
2.11C ii). Next, we also monitored conformational changes in CNB:A regions of RD upon 
complexation. Bimodal spectra at interdomain linker (171-190) helped in monitoring the 
interconversion of different short-lived conformations. While cAMP binding had no 
effects in this linker regions, RegAC binding increased the disorder of the linker peptide. 
As shown previously for apo RD, the linker region exhibited a sharp bimodal behavior of 
the mass spectra implying towards a residual conformation. However, interaction with 
RegAC eliminated this residual conformation as the observed clear binomial distribution 
of the peptide, corresponding to increased dynamics or disorder.  
These results indicate that RegAC binds to RD at CNB:B by inducing considerable 
ordering in CNB:B, while simultaneously inducing long-range conformational changes in 
CNB:A. Ordering in CNB:B is transient, and with increase in reaction time, we observed 
increased overall dynamics across most regions of RD, providing evidence for the transient 
nature of the RegAC:RD interaction in the absence of cAMP. While cAMP binding showed 
local effects in deuterium exchange in the cAMP binding pocket, RegAC binding has a 
protein- wide effect, providing a case for RegAC mediated allosteric effects on RD. 
2.3.5 Stable complexation between RegAC:RD in presence of cAMP 
 RegAC mediated cAMP dissociation from mammalian R-subunit was monitored 
previously, using a non-hydrolysable cAMP analog (Sp-cAMPS) and resulted in a short-
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lived ternary complex of RIαA:Sp-cAMPS:RegAC (Krishnamurthy, Moorthy et al. 2013). 
In continuation, to determine similar interactions for slime mold regulatory subunit RD, 
we employed HDXMS to characterize the conformational dynamics of RegAC:RD:cAMP 
ternary complex. Complexation was initiated by simultaneous addition of RD (6 µM), 
cAMP (330 µM) and RegAC (2 µM) along with deuteration reaction. This allowed us to 
monitor the time-course kinetics of the reaction progression. The rationale behind using 
excess RD (3:1) was to channel all of the RegAC towards the complex formation and to 
obviate any hydrolysis of cAMP by unbound RegAC in the experiment.  
 HDXMS results for the ternary complex provided a conclusive evidence for stable 
complexation of RD, RegA, and cAMP. These results are compared with the cAMP-bound 
form of RD and summarized in Fig. 2.8. Interestingly, peptides spanning the CNB:B region 
of RD showed decreased deuterium exchange for the ternary complex at all labeling times, 
while peptides spanning CNB:A region show decreased exchange only at longer labeling 
times (Fig. 2.8B). The interdomain linker showed increased deuterium exchange with 
time, indicating unfolding of the linker region. This increased dynamics suggest a mode 
of allosteric communication between the two domains result in an altogether novel 
conformation of RD as a ternary complex form. A better understanding of these HDXMS 
results was obtained by mapping the differences onto modeled structure of RD (Fig. 2.8 
C), which clearly identifies the CNB:B region as the interaction interface for RegAC:RD 
complex. Peptide spanning 266-279 that exhibited bimodal behavior in other states, 
showed a low-exchanging ordered conformation with a binomial distribution. These 




Figure 2.8 Mapping the RegAC:RD:cAMP ternary complex by HDXMS. A) Plot of absolute 
difference in deuterons (Y-axis) between RD:cAMP and the RD:cAMP:RegAC ternary complex for 
each pepsin fragment peptide listed from the N to C-terminus (X-axis). Negative differences denote 
decreased deuterium exchange, while positive differences denote increased exchange in the ternary 
complex. Peptides spanning the cAMP binding pocket in CNB:A and CNB:B are highlighted in 
red. Each deuterium labeling time for every peptide is depicted and colored according to the key. 
Red-dashed line represents a significant difference of ±0.5 Da and gray area represents the standard 
deviations. (B) Significant differences in deuterium exchange in the ternary complex are mapped 
onto the modeled structure of RD. Regions showing increased exchange in the ternary complex are 
colored in red, while regions showing decreased deuterium exchange are in blue. cAMP molecules 
are represented in the structure as yellow sticks. The CNB:A (residues 1-180) domain is in yellow 
and CNB:B domain (residues 181-327) is in green. (C) (Left panel) Stacked mass spectra of peptide 
spanning residues 266-279 in CNB:B domain of RD with an increase in labeling time. Bimodal 
spectra from RD:cAMP are compared with spectra from the ternary complex. (Right panel) 
Deuterium exchange plot comparing RD:cAMP and RD:cAMP: RegAC for the same peptide is 
depicted. Semi-log deuterium exchange plots are generated with X-axis in log scale and Y-axis in 
linear scale, error bars are indicated. Plots are generated in GraphPad Prism software version 6 





2.3.6 Fluorescence polarization confirm ligand facilitated stabilization of RegA:RD 
complex 
 While HDXMS results gave a comprehensive overview of the protein dynamics, 
our fluorescence polarization results allowed us to track the ligand mobility. Firstly, we 
monitored intrinsic association/dissociation of the fluorescent ligands from the ligand-
saturated RD, and we observed constant polarization through the time scale of the 
experiment (100 min), as shown in Fig. 2.9. This indicates that in the absence of RegA or 
cAMP, there is no intrinsic dissociation of fluorescent cAMP from RD (green plot, Fig. 
2.9), consistent with high affinity binding of substituted cAMP analogs to PKA R-subunit 
(Ogreid, Ekanger et al. 1989). Next, we compared the binding kinetics of the fluorescent 
analog with natural cAMP, by adding excess cAMP to the fluorescent ligand saturated RD 
at two different time-points (0 and 20 min). Addition of excess cAMP to fluorescent 
ligand-saturated RD resulted in competitive displacement of 8-[fluo]-cAMP as evident 
from the decrease in polarization (open and closed orange squares, Fig. 2.9). Free 
fluorescent moieties not bound to the proteins, undergo unrestricted tumbling and result 
in lower polarization.  
 In the next set of experiments, we set out to monitor complexation of the two 
proteins in presence/absence of ligand. When stoichiometric ratios of RegA was added to 
8-[fluo]-cAMP:RD at the beginning of the assay (t = 0 min), it resulted in an upward shift 
in the polarization intensity of the complex (red plot, Fig. 2.9). We then confirmed this 
increase is indeed due to complexation, by adding RegA to the reaction at 20 min. Again, 




Figure 2.9: Fluorescence polarization of RD with cAMP and RegA confirms stable ternary 
complex. Full-length RD (●) was saturated with 8-[fluo]-cAMP. In the first set of experiments, 
competitive displacement was tested by adding 330 µM of cAMP to 8-[fluo]-cAMP:RD, at 0 
min (□) or 20 min (■) as indicated in the key. Next, an association of RegA to fluorescent 
cAMP saturated RD was carried out by the addition of 10 µM of PDE8AC to individual rec 8-
[fluo]-cAMP:RD, at 0 min (▲) or 20 min (▼) as indicated in the key. Polarization of 5 µM 
RegA (◆) and 5 µM 8-[fluo]-cAMP ( ) was also monitored as controls. Polarization values 
are plotted against time using GraphPad Prism 6.0 (San Diego, CA). Each point represents an 
average value obtained from two experiments performed in triplicate, error bars are shown. 
 
This suggests that RegA binds to ligand-saturated RD and forms a stable complex. 
Importantly, we also checked binding of 8-[fluo]-cAMP (black plot, Fig.2.9) to free RegA 
by mixing them in an equimolar ratio. No significant change in polarization was detected 
(purple plots, Fig. 2.9). This further emphasizes that increased polarization recorded for 
PDE-resistant fluorescent cAMP 8-[fluo]-cAMP for the RegA:RD reaction, is in fact due 
to their complexation. These results from fluorescence polarization spectroscopy are 
essential and in accordance with the HDXMS results obtained before and clearly point to 
a ligand-mediated stabilization of the RegA:RD complex. 
2.3.7 RegA facilitates cAMP dissociation from RD by substrate channeling 
 The above results show distinct effects of cAMP and RegAC phosphodiesterase 
on dynamics of RD, indicating ligand-mediated stable complexation of RegAC:RD:cAMP. 
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In order to determine the mechanism of release of cAMP, deuterium exchange kinetics of 
the RegAC:RD complex was compared in the presence and absence of excess cAMP (330 
µM) as summarized in Fig. 2.10A. Large magnitude differences were observed in both 
the cAMP binding pockets of RD (highlighted in orange) and increased deuterium 
exchange with time at the PKA C-subunit binding site and inter-domain linker.  
 
Figure 2.10: RD:RegA complex facilitates turnover of cAMP via RD . A) Difference plot, plotting 
absolute difference in deuterons (Y-axis) between RegAC:RD complex and the RegAC:RD:cAMP 
ternary complex for each pepsin fragment peptide listed from the N to C-terminus (X-axis). 
Negative differences represent an increase in deuterium exchange, while positive differences 
denote decreases in deuterium exchange in the RegAC:RD in the presence of excess cAMP. Peptides 
spanning the cAMP binding pocket in CNB:A and CNB:B are highlighted by orange boxes. Each 
deuterium labeling time for every peptide is depicted and colored according to the key. A difference 
of ± 0.5 Da is considered significant and is represented by a red dashed line and standard deviations 
are shown in gray. (B) Relative deuterium uptake plots of peptides from CNB:A (138-150) and 
CNB:B (266-279) with different labeling times are shown for apo and excess cAMP states of free- 
and RegAC-bound RD as indicated in the key. Semi-log deuterium exchange plots are generated 
with X-axis in the log scale and Y-axis in linear scale, error bars are indicated. Plots are generated 




At shorter labeling times (1-10 min), decreased deuterium exchange was seen in 
RegAC:RD complex in the presence of excess cAMP at the CNB domains, indicating 
cAMP binding at these regions. With increase in labeling time (30-100 min), these regions 
showed increased deuterium exchange, comparable to apo RD or cAMP-free complex 
(kinetic plots, Fig. 2.10B) suggesting that RegAC:RD complex facilitated turnover of all 
cAMP molecules. Time-dependent increase in deuterium exchange was observed in 
peptides spanning the inter-domain linker (171-183 and 183-201) in RegAC:RD complex 
in the presence of excess cAMP. This region undergoes a rigid and compact conformation 
in cAMP-bound form (Kim, Xuong et al. 2005, Kim, Cheng et al. 2007) of PKA R-subunit 
or RD and open conformation in cAMP-free state of RD.  
Given that direct interaction with RegAC mediates cAMP release from RD and is 
coupled with allosteric changes in the inter-domain linker, increased deuterium exchange 
observed for the inter-domain linker is also a proof for our model - RegAC mediated cAMP 
release from RD. Furthermore, at higher deuterium labeling times protein-wide increased 
deuterium exchange, similar to that observed for apo RD (open circle, Fig. 2.10B) suggests 
that RegAC stably binds to cAMP-bound RD and these direct interactions expedite cAMP 
dissociation from RD.  
2.3.8 Deconvolution of EX1 kinetics observed at CNB:B 
 EX1 kinetics observed at the cAMP binding region of CNB:B were quantitated 
by deconvolution of the bimodal spectra. We obtained the centroid and amplitude values 
for the low exchanging and high exchanging envelopes and their ratios with changes in 
time, which are key parameters in quantitating EX1 kinetics data. The quantitated data are 
summarized in Figure 2.11.   
 In apo RD (Fig. 2.11A), the centroid of the lower exchanging envelope (blue 
peaks) shifts with time while the higher exchanging (red peaks) envelope stays constant. 
Upon addition of excess cAMP, it is seen that the centroids of both the lower and higher 
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exchanging populations stay constant with time (Fig. 2.11B, i). In the RegAC:RD binary 
complex, like the apo RD, centroids of the lower exchanging population shifts with time 
(Fig. 2.11C i). However, the amplitude ratio shows an inversion with time with lower 
exchanging population predominating at earlier time points and the higher exchanging 
population predominating at higher time points (Fig. 2.11C ii). RegAC:RD:cAMP ternary 
complex data shows that the lower exchanging population predominates through the entire 
time course and the centroids stay constant with time (Fig. 2.11D i, ii). These results 
highlight the role of cAMP in stabilizing conformations and preventing interchange 




Figure 2.11 Deconvolution of EX1 deuterium exchange kinetics for CNB:B domain peptide 
(266-279). Stacked 3D graphs represent the distribution of the bimodal kinetics of the RD in its 
different conditions. A) apo RD; B) RD with an excess of cAMP; C) RegAC:RD binary complex in 
the absence of ligand; D) RegAC:RD:cAMP ternary complex. Each peak depicts average amplitude 
value (Y-axis) for the respective centroid values (X-axis) of the lower exchanging (shades of blue) 
and higher exchanging envelopes (shades of red) at different time points (Z-axis). The intensities 
of the two populations were calculated using an equation for the sum of two Gaussians on 
GraphPad Prism 6.0 (San Diego, CA). ii) Relative envelope distributions (percentages) were 
calculated by normalizing the intensities of peaks from each envelope relative to sum total 
intensities. Y-axes represent the percentage of the normalized intensities and X-axes show 
deuterium exchange (min). Blue bars represent relative intensities of the distribution of lower 
 75 
 
exchanging envelopes and the red bars represent those for the higher exchanging envelope. The 
corresponding intensities and deuterium exchange values calculated are listed in Table 2.2 
 
Table 2.2. Percentage values of amplitudes and centroid mass shifts from deconvolution of 
deuterium exchange kinetics for RD. The table lists the calculated values for the amplitude 
intensities and respective exchange of deuterons as compared with the undeuterated control, for 
the two types of exchanging envelopes corresponding to Fig. 2.8. 
 
(i) Apo RD  
Time Amp_1 Centroid_1 DEx ± SD Amp_2 Centroid_2 DEx ± SD 
0.5 7.59 730.8 2.12 ± 0.07 12.99 733.6 7.72 ± 0.07 
1 6.67 730.9 2.45 ± 0.08 12.83 733.6 7.72 ± 0.08 
5 6.30 731.5 3.52 ± 0.09 11.88 733.7 7.92 ± 0.09 
10 5.95 731.8 4.12 ± 0.07 11.53 733.8 8.12 ± 0.07 
30 7.52 732.7 5.92 ± 0.06 7.44 733.8 8.12 ± 0.06 
60 7.34 732.7 6.05 ± 0.07 6.69 733.7 7.92 ± 0.07 
100 6.52 732.8 6.25 ± 0.07 7.37 733.7 8.05 ± 0.07 
(ii) RD: cAMP 
Time Amp_1 Centroid_1 DEx ± SD Amp_2 Centroid_2 DEx ± SD 
0.5 11.10 730.3 1.19 ± 0.05 13.22 733.3 7.12 ± 0.05 
1 12.25 730.2 0.92 ± 0.06    13.44 733.3     7.12 ± 0.06 
5 8.94 730.4 1.32 ± 0.05 12.72 733.3 7.25 ± 0.05 
10 9.59 730.5 1.52 ± 0.05 13.80 733.4 7.32 ± 0.05 
30 9.93 730.6 1.79 ± 0.05 13.89 733.3 7.25 ± 0.05 
60 7.67 730.8 2.19 ± 0.08 13.65 733.4 7.39 ± 0.08 
100 8.25 730.9 2.32 ± 0.06 13.41 733.5 7.52 ± 0.06 
(iii) RegAC:RD 
Time Amp_1 Centroid_1 DEx ± SD Amp_2 Centroid_2 DEx ± SD 
0.5 14.11 730.9 2.32 ± 0.14 5.97 733.6 7.82 ± 0.14 
1 14.26 731.1 2.72 ± 0.10 6.98 733.7 7.92 ± 0.10 
5 12.05 731.6 3.65 ± 0.07 14.70 733.7 7.99 ± 0.07 
10 6.59 731.7 3.99 ± 0.12 12.25 733.7 8.05 ± 0.12 
30 4.89 733.1 6.79 ± 0.14 10.84 733.6 7.85 ± 0.14 
60 3.16 732.9 6.39 ± 0.14 9.93 733.6 7.79 ± 0.14 
100 1.03 733.1 6.72 ± 0.16 10.11 733.7 7.99 ± 0.16 
(iv) RegAC:RD:cAMP 
Time Amp_1 Centroid_1 DEx ± SD Amp_2 Centroid_2 DEx ± SD 
0.5 11.70 730.1 0.65 ± 0.24 1.67 732.4 5.32 ± 0.24 
1 12.64 730.1 0.79 ± 0.23 2.03 732.4 5.32 ± 0.23 
5 13.24 730.2 1.05 ± 0.17 2.22 732.5 5.52 ± 0.17 
10 11.09 730.3 1.19 ± 0.19 1.90 732.5 5.59 ± 0.19 
30 13.45 730.6 1.85 ± 0.16 3.15 732.8 6.12 ± 0.16 
60 13.44 730.8 2.12 ± 0.14 3.80 733 6.52 ± 0.14 
100 13.27 730.9 2.32 ± 0.14 4.76 733 6.59 ± 0.14 
 
All calculations were done using the sum of two Gaussians equation in GraphPad Prism 6.0. 
*Amp_1: Amplitude, Centroid_1: centroid in m/z for +2 charge state, DEx_1± SD: number of 
deuterons exchanged and the standard deviations for the lower exchanging envelope; **Amp_2: 
Amplitude, Centroid_2: representative m/z value of centroid peak for +2 charge state, DEx_2± SD: 




In this study, we set out to determine the interactions during the dynamic interplay 
of PKA regulatory subunit and phosphodiesterase from lower eukaryote model system, 
D. discoideum, in presence and absence of the ligand cAMP. We used HDXMS as a tool 
to study the complex formation and dissociation in real-time and fluorescence polarization 
spectroscopy as a probe for monitoring the kinetics of ligand binding to/release from the 
RegA:RD complex. These results aid the understanding the mechanism of 
phosphodiesterase-mediated allosteric interactions between cAMP-target PKA R-subunit 
and cAMP hydrolase PDE that regulated cAMP signal termination. In this chapter, results 
are presented for cAMP-PKA-PDE signaling from a lower eukaryote model system, D. 
discoideum, and we believe that the mechanism is broadly conserved as a universal model. 
Previously, the role of RegA in mediating interactions with R-subunit was unclear 
to fully understand their dynamics and thus decipher the steps involved in the initiation of 
the termination phase by the phosphodiesterase. The results from this chapter shed light 
on the association and dissociation of the two proteins at various stages. In the stimulated 
state of slime mold, adenylyl cyclase actively generates cAMP from ATP, and hence 
increasing internal cAMP concentrations. These cAMP are then supposed to be passively 
hydrolysed by different phosphodiesterases within the cytoplasm. Here, we resembled 
cytoplasmic condition and have shown that in the presence of cAMP, RD and RegA form 
a stable ternary complex with the interaction interface at CNB:B and increased dynamics 
at CNB:A. Deconvolution of EX1 kinetics of CNB:B (peptide spanning 266-279) showed 
the different conformations populated in different conditions at different stages of the 
reaction. A distinct envelope distribution is seen for this peptide, stating that it is not 
merely a sum of profiles seen for RD in cAMP-saturated or RegAC-bound states. The 
greatly diminished profile of higher exchanging envelope in the ternary complex state, 
compared to the RegAC:RD and RD:cAMP states clearly reflects these discrepancies. This 
provides important evidence for formation of a stable ternary complex in cAMP signal 
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termination and lends itself to the proposed substrate channeling model for cAMP release 
(Fig. 2.12) and hydrolysis from R-subunit (Krishnamurthy, Moorthy et al. 2014). 
Three dynamic loci - α:C helix, CNB:A, and CNB:B are involved in an allosteric 
regulation of RD function in the presence of RegA. In a cAMP depleted state, RegA:RD 
is transient in nature as inferred from CNB:B and CNB:A domain analysis. Increased 
dynamics observed at PKA C-subunit binding motif of RD (Akimoto, Selvaratnam et al. 
2013), further highlights the importance of complex formation to prime RD for subsequent 
binding with PKA C-subunit. In addition, the dynamic linker that shows bimodal 
characteristics is known to play a crucial role in cooperative cAMP binding to both the 
CNB domains and thus in PKA activation (Popovych, Sun et al. 2006).  
 
Figure. 2.12: Steps in PDE-mediated cAMP signal termination pathway. A) cAMP binding at 
CNB:A of RD (in gray surface representation) results in an allosteric relay (green arrow) that 
stabilizes structural transitions in CNB:B. This presents an interaction interface for RegA (green 
surface representation) binding. (B) In the first step of the cAMP termination pathway, with high 
local cAMP (yellow spheres) concentrations, RD and RegA form a stable complex. cAMP from the 
local environment binds at the RD CNB:B cAMP binding pocket and subsequently is channeled 
into the active site of RegA, as an example for substrate channeling in a signaling complex. (C) 
Once free cAMP is depleted by substrate channeling; RegA and RD form transient complexes 
(indicated by the black arrow). RegA binding also results in an allosteric relay (red arrow) that 
results in dissociation of cAMP from CNB:A. Thus RegA hydrolyzes all cAMP bound to the 
receptor and results in apo RD. D) RegA dissociates from RD and subsequently primes RD to 
reassociate with PKAC resulting in termination of the cAMP signaling pathway. RegA, cAMP and 




In this study, we also highlight this role of the domain-connecting linker in a 
manner reverse of its role in binding of cAMP to RD, i.e. in the removal of cAMP from 
the two domains upon RegA interaction. The combined effects of cAMP and RegA 
suggest that they independently modulate the dynamics of RD by parallel allosteric relays. 
In a stimulated state of excess intracellular cAMP, RegA and RD remain associated 
together by forming a stable ternary complex. We predict that this would result in a 
functionally active catalytic complex that removes and hydrolyzes most cAMP in the 
vicinity, suggesting a role for substrate channeling in cAMP signal termination by 
resetting the cellular milieu for subsequent stimuli. Again, the allosteric effects in RD, 
particularly at the PKA C-subunit binding motif, suggest that the phosphodiesterase RegA 
primes RD to reassociate with PKA C-subunit and thereby terminate the cAMP signaling 
pathway. 
Conformational dynamics of RD play an important in the different stages of cAMP 
signaling pathway. The R-subunit has been shown to allosterically respond to both C-
subunit binding as well as cAMP (Anand, Hughes et al. 2002, Kim, Xuong et al. 2005, 
Das, Abu-Abed et al. 2006, Abu-Abed, Das et al. 2007, Das, Esposito et al. 2007, Kim, 
Cheng et al. 2007). This highlights the importance of allostery in R-subunit for 
coordinating the activation phase and proceed primarily through CNB:A. Our results 
reported here indicate the importance of CNB:B in binding PDEs and this interaction is 
then allosterically coupled to CNB:A through relays that are independent to that mediated 
by cAMP and the C-subunit. CNB:B domain of RD from D. discoideum is distinct as it 
has a very low affinity for cAMP compared to the mammalian homologs. Despite its low 
affinity, our results highlight its importance as a dynamic node for PDE action. This 
underscores the importance of R-subunits in serving as integrative nodes by coordinating 
multiple allosteric relays that ultimately govern the output response in both activation and 






Substrate channeling in termination phase of 
cAMP signaling: Monitoring dynamics of 




Cyclic AMP signaling is governed by two phases, an activation phase where 
hormonal stimulates cAMP synthesis catalyzed by adenylyl cyclases and activates cellular 
targets such as PKA and a termination phase that operates through PDEs to hydrolyze 
cAMP to 5′-AMP. The output of the pathway can be altered by regulating cAMP synthesis 
or through regulation of the rate of cAMP hydrolysis (Conti and Beavo 2007). The 
activation phase is well characterized where cAMP binding mediates conformational 
changes leading to dissociation of inactive PKA holoenzyme. However, little is known 
about how cAMP tightly bound to the R-subunit is released to facilitate reassociation with 
the C-subunit (termination phase) for resetting of PKA holoenzyme to resume a new cycle 
of activation-termination (Fig. 3.1). For inactivation, C-induced cAMP release and 
passive, PDE-mediated hydrolysis of displaced cAMP would offer only a minimal 
contribution towards cAMP signal termination. The only route to terminate the catalytic 
activity of PKA C-subunit necessitates reassociation with cAMP-free R-subunit, 
generated by direct hydrolysis of bound-cAMP by PDEs through the substrate channeling 
model proposed earlier (Moorthy, Gao et al. 2011).  
The concept of substrate channeling has been primarily described in metabolic 
enzymes where in addition to compartmentalization, supramolecular complexes function 
to restrict the diffusion of reaction intermediates through the formation of specific 
channels between the associated constituent proteins (Spivey and Ovadi 1999). In 
Tryptophan Synthase and Pyruvate Dehydrogenase complex (Miles 2001, Wang, Baker 
et al. 2010), for example, substrate channeling occurs by translocating the product of one 
enzyme directly into the other active site within the same supramolecular assembly. While 
channels have only rarely been described in signaling pathways, we have recently 
proposed substrate channeling as a mechanism for rapid hydrolysis of cAMP bound to its 




Figure 3.1: Overview of activation and termination phases of cAMP signaling. In a stimulated 
cell cAMP flux activates PKA holoenzyme (PDB ID: 2QCS) by mediating dissociation of the 
regulatory subunit (gray, 1RGS) and catalytic subunit (magenta, PDB ID: 1ATP). Active C-subunit 
phosphorylates various downstream targets, including PDE8. PDE8 (catalytic domain in yellow, 
PDB ID: 3ECN) catalyzes the passive hydrolysis of cAMP to 5′-AMP. Red oval highlights active 
hydrolysis of cAMP bound to PKA R-subunit by PDE8 leading to decreased in cAMP levels and 
generation of cAMP-free R-subunit, discussed in this chapter. This inactivates C-subunit and 
facilitates termination of the cAMP signaling pathway. This image is taken and modified from our 
published article (Krishnamurthy, Moorthy et al. 2014). 
 
In this chapter, I describe how this channel functions to directly access cAMP 
tightly bound to its target, the regulatory subunit of PKA and enables steering towards the 
active site of PDE8. In order to describe this, I have used multiple biophysical and 
structural approaches to characterize the PDE8:PKAR complex and determine the 
mechanism and rate of cAMP release. The results show that the ligand stabilizes the 






3.2 MATERIALS AND METHODS 
3.2.1 Methods 
Chemically ultra-competent Escherichia coli BL 21 (DE3) bacterial strains used 
for protein expression were obtained from Life Technologies (Carlsbad, CA). TALON® 
cobalt resin for his-tagged affinity purification was from ClonTech (Mountain View, CA) 
while BioGel HTP hydroxyapatite beads were from BioRad laboratories (Hercules, CA). 
Fluorescent analogs of cAMP: 8-[fluo]-cAMP (8- (2-[Fluoresceinyl] aminoethylthio) 
adenosine- 3', 5'- cyclic monophosphate) and 2′-fluo-AHC-cAMP (2′- (6- [Fluoresceinyl] 
aminohexylcarbamoyl) adenosine- 3', 5'- cyclic monophosphate) were acquired from 
Biolog Life Science Institute (Bremen, Germany). AMP-GloTM assay kit was from 
(Promega, Madison, WI). Carbon-coated copper grid was obtained from TedPella Inc. 
(USA). LC/MS grade acetonitrile, methanol, and water were from Fisher Scientific 
(Waltham, MA); and trifluoro acetic acid (TFA), sequence analysis grade from Fluka 
BioChemika (Buchs, Switzerland). Deuterium oxide was from Cambridge Isotope 
Laboratories (Tewksbury, MA). All other reagents and chemicals were research grade or 
higher and obtained from Sigma-Aldrich (St. Louis, MO). 
3.2.2 Expression and purification of RIα and PDE8AC 
Full-length construct of bovine PKA regulatory subunit (PRKAR1A, UniProt ID: 
P00514) and deletion construct spanning the catalytic domain of PDE8A1 (UniProt ID: 
O60658) were expressed and purified as described in methods section of chapter 1.  
3.2.3 Fluorescence polarization spectroscopy of RIα and PDE8 
Fluorescence polarization assays (Rossi and Taylor 2011) were performed using 
two fluorescent analogs of cAMP: (i) a PDE-resistant analog – 8-[fluo]-cAMP and (ii) an 
analog susceptible to PDE hydrolysis – 2′-fluo-AHC-cAMP (Fig. 3.2). Both ligands have 
been shown to bind RIα with high affinities, comparable to cAMP (Ogreid, Ekanger et al. 
1989). Purified RIα was saturated with the fluorescent cAMP analogs (20 µM) 
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individually at 277 K with constant slow mixing. Unbound ligands were removed by size 
exclusion chromatography on HiLoad 16/60 Superdex 200 pg column on AKTATM FPLC 
system. Fluorescence polarization (FP) assays were performed in 96-well opaque black 
plates from Greiner Bio-One (Germany) using Synergy 4 multi-detection microplate 
reader (BioTek, Winooski, VT) operated in FP mode. For both ligands, excitation 
wavelength λex = 485 nm and emission wavelength λem =524 nm were used with a 
bandwidth of 20 nm and instrument G-factor set at 0.87. All FP experiments were carried 
out with fluorescent cAMP-bound RIα at a final concentration of 5 µM at 298 K. In the 
first set of experiments, unlabeled cAMP (330 µM) and PDE8AC (10 µM) (final molar 
ratio of 2:1 PDE8AC:RIα) were added separately to fluorescent cAMP analog saturated 
RIα at t = 0 min and t = 20 min. To monitor PDE-mediated unbinding of cAMP, PDE8AC 
was added at time t = 20 min to sample set containing fluorescent cAMP-saturated RIα 
and unlabeled cAMP (330 µM. t = 0 min). In the next set of experiments, the complex 
was ‘pre-formed’ by adding PDE8AC (10 µM) to fluorescent cAMP bound RIα (5 µM) at 
t = 0 min followed by unlabeled cAMP (330 µM) or AMP (2 mM) at 20 min. FP values 
of 8-[fluo]-cAMP (5 µM), 2′-fluo-AHC-cAMP (5 µM), and PDE8AC (10 µM) were also 
obtained as control experiments. All experiments were performed thrice, each time in 
technical triplicates. Mean and standard deviation values were analyzed and the graphs 
were plotted using GraphPad Prism 5.0 (San Diego, CA). 
3.2.4 Size-exclusion chromatography of PDE8A and PKA RIα complex 
To determine complex formation between PDE8A and RIα proteins, size-
exclusion chromatography (SEC) was performed using different ligands in the 
chromatography buffer (Bloustine, Berejnov et al. 2003, Mayer, Snyder et al. 2009). In 
the first set, PDE8A and RIα were mixed in 3:1 ratio (45 µM: 15 µM) and incubated for 
5 min on ice with and without excess cAMP (10 mM) and 3 ml of sample mixture were 
separately injected. In the next chromatography run, the two proteins were incubated with 
0.5 mM 2′-fluo-AHC-cAMP ligand (PDE-hydrolysable) and incubated on ice for 5 min. 
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A series of SEC runs were carried out for determining complexation between PDE8 and 
RIα in different conditions, where the chromatography buffer was complemented with: 
(1) 5 mM EDTA (to strip PDE activity), (2) 2 mM cAMP (to monitor cAMP stabilization 
of the complex), and (3) 10 mM AMP (to monitor AMP-mediated stabilization of the 
complex). The chromatography columns were pre-equilibrated with respective buffers 
before sample injection. Each sample mixture was injected onto HiLoad 16 60 S200 pg 
column installed on AKTATM FPLC system (GE Healthcare, Marlborough, MA), at 0.5 
ml/min flow rate of respective chromatography buffer. Elution of proteins was detected 
by ultraviolet absorbance at 280 nm. The fractions were collected for analysis by 
denaturing SDS-PAGE and detected via coomassie brilliant blue staining. Additionally, 
PDE8A complexation with 2′-fluo-cAMP saturated RIα in the presence of excess AMP 
(10 mM) in the chromatography buffer was carried out on analytical size-exclusion 
chromatography HiLoad 10/300 S 200 pg column too and eluate fractions were analyzed 
by SDS-PAGE electrophoresis. 
3.2.5 Cryo-Electron Microscopy (Negative Staining) 
Single particle electron microscopy of RIα and PDE8A as a complex was 
performed to determine the structure of the complex (Booth, Avila-Sakar et al. 2011, De 
Carlo and Harris 2011). Firstly, the stoichiometric ratio of PDE8A:RIα interaction was 
determined by diluting different ratios of RIα and PDE8AC in buffer with excess cAMP, 
followed by size exclusion chromatography using buffer (50 mM Tris pH 7.5, 100 mM 
NaCl, 5 mM MgCl2, 20 µM ZnSO4, 5 mM β-ME). In addition to cAMP, PDE-resistant 
cAMP analog 8-[fluo]-cAMP was also used to stabilize the PDE8A:RIα complex. Peak 
elution fractions were quantified by Bradford colorimetric method and a concentration of 
1 mg/ml for complex was used. For determining the structure, PDE8AC:RIα (1:1 and 3:1 




Samples were diluted 500x prior to negative stain and 5 µl of the diluted samples 
were placed on glow-discharged carbon coated copper grid (Ted Pella Inc., USA). After 
30 seconds for sample absorption, the excess sample was blotted dry using a filter paper, 
followed by two washes with drops of distilled water. Individual samples (cAMP and 
AMP) were then stained with 0.75% uranyl formate (Hatfield, PA) solution for 45 seconds 
and excess stain dried away by blotting before TEM observation. Prior to sample 
insertion, alignment of the microscope in freezing conditions was checked, followed by 
loading the grid in the single-tilt standard sample holder. Samples were imaged by Tecnai 
T12 transmission electron microscope (FEI Company, Hillsboro, Oregon) operating at 
120 keV, equipped with Gatan 4k x 4k CCD camera, at two magnifications 67,000 (1/25 
Å/pixel) and 110,000 (1 Å/pixel) with defocus set to -1.5 µm to -2.5 µm. TEM images, 
proteins with white contrast against the dark background of carbon grid from an evenly 
stained area were captured at different magnifications were then analyzed using EMAN2 
(Tang, Peng et al. 2007) software to determine the sizes of particles and the formation of 
protein complexes were visualized.  
[The electron microscopy experiments were performed at NUS Cryo-EM facility under 
the guidance of Tran Bich Ngoc (Ann).] 
3.2.6 Phosphodiesterase activity assay of PDE8A:RIα 
 Activity of purified catalytic domain of PDE8A was determined by performing a 
phosphodiesterase assay using BioMol malachite green assay kit, which quantifies the 
phosphate indirectly released from PDE8A activity (reaction mixtures contained alkaline 
phosphatase, which hydrolyses 5′-AMP to adenosine and inorganic phosphate). To 
measure the enzymatic efficiency of PDE8A bound to RIα and compare its kinetics with 
free PDE8AC, a sensitive AMP-GloTM assay (Promega, Madison, WI) was employed. This 
commercial assay quantifies the amount of AMP product generated as a result of 
enzymatic activity, by conversion of AMP to ATP by a two-step reaction. The ATP 
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generated from AMP then binds to an in-built luciferin-luciferase system that produces a 
luminescent signal (Mondal, Hsiao et al. 2016).  
Using this high-throughput assay, the ability of PDE8AC to hydrolyze cAMP as 
a free enzyme and as RIα-bound complex enzyme was tested with a range of cAMP 
concentrations (0.1, 0.25, 0.5, 1, 5, 10 and 25 µM) in a final volume of 10 µl. The AMP-
GloTM assays were carried out in 384-well white opaque plates from Greiner Bio-One 
(Germany), incubating the reactions for 60, 120 and 300 seconds at room temperature, 
and quenched using reagents from the kit. The amount of AMP produced by cAMP 
hydrolysis was detected by following manufacturer’s instructions, and the luminescence 
was detected by GloMax® Discover multimode plate reader (Promega, Madison, WI). The 
luminescence values were converted to amount of AMP product formed by referring to 
an AMP-standard curve. An average of three independent reaction measurements was 
calculated and fitted onto a curve for Michaelis-Menten equation using GraphPad Prism 
6.0 (San Diego, CA). 
3.2.7 Amide hydrogen-deuterium exchange mass spectrometry of RIα and PDE8A 
To monitor conformational dynamics of RIα, HDXMS experiments were carried 
out using 1.5 µM of RIα without addition of any external cAMP, in 30 µl reaction volume 
with D2O at a final concentration of 90%. To monitor real-time dissociation of the bound-
cAMP from RIα, PDE8AC (4.5 µM, 1:3 molar ratio) was simultaneously added to the 
reaction mixture in deuterium buffer (99.9% D2O, 20 mM Tris pH 7.5, 50 mM NaCl, 5 
mM MgCl2, 20 µM ZnSO4, 5 mM β-ME). The reaction was allowed to proceed for 
different labeling times (0.5, 1, 5, 10, 30, 60 and 100 min) and subjected to pepsin 
hydrolysis followed by LC-MS. 
To capture the conformational dynamics of two proteins in the complex, HDXMS 
experiments were done in two different ways – (i) to map the changes on RIα (1.5 µM), 
saturating amounts of PDE8C (4.5 µM) were maintained (PDE8AC:RIα = 3:1 molar ratio) 
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during the reaction conditions to channel all RIα in the complex form; (ii) to map the 
changes on PDE8AC (1.5 µM), saturating amounts of RIα (4.5 µM) were used 
(PDE8AC:RIα = 1:3 molar ratio) to maintain all of the PDE8AC in the complex form. Each 
sample set was tested out in no cAMP and excess cAMP conditions (330 µM). Control 
experiments to determine intrinsic dynamics of PDE8AC (3 µM) and PDE8AC:cAMP (3 
µM:330 µM) were also implemented. In all experimental sets, complexation reaction and 
deuterium exchange were initiated by simultaneous addition of the components and 
deuterium buffer (99% D2O, 20 mM Tris pH 7.5, 50 mM NaCl, 5 mM MgCl2, 20 µM 
ZnSO4, 5 mM β-ME) to obtain real-time measurements. 
All reactions were done in triplicates at 298 K with labeling times of - 0.5, 1, 5, 
10, 30, 60 and 100 minutes. The exchange reaction was quenched by lowering the pH to 
2.5 using chilled 0.1% TFA. The quenched protein samples were then injected to nano-
UPLC sample manager subjected to pepsin cleavage, followed by reverse-phase 
chromatographic separation and identification by UPLC-coupled to mass spectrometer as 
explained in chapter 1.  
3.3 RESULTS 
3.3.1 Fluorescence polarization reveals ligand-mediated stabilization of PDE8:PKAR 
complex  
In order to determine the mechanism of recognition of cAMP-bound RIα by 
PDE8, we set out to use fluorescent analogs of cAMP as reporters to monitor changes in 
the ternary complex of PDE8AC:PKAR:cAMP by monitoring anisotropy changes using 
fluorescence polarization (FP) spectroscopy (Rossi and Taylor 2011). We chose two 
fluorescent analogs of cyclic AMP: (i) a PDE-resistant analog– 8-[fluo]-cAMP (Ogreid, 
Ekanger et al. 1989) and (ii) analog susceptible to PDE hydrolysis – 2′-fluo-AHC-cAMP 
(Huang, Zhang et al. 2002) henceforth referred to as ‘8-[fluo]-cAMP’ and ‘2′-fluo-cAMP’ 




Figure 3.2: Fluorescent cAMP analogs. Chemical structures of the two fluorescent analogs of 
cAMP used in this study - PDE non-hydrolysable 8-fluo-cAMP on the left and PDE-hydrolysable 
2′-fluo-AHC-cAMP on the right. The fluorescein moieties are highlighted in blue. 
 
Full-length dimeric PKA R-subunit (RIα) was saturated with the two fluorescent 
cAMP analogs (henceforth referred to as ‘8-[fluo]-cAMP:RIα’ and ‘2′-fluo-cAMP:RIα’ 
for RIα bound to 8-[fluo]-cAMP and 2′-fluo-cAMP respectively) as described in methods. 
The resistant analog 8-[fluo]-cAMP would report the effects of ternary interactions 
between cAMP-bound to RIα with PDE8AC, i.e. recognition and complexation of PDE8 
to cAMP-bound RIα  without hydrolysis (Fig. 3.3, 1); while 2′-fluo-cAMP would allow 
monitoring of PDE8AC binding and hydrolysis events of cAMP-bound RIα (Fig. 3.3, 2 
and 3). Without addition of PDE8AC, FP of 8-[fluo]-cAMP:RIα and 2′-fluo-cAMP:RIα 
remain unchanged throughout the timescale of the experiment (100 min) (blue plots in 
Fig. 3.3A, B), indicative of strong association of the fluorescent cAMP analogs with RIα 
without any detectable dissociation during the time course of the experiment. Addition of 
excess cAMP at 0 min or 20 min, resulted in competitive displacement of 8-[fluo]-cAMP 
and 2′-fluo-cAMP from RIα respectively, as seen by the decrease in fluorescence 
polarization (orange plots in Fig. 3.3A, B).  
Step 1: To monitor the formation of a ternary complex of PDE8AC with cAMP-
bound RIα, equimolar PDE8AC was added to RIα saturated either with 8-[fluo]-cAMP or 
2′-fluo-cAMP. An increase in polarization for PDE8AC complexes with 8-[fluo]-
cAMP:RIα or 2′-fluo-cAMP:RIα (green plots in Fig. 3.3A, B) was observed, which were 
greater than that observed for 8-[fluo]-cAMP:RIα or 2′-fluo-cAMP:RIα. The increase in 
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FP values reflects the formation of a stable ternary complex of PDE8 and RIα in the 
presence of fluorescent cAMP analogs. We did not observe any significant changes in 
polarization for PDE8AC alone with the two fluorescent cAMP analogs (Fig. 3.4), hence 
the increased polarization observed for the above reactions can be attributed only to 
complexation. These results confirm that PDE8AC preferentially interacts with cAMP-
bound RIα and forms a stable complex with the RIα. 
Step 2: While increased polarization was observed upon addition of PDE8AC, the 
differences in FP between 8-[fluo]-cAMP:RIα:PDE8AC and 2′-fluo-cAMP:RIα:PDE8AC 
complexes highlight the different properties of the two fluorescent cAMP analogs. 
Constant FP values in Fig. 3.3A i (green triangles plot) indicate an inactive initiation 
complex of 8fl-cAMP:RIα:PDE8AC, while reduced FP values in Fig. 3.3B i (green 
triangles plot) at the end of the experiment (100 min) indicates an endpoint complex bound 
to product, i.e., 2′fl-AMP:RIα:PDE8AC. Importantly, these results also suggest that the 
cAMP was directly translocated to PDE8AC (without dissociation of the PDE8:PKA-RIα 
complex), as neither an abrupt decrease in polarization during the reaction nor progressive 




Time plots of polarization were generated using GraphPad Prism 6.0 (San Diego, CA). Each point represents an average value obtained from triplicate measurements from two 
independent experiments. Error bars (0-3 mP units) are too small to be readily visible in the plots. 
Figure 3.3. Complexation of PDE8:PKA-
RIα facilitates hydrolysis of cAMP by direct 
channeling. (i) To full-length RIα (●) 
saturated with either 8-[fluo]-cAMP in panels 
A or 2′-fluo-cAMP panels in B, 330 µM 
cAMP (■) and 10 µM PDE8AC (▲) were 
added at 20 min and polarization values 
recorded for 100 min. Higher polarization 
indicates reduced mobility of the fluorescent 
ligand, and hence the complexation of 
PDE8AC and RIα (1). Differences between 
the properties of the two fluorescent cAMP is 
demonstrate PDE8-mediated hydrolysis of 
cAMP (2), and hence decreased polarization 
by the end of 100 min. (ii) To fluorescent 
cAMP saturated RIα, cAMP (□) and PDE8AC 
(△) were added at 0 min, cAMP (0 min) 
followed by PDE8A
C
 at time t = 20 min to 
reactions with 8-[fluo]-cAMP and 2′-fluo-
cAMP (◆), which depicts the processive 
cAMP hydrolysis by PDE8AC:RIα complex 
(3). (iii) Competitive displacement of 8-
[fluo]-cAMP (A) and 2′-fluo-cAMP (B) from 
PDE8A
C
:RIα complex by cAMP (◆) or 2 





Step 3: We next set out to measure how this ternary complex processed cAMP, 
by adding PDE8AC at time t = 20 min, to both 8-[fluo]-cAMP:RIα and 2′-fluo-cAMP:RIα 
samples initially (0 min) incubated with a large molar excess of cAMP (330 µM). At time 
t = 0 min, decreased polarization was recorded as cAMP displaced out the fluorescent 
cAMP analogs. Addition of PDE8AC to this reaction showed no change in FP values for 
the 8-[fluo]-cAMP:RIα reaction alone but a sharp increase in the 2′-fluo-cAMP:RIα (red 
plots in Fig. 3.3 Aii, Bii). This indicated that addition of PDE8AC catalyzes a rapid 
hydrolysis of cAMP leading to quick reassociation of 2′-fluo-cAMP (or 2′-fluo-AMP) to 
PDE8AC:RIα complex. Estimated rates of hydrolysis observed in this experiment were 
comparable to those reported previously for PDE8AC (Wang, Yan et al. 2008) . 
Surprisingly, no increase in FP was observed upon addition of PDE8 to 8-[fluo]-
cAMP:RIα, indicating that this particular analog was unable to reassociate with the 
PDE8AC:RIα complex. Lack of reassociation of a non-PDE hydrolysable cAMP analog 
suggested that PDE8AC:RIα is a catalytic complex, as observed with the additional set of 
experiments. This shows that the PDE8:RIα:cAMP complex does not dissociate in the 
presence of excess cAMP substrate or the 5′-AMP (henceforth referred to as ‘AMP’) PDE 
product over the duration of the experiment (100 min).  
Next, an excess of PDE-substrate (red plot, 330 µM cAMP) or PDE-product (lilac 
plot, 2 mM AMP) were added to preformed RIα:cAMP:PDE8 complex. No change in 
polarization was observed indicating that presence of ligands did not competitively 
displace ‘pre-formed’ PDE8AC:RIα complex interactions (Fig. 3.3A iii, 3.3B iii), but may 
have helped in stabilizing it further. These results prove that the larger fluorophore 
cAMP/AMP ligand stays stably bound to the complex. We did not observe any significant 
changes in polarization between free PDE8AC with the two fluorescent cAMP analogs, 
and hence the increased polarization observed for the above reactions can only be 
attributed to complexation. 
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The fluorescence polarization results reveal complexation of RIα and PDE8AC in 
the presence of cAMP, which is also stably maintained in the presence of the product 
AMP. 8-[fluo]-cAMP is unable, but 2′-fluo-cAMP is capable of binding the PDE8-RIα 
complex. Pre-bound 8-[fluo]-cAMP:RIα:PDE8AC and 2′-fluo-cAMP:RIα:PDE8AC 
complexes do not show any fluorescent cAMP analog dissociation from the complex. This 
can be attributed to substitutions at the 2′ and 8-positions of cAMP together with 
additional binding contributions from the bulky fluorescein moiety blocking the release 
of the fluorescent analogs from the complex (Fig. 3.3A iii, 3.3B iii). Together, these 
results confirm the formation of stable PDE8AC:RIα complex in the presence of ligand, 
and that the complex facilitates hydrolysis of cAMP through direct translocation of cAMP 
from RIα to PDE8 (substrate channeling). 
 
Figure 3.4: Fluorescence Polarization of fluorescent analogs and PDE8AC: Depiction of 
the control fluorescence polarization experiment carried out for free PDE8AC with the two 
fluorescent cAMP analogs. PDE8AC (10 µM) was treated with 8-[fluo]-cAMP (10 µM, ●) and 
2′-fluo-AHC-cAMP (10 µM, ○) and the fluorescence polarization was recorded for total time 
of 50 minutes. No significant changes in polarization was observed for PDE8AC with 8-fl-
cAMP (●) or PDE8AC with 2′-fluo-cAMP (●). Each point represents an average of technical 
triplicate and standard errors are also shown. 
 
3.3.2 SEC binding assays show complexation of PDE8A, RIα in excess cAMP 
Size-exclusion chromatography is routinely used as a standard protein 
purification procedure and determine the stability of protein-protein complexes in vitro. 
Fractionation or resolution of the proteins depends not only on their size but also on their 
shape and morphology (Erickson 2009, Mayer, Snyder et al. 2009). To determine the 
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stability of the complex formation between PDE8A and RIα, size exclusion 
chromatography (SEC) was performed. Initially, the efficiency of the chromatographic 
column was tested using a set of low-molecular weight and high-molecular weight protein 
standards (GE Lifesciences) for calibration. Their elution profiles and resolution were 
similar to the standard profiles provided by the manufacturer, except that we observed a 
+10 ml shift in elution volumes of the proteins (Appendix – A5).  
A series of SEC runs were performed using different ligands and the results are 
shown in Fig. 3.5. Firstly, when RIα and PDE8AC were taken together in limited 
concentrations of cAMP (Fig. 3.5 iii, iv), we observed elution of two peaks, one at ~81 
ml and second at ~96 ml respectively. The elution profiles of these two peaks 
corresponded to the peaks elution observed for the individual proteins RIα and PDE8AC 
respectively (Fig. 3.5 i, ii), indicating that the complex was unstable in minute 
concentrations of cAMP. This can be attributed to transient nature of complex which got 
dissociated by the continuously flowing buffer. In accordance with the fluorescence 
polarization assay, we then used PDE-hydrolysable analog of cAMP (2′-fluo-cAMP) in 
the reaction to form a complex and an excess of ligand in the chromatography buffer. We 
observed elution of two peaks, where a positive shift of the first peak (from 82 ml to ~87 
ml), and no shift of the second peak was detected in the chromatogram (Fig. 3.5 v, vi). 
Analysis of these peaks by denaturing acrylamide gel electrophoresis showed protein 
bands at molecular weights corresponding to both RIα and PDE8AC purified proteins, as 
shown in Fig. 3.5 B (lanes B5 and B6). As PDE8AC was used in much higher 
concentrations than RIα, the second peak was also detected whose fractions on denaturing 
electrophoresis corresponded to molecular weight ~40 kDa (Fig. 3.5B lanes B1-B4; Fig. 
3.5C lanes C1, C3). 
To check if the shifted peak (first peak) corresponded to PDE8AC:RIα complex, 
another chromatography run was performed, except that the PDE8 catalytic activity was 
abolished by stripping away the metal cations by EDTA (Fig. 3.5 vii). Consistent with our 
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expectations, two peaks were eluted at volumes respective to that of individual proteins 
RIα and PDE8AC (~82 ml and ~95 ml, respectively), indicating lack of complexation. 
Peak fractions from these SEC runs were analyzed by denaturing SDS-PAGE, we did not 
observe two protein bands in early peak fractions (Fig. 3.5 C, C7), but observed a band of 
PDE8AC from the later peak (Fig. 3.5C, C2 and C4). Control samples of PDE8AC, samples 
injected were also analyzed by SDS-PAGE and are indicated in Fig. 3.5B, C. 
 
Figure 3.5: Size-exclusion chromatography profiles of PDE8 and RI  in various conditions. (A) 
Purification of full-length RIα (i) and the catalytic domain of PDE8A (ii) by size exclusion 
chromatography. Chromatograms of PDE8A (45 µM) with RIα (15 µM) in different conditions are 
shown without external cAMP (iii) and with 10 mM cAMP (iv) in the reaction mixture. Next, 0.5 
mM 2′-fluo-cAMP was added to PDE8AC:RIα reaction mixture and SEC buffer was complemented 
with 5 mM EDTA (v), 2 mM cAMP (vi) and 10 mM AMP (vii). Vertical red dashed lines 
correspond to the peaks with their respective elution volumes indicated. (B) Coomassie brilliant 
blue stained acrylamide gels for SEC runs with 2′-fluo-cAMP and 10 mM AMP (vii). Lanes B1- 
B3 are fractions from peak 2, B4 - trough between two peaks; B5-B6 - early peak fractions; B7 - 
early fraction (control), B8 - sample injected onto FPLC, B9 - PDE8AC protein, B10 – standard 
protein molecular weight marker (Fermentas pre-stained protein ladder) with band weights shown 
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in kDa. In B5-B6, top band corresponds to RIα and bottom band corresponds to PDE8AC. (C) 
Acrylamide gels of fractions analyzed from RIα-PDE8AC reaction with 2′-fluo-cAMP in presence 
of cAMP (v) and EDTA (vi). Fractions from peak 2 of reaction v – C1, C3; reaction vi - C2, C4, 
fractions from peak 1 from EDTA-stripped PDE8AC (v) in lanes C5, C6; and reaction in vi  in lane 
C7; C8 – protein molecular weight standard with values in kDa; samples injected into FPLC, for 
reaction v in lane C9, and reaction vi in lane C10. 
 
 
To further confirm our observations that the shift in elution is indeed due to 
complexation, SEC of PDE8AC, RIα and 2′-fluo-cAMP along with excess AMP in 
chromatography buffer was performed again on an analytical column, and similar results 
were observed (Fig. 3.6A). A shift in early peak corresponded to PDE8AC:RIα complex 
and second peak corresponded to remaining PDE8AC (Fig. 3.6B). These results, therefore, 
show a stable complexation between RIα and PDE8AC in the presence of ligand. 
Moreover, the intensities of peaks were similar across different SEC runs, with the 
intensity of peak corresponding to PDE8AC:RIα complex being higher, unlike to the SEC 
runs that lack of complexation having higher intensities for the PDE8AC peak. 
 
   
 
Figure 3.6: Determining the 
association of PDE8A and RIα as a 
complex. (A) Size exclusion 
chromatogram of PDE8A with RIα 
in presence of 2′-fluo-cAMP and 10 
mM AMP in buffer performed on 
HiLoad 10 300 S200 analytical 
column. Elution of proteins were 
measured by absorbance at 280 nm, 
with arrows indicating the peak 
fractions at 14.3 ml (0.6 cv, early 
peak) and 16.8 ml (0.7 cv second 
peak). (B) Coomassie stained 
acrylamide gels of fractions 
corresponding to peak 1 (L1-L3); 
peak 2 (L4-L5); and peak 3 (L6-L7); 
and M is protein molecular weight 
standard. The peak fraction showing 
the presence of bands of both 
proteins RIα and PDE8AC are 




Elution of protein-protein complexes is determined by its Stoke’s radius and the 
frictional coefficients rather than just its molecular weight. The extended bilobal structure 
of RIα and the groove containing structure of PDE8A dimer interact/associate to form a 
compact globular structure of PDE8AC:RIα complex and hence the elution was observed 
at a later volume. A computational model of deletion construct of RIα (RIαAB) with 
PDE8AC dimer was modeled previously, which showed that a monomer of RIα could fit 
in the groove between PDE8AC dimer (Krishnamurthy, Moorthy et al. 2014). Moreover, 
it has been shown that isoforms of PDE4D of same molecular weight take up different 
shapes and have different size-exclusion chromatography elution profiles (Richter 2005). 
A qualitative similarity between the size-exclusion chromatograms along with the other 
results from fluorescence polarization, HDXMS, and cryo-EM can be clearly observed. 
Moreover, stable complexation of PDE8Ac and RIα in low micromolar concentrations 
(15-50 µM) in the chromatography runs, suggests an affinity of ~ sub-micromolar range 
of PDE8AC:RIα complex in the presence of ligand. 
3.3.3 PDE8A:PKA-RIα complex visualized by Cryo-Electron microscopy 
The results from fluorescence polarization assay and size-exclusion 
chromatography provided insights into stable association of PDE8AC and PKA-RIα to 
each other in the presence of excess cAMP and the non-hydrolysable cAMP substrate. 
High-resolution structures of these two individual partner proteins have been solved by 
X-ray crystallography and partly by NMR (Su, Dostmann et al. 1995, Yan, Wang et al. 
2009, McNicholl, Das et al. 2010). In order to structurally characterize the PDE8AC:RIα 
complex, we attempted to co-crystallize the proteins under different crystallization 
screening conditions. However, various studies have shown that the unstructured region 
at N-terminus of RIα is highly dynamic and the electron density of this region could not 
be assigned (Bruystens, Wu et al. 2014). Besides, RIα binds to AKAPs firmly and many 
groups have solved the AKAP-bound structures of RIα by cryo-electron microscopy 
(Smith, Langeberg et al. , Gold, Lygren et al. 2006). In addition to X-ray crystallography, 
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I set out to elucidate the structure of PDE8A:RIα complex by cryo-electron microscopy, 
an important structural tool to solve structures of large biological assemblies such as 
viruses or protein-protein complexes in a non-crystalline manner (Thompson, Walker et 
al. 2016). In certain cases it has been showed that cryo-EM technique is complementary 
to X-ray crystallography, thus obtaining a cryo-EM structure for PDE8A:RIα complex, 
and along with their available crystal structures would allow us to decipher its topology. 
Previous studies have reported that RIα monomer binds to PDE8AC dimer. In this 
study, I have used full-length construct of RIα, which exists as a dimer. Hence, a dimer 
of RIα would bind to two PDE8 dimers giving a complex of ~250 kDa, which can be 
visualized by cryo-EM technique. Preliminary negative stain images for PDE8AC and RIα 
complex in the presence of non-hydrolysable analog of cAMP (8-[fluo]-cAMP) showed 
a white contrast of protein-protein complexes, indicating a stable complex formation of 
PDE8AC with RIα in the presence of 8-[fluo]-cAMP. As shown in Fig. 3.7, TEM images 
of this sample were taken at two magnifications - 45,000x (left) and 110,000x (right) 
which showed white particles of ~15 nm in size, corresponding to that expected for this 
protein-protein complex. However, the sample appeared to be partly heterogeneous and 
aggregated. 
 
Figure 3.7: Transmission Electron Microscopy of PDE8A:RIα complex in presence of 
fluorescent cAMP. Negative stained images of 8-[fluo]-cAMP saturated RIα complexed with 
PDE8AC are shown at two magnifications 45,000 x (left panel) and 110,000x (right panel) with 
their scale bars indicated on bottom right. Randomly selected white protein particles against dark 
background of carbon-coated grid are highlighted by red triangles. Images were taken using Tecnai 




 To improve the homogeneity of the sample and exclude any aggregates, a 1:3 
molar ratio of PDE8AC and a large excess of cAMP and AMP (1000-fold) were used. 
Negative stain images of these hydrate protein complexes were taken and representative 
images are shown in Fig. 3.8.  No particles were visible at high magnification in samples 
without addition of cAMP, indicating lack of complexation. This served as an important 
control for subsequent results, where white protein-protein complex particles of 
PDE8A:RIα were clearly visible in the presence of excess cAMP (Fig. 3.8 ii) as well as 
excess AMP (Fig. 3.8iii). Interestingly, a more homogeneous sample of 
PDE8AC:AMP:RIα complex was visible indicating a catalytically inactive end-state 
complex. The sizes of these protein particles observed are estimated to be ~15-17 nm, 
which is postulated to be the size of RIα dimer with two dimers of PDE8AC.  
 
Figure 3.8: Negative staining by Transmission Electron Microscopy of PDE8A:RIα complex 
with excess ligand. Negative stain images of PDE8AC:RIα complex without ligand (i); in presence 
of cAMP (ii) and in presence of AMP (iii) are shown at 67,000x magnification. White particles 
indicate protein(s) complexes. Lack of visible protein-protein assemblies in absence of cAMP, 
while ~15 nm sized PDE8AC:RIα complex in presence of cAMP or AMP are highlighted by 
triangles. The scale bars are also indicated. 
 
 
These results provide a visual aid of the complex, where excess ligand stabilizes PDE8A 
complexation with RIα and be detected by cryo-electron microscopy. In continuation with 
negative staining procedure, vitrifying of the complex for cryo-EM test imaging were also 
carried out and showed the presence of protein-protein complex. Further studies and 
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optimization of PDE8A:RIα complex are on-going to yield a sub-atomic resolution 
structure of PDE8AC:RIα complex. 
3.3.4 RIα activates PDE8: Increased cAMP hydrolysis by PDE8AC:RIα 
Substrates of intracellular PDEs are assumed to predominantly be free, unbound 
cyclic nucleotides in solution. Cyclic AMP specific PDEs, such as PDE8, however show 
hydrolytic activity for unbound cAMP in solution as well as cAMP bound to their protein 
targets. Furthermore, we previously reported RIα-mediated 13-fold activation in RegA 
phosphodiesterase activity (Moorthy, Gao et al. 2011). The fluorescence polarization 
experiments revealed that the PDE8A:RIα complex was maintained in the presence of 
excess cAMP (ligand) or AMP (product). We set out to measure the rate of cAMP 
hydrolysis by PDE8A:RIα complex, a comparison of hydrolysis rates of free cAMP by 
PDE8A alone with that of hydrolysis of cAMP bound to its receptor by the PDE8:RIα 
complex. For this, we performed a linked assay (Mondal, Hsiao et al. 2016) where AMP 
generated was measured by conversion to ATP and subsequently detected as an increase 
in Luciferin luminescence by commercial AMP-GloTM assay (Promega, Madison, WI) as 
described in methods. The catalytic domain of PDE8AC has a KM of 1-1.5 µM (Yan, Wang 
et al. 2009), and for these experiments, 0.1-25 µM range of cAMP concentrations were 
used.  
Enhanced AMP synthesis (cAMP hydrolysis) was observed in PDE8A:RIα complex 
over PDE8A alone as seen in the Michaelis-Menten plot (Fig. 3.9). As RIα encompasses 
two cAMP binding sites, a two-site binding equation was used to fit the plot of hydrolysis 
of bound-cAMP by PDE8AC. Significantly, plots of AMP synthesis (cAMP hydrolysis) 
with time for PDE8AC in the presence of RIα revealed an interesting burst and lag phase 
kinetic profile, suggesting two catalytic rates of cAMP hydrolysis. This can be explained 
by the different affinities of the two distinct cAMP binding sites in the RIα, CNB:A and 
CNB:B, each coupled to the active site of each PDE8AC monomer in the PDE8AC:RIα 
complex. This would result in two distinct composite active sites, each saturable with 
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cAMP at different concentrations. One active site was inferred to be saturable at 
concentrations up to 5 µM cAMP (Fig. 3.10A), which was hydrolyzed at high initial 
velocity, while the second active site was saturable with cAMP at concentrations > 10 µM 
(Fig. 3.10B).  
 
Figure 3.9: Enhanced cAMP hydrolysis by PDE8A:RIα complex. (i) Plot of AMP generation 
(µM/min) reflecting cAMP hydrolysis, versus substrate cAMP concentrations (µM) by 
PDE8AC (◼) with curve fit onto Michaelis-Menten kinetics, while for PDE8AC:RIα complex 
(●) curve was fit to a curve describing sum of two-site binding of ligand. The plot for PDE8AC 
hydrolysis of cAMP-bound to RIα showed biphasic kinetics of cAMP hydrolysis where an 
initial burst phase of rapid cAMP hydrolysis was followed by a lag phase of slower cAMP 
hydrolysis. (ii) We resolved the burst phase kinetics by fitting the curve to Michaelis-Menten 
equation for calculating the hydrolysis rate. The values obtained were an average of triplicate 
measurements with error bars shown, and the graph was plotted by fitting into a curve for 
Michaelis-Menten equation in GraphPad Prism 6.0 (San Diego, CA). 
 
 
Consequently, the plot for hydrolysis of bound-cAMP was fit only for the fast 
hydrolyzing site (Fig. 3.9B) using Michaelis-Menten equation. The Vmax and KM values 
for hydrolysis of varying concentrations of cAMP by free PDE8AC were calculated to be 
Vmax = 0.04 ± 0.001 µM/sec and KM = 1.5 ± 0.3 µM, and for hydrolysis of different 
concentrations of cAMP by PDE8AC in the presence of RIα were Vmax = 0.16 ± 0.009 
µM/sec and KM = 0.98 ± 0.05 µM.  
Calculation of the Michaelis-Menten constants from these two phases for 
PDE8AC:RIα were based on the amount of AMP formed (product) as a function of time 
at different concentrations of cAMP (Fig. 3.10). The values for burst phase were plotted 
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by fitting the values of low concentrations of cAMP in a linear regression equation (Fig. 
3.10A), values at high concentrations constituting lag phase from two-site binding site 
hyperbola equation (Fig. 3.10B) using GraphPad prism 6.0. Similarly, the amount of AMP 
formed by cAMP hydrolysis by free PDE8A were also plotted (Fig. 3.10C). 
 
Figure 3.10: Amount of AMP formed by hydrolysis of cAMP by PDE8A:RIα complex and 
PDE8A. The amounts of AMP formed at different substrate concentrations is plotted as a function 
of time (1, 2 and 5 min) for the two enzymatic sites – PDE8AC:RIα complex and PDE8AC. (i) For 
cAMP hydrolysis by PDE8AC:RIα, concentration of AMP formed in the linear range of cAMP 
concentrations (0.1 – 5 µM) is depicted and their slopes calculated by linear regression equation. 
(ii) The biphasic burst and lag velocities for 10 µM and 25 µM were calculated using two-site 
binding equation for hyperbola, as shown. (iii) Concentration of AMP formed by cAMP hydrolysis 
by PDE8A at different cAMP concentrations are plotted with kinetics fitted into linear regression 
equation. The slopes for each graph were calculated from average of three independent 
measurements and their standard deviations are also shown. The graphs were plotted using 
GraphPad Prism 6.0 (San Diego, CA). 
 
Enhanced cAMP hydrolysis rates were observed for the PDE8AC reaction in the 
presence of stoichiometric amounts of RIα, indicating that PDE8AC preferentially 
hydrolyzed cAMP bound to RIα resulting in faster cAMP hydrolysis by the resultant 
PDE8AC:RIα complex. This preference of PDE8AC for cAMP-bound to its effector target 
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was observed despite unbound cAMP being in vast excess in the reaction and the strong 
cAMP binding affinity for the RIα (KD ~ 2 nM) (Ogreid and Doskeland 1983, Ogreid, 
Ekanger et al. 1989). Considering the higher affinity of RIα (>1000 times) for cAMP than 
PDE8A and the lowering of cAMP affinity for PDE8A by its association with RIα (0.98 
µM vs 1.5 µM for free PDE8A), it is clear that the RIα-mediated activation of PDE8AC 
must result from formation of a stable PDE8AC:RIα complex with altered catalytic 
properties, mediating processive hydrolysis of unbound cAMP in solution at enhanced 
rates. Comparison of the cAMP turnover rates indicated accelerated hydrolysis (5-fold 
activation) of cAMP by the new enzymatic core of the PDE8AC:RIα complex having a 
kcat of 4 s-1, whereas the kcat for free PDE8AC was 0.8 s-1. A five-fold activation of PDE8 
by RIα, and the polarization assay results, points towards hydrolysis of cAMP by coupling 
of the two active sites with subsequent cAMP channeling from the receptor site (CNB:A 
and CNB:B on RIα) to the PDE8 active site. This enhancement of enzymatic activity by 
PDE8A:RIα complex points towards the robustness in cAMP hydrolysis and faster 
desensitization to enable stimulation from next stimulus. This provides an important 
regulatory mechanism for dynamic levels of cAMP inside the cell and that the cell is 
activated during cAMP fluxes only. 
3.3.5 Dynamics of PDE8A:cAMP:PKA RIα interactions in the ternary complex 
 Our fluorescence polarization and cryo-EM results clearly pointed to stable 
complexation of cAMP-bound RIα and PDE8AC and enzyme kinetics showed that this 
complex enhanced hydrolysis in the presence of excess cAMP. Further, excess cAMP was 
capable of stably maintaining the dynamic complex of PDE8 and PKA-RIα. To map the 
interactions in the ternary complex and probe how the complex catalyzes turnover of 
excess cAMP, we used amide hydrogen-deuterium exchange mass spectrometry 
(HDXMS), which provides insights into the conformational dynamics of the protein(s)-
ligand complex at peptide resolution.  
 103 
 
We first set out to monitor PDE8A-aided cAMP release from full-length dimeric 
RIα with PDE8AC and to monitor how PDE8 hydrolyzed bound cAMP. HDXMS studies 
yielded 63 reporter peptides corresponding to a sequence coverage of ~85% of RIα as 
shown in Fig. 3.11.  
 
Figure 3.11: Sequence coverage of R-subunit by HDXMS. Primary sequence of full-length RIα 
is depicted. The lilac boxes indicate all peptide fragments spanning regions of the primary sequence 
obtained from our analysis for describing the effects of cAMP and PDE8A using HDXMS.  
Approximately 85% sequence coverage was observed. 
 
 
Comparison of HDXMS of the PDE8AC:RIα complex with cAMP-bound RIα 
(Fig. 3.12A) showed major differences in the following regions: (i) residues 112-144, (ii) 
αB:C helix (227-244), (iii) regions 157-161, 271-275; and (iv) both cAMP binding 
pockets (CNB:A and CNB:B) in the PDE8:RIα complex. Firstly, αB:C helix connecting 
the two CNB domains showed differences, with no considerable changes upon PDE8 
interaction in absence of external cAMP, and minor increases in relative deuterium 
exchange in ternary complex (with excess cAMP). Secondly, subtractive peptide analysis 
identified two regions (157-161 and 271-275) on RIα, which showed decreased exchange 




Figure 3.12: Mapping the PDE8:PKA-RIα interaction interface on cAMP-bound RIα by 
HDXMS. (A) Differences in average deuterons exchanged (Y-axis) in PDE8AC:RIα relative to 
cAMP-bound RIα for each pepsin fragment peptide listed from N to C-terminus (X-axis). Peptides 
spanning continuous regions grouped by brace brackets and domain organization of RIα is shown. 
Peptides spanning the cAMP binding regions in CNB:A (199-222) and CNB:B (329-338) are 
highlighted in orange and peptides specific to PDE8AC binding in green. Positive differences 
indicate increased exchange, while negative differences indicate decreased exchange in the 
PDE8AC:RIα complex. Deuterium exchange times for every peptide are depicted and colored 
according to key. Red dashed line represents a significance threshold of ±0.5 Da for differences in 
deuterium exchange and standard deviations are shaded gray. (B) Stacked mass spectra for RIα 
and PDE8AC:RIα binary complex after 10 min deuterium labeling are shown for the two peptides. 
Mass differences indicated by centroid are represented by red double-headed arrows, compared to 
undeuterated control. (C) Significant differences (>0.5 Da) in deuterium exchange in the binary 
complex compared to RIα are mapped on to the structure of RIα represented in cartoon as indicated 
in the key. The two RIα monomers are differentiated as R (left) and R’ (right). cAMP molecules 
are shown as yellow sticks. Parts of protein with no coverage are black.  
 
 
These residues spanning the β2-3 loop have been predicted to play an allosteric 
role in cAMP binding, and together with β4-5 loop been identified as potential sites for 
binding additional partner proteins (Kornev, Taylor et al. 2008). Significantly, compared 
to free RIα, these regions showed decreased hydrogen-deuterium exchange in the 
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PDE8AC:RIα complex and was consequently identified as sites for binding interactions 
with PDE8AC. Mass spectra of deuterium exchanged peptides highlighting the changes in 
average deuterons exchanged between cAMP-bound RIα and the ternary complex are 
shown in Fig. 3.12B. Differences between the PDE8AC:RIα and RIα after 10 min of 
deuterium labeling are mapped on the structure of dimeric RIα (PDB ID: 4MX3 
(Bruystens, Wu et al. 2014)) in Fig. 3.12C, with the two PDE8-binding regions 
highlighted in green.  
It must be noted that PDE8 binding to cAMP-bound RIα, mediates catalytic 
dissociation and hydrolysis of bound cAMP. This is reflected in the increased exchange 
in the CNB-domains (orange boxes) and exchange at the PDE8 interaction sites (green 
boxes) that is more pronounced at earlier time points of exchange but diminish with 
increasing exchange times. PDE8AC binding resulted in considerable disordering in the 
cAMP binding regions and reflects PDE8-mediated cAMP release through the weakening 
of interactions between cAMP and the RIα binding residues. Accompanying allosteric 
changes across other parts of RIα are seen by the overall increased deuterium uptake at 
longer labeling times. These together with the fluorescence polarization results point to a 
dynamic ternary complex with short dwell times (fast koff) (Chandramohan, 
Krishnamurthy et al. 2016).  
Table 3.1 tabulates the deuterium uptake values at 1, 10 and 30 min for R-subunit in 




Table 3.1:  Summary of deuterium uptake values exchanged for peptides spanning full length RIα, in limited cAMP and PDE8A-bound condition for 1, 
10 and 30 min deuterium labeling times. 
  
  
      
No. of deuterons 
exchanged after 1 min                          
(Mean± SD)b 
No. of deuterons 
exchanged after 10 min                   
(Mean± SD)b 
No. of deuterons 




Peptide sequence (MH+) Residues z MEAa PDE8A:RIα RIα PDE8A:RIα RIα PDE8A:RIα RIα 
1 LYVQKHNIQAL (1326.75) 19-29 2 10 n.a. 3.16 ± 0.04 n.a. 4.20 ± 0.1 n.a. 4.09 ± 0.04 
2 YVQKHNIQA (1100.58) 20-28 2 8 2.15 ± 0.01 2.50 ± 0.04 2.65 ± 0.04 3.18 ± 0.07 2.71 ± 0.04 3.05 ± 0.07 
3 YVQKHNIQAL (1213.67) 20-29 2 9 2.44 ± 0.03 2.50 ± 0.03 3.33 ± 0.02 3.40 ± 0.12 3.41 ± 0.06 3.31 ± 0.04 
4 QALLKDSI (887.52) 27-34 2 7 n.a. 0.99 ± 0.02 n.a. 1.57 ±  0.04 n.a. 1.94 ± 0.04 
5 LKDSIVQL (915.55) 30-37 2 7 0.59 ± 0.03 0.37 ± 0.01 1.13 ± 0.03 1.15 ± 0.05 1.57 ± 0.07 1.64 ± 0.06 
6 KDSIVQL (802.47) 31-37 1 6 n.a. 0.42 ± 0.02 n.a. 1.16 ± 0.05 n.a. 1.65 ± 0.06 
7 YFEKLEKEEAKQ (1541.78) 52-63 2 11 n.a. 3.34 ± 0.07 n.a. 3.91 ± 0.21 n.a. 4.27 ± 0.04 
8 EKEEAKQIQNL (1329.7) 57-67 2 10 4.22 ± 0.05 4.26 ± 0.03 4.14 ± 0.06 4.31 ± 0.04 4.74 ± 0.01 4.36 ± 0.01 
9 IQNLQKAG (871.5) 64-71 2 7 n.a. 0.91 ± 0.02 n.a. 1.43 ± 0.02 n.a. 1.77 ± 0.04 
10 DEISPPPPNPVVK (1388.74) 79-91 2 7 3.52 ± 0.08 3.96 ± 0.05 3.57 ± 0.04 3.97 ± 0.05 3.55 ± 0.04 3.9 ± 0.05 
11 YVRKVIPKD (1117.67) 112-120 3 7 3.23 ±  0.09 2.99 ± 0.02 3.28 ± 0.1 3.22 ± 0.05 3.22 ± 0.09 3.16 ± 0.04 








112-127 3 14 5.41 ± 0.09 5.09 ± 0.04 5.92 ± 0.09 5.88 ± 0.1 5.91 ± 0.1 5.85 ± 0.1 
15 VRKVIPKD (954.61) 113-120 2 6 2.49 ± 0.02 2.41 ± 0.02 2.61 ± 0.04 2.57 ± 0.04 2.54 ± 0.02 2.53 ± 0.04 
16 LAKAIEKNVL (1098.68) 127-136 2 9 3.02 ± 0.04 2.72 ± 0.03 3.85 ± 0.03 3.82 ± 0.09 4.15 ± 0.06 4.08 ± 0.03 
17 AKAIEKNVL (985.60) 128-136 2 8 2.66 ± 0.03 2.37 ± 0.03 3.23 ± 0.01 3.01 ± 0.1 3.52 ± 0.06 3.23 ± 0.07 






158-173 2 15 1.76 ± 0.05 2.63 ± 0.03 2.3 ± 0.02 3.05 ± 0.04 2.82 ± 0.03 3.21 ± 0.04 
20 TVIQQGDEGDNF (1322.58) 162-173 2 11 1.80 ± 0.01 2.34 ± 0.02 2.15 ± 0.02 2.61 ± 0.03 2.39 ± 0.06 2.61 ± 0.04 
21 VIQQGDEGDNF (1221.54) 163-173 2 10 1.82 ± 0.03 2.03 ± 0.03 1.99 ± 0.04 2.23 ± 0.02 2.04 ± 0.03 2.23 ± 0.03 
22 YVIDQGEM (954.42) 174-181 2 7 0.87 ± 0.01 0.81 ± 0.01 2.28 ± 0.01  1.02 ± 0.01 2.43 ± 0.05 1.5 ± 0.01 
23 YVIDQGEMDV (1168.52) 174-183 2 9 0.78 ± 0.03 0.76 ± 0.05 0.78 ± 0.03 0.92 ± 0.05 0.99 ± 0.03 1.40 ± 0.07 
24 WATSVGEGGSF (1097.49) 189-199 1 10 2.67 ± 0.08 2.52 ± 0.01 3.25 ± 0.04 2.77 ± 0.06 3.60 ± 0.12 2.82 ± 0.02 
25 FGELALI (762.44) 199-205 1 6 0.36 ± 0.01 0.22 ± 0.01 0.99 ± 0.05 0.34 ± 0.05 1.86 ± 0.1 0.39 ± 0.04 




203-218 2 14 3.31 ± 0.14 2.37 ± 0.02 4.3 ± 0.01 3.52 ± 0.09 4.92 ± 0.1 4.14 ± 0.03 








205-222 3 16 3.14 ± 0.1 1.68 ± 0.04 4.05 ± 0.13 2.52 ± 0.1 4.78 ± 0.2 3.15 ± 0.09 
31 VKAKTNVKL (1000.65) 214-222 2 8 n.a. 0.91 ± 0.1 n.a 1.06 ± 0.12 n.a. 1.32 ± 0.12 




223-239 3 16 2.05 ± 0.15 1.40 ± 0.05 3.1 ± 0.12 2.58 ± 0.06 4.1 ± 0.16 3.45 ± 0.14 
34 RRILMGST (933.53) 231-238 2 7 2.05 ± 0.03 1.73 ± 0.01 2.36 ± 0.03 2.61 ± 0.07 2.86 ± 0.14 2.59 ± 0.04 
35 RRILMGSTL (1043.61) 231-239 2 8 2.19 ± 0.04 1.55 ± 0.01 2.71 ± 0.03 2.34 ± 0.08 3.02 ± 0.09 2.69 ± 0.03 
36 LRKRKMYEEF (1399.75) 239-248 2 9 1.78 ± 0.02 1.34 ± 0.01 2.04 ± 0.04 1.98 ± 0.1 2.02 ± 0.05 2.00 ± 0.02 
37 RKRKMYEEF (1286.67) 240-248 3 8 2.03 ± 0.02 1.28 ± 0.01 2.32 ± 0.06 1.86 ± 0.1 2.30 ± 0.06 1.88 ± 0.02 
38 FLSKVSIL (906.56) 248-255 2 7 1.92 ± 0.01 1.91 ± 0.02 2.71 ± 0.01 2.83 ± 0.08 2.88 ± 0.05 2.91 ± 0.06 
39 LSKVSIL (759.49) 249-255 1 6 1.76 ± 0.03 1.62 ± 0.05 2.56 ± 0.03 2.53 ± 0.09 2.76 ± 0.04 2.61 ± 0.1 
40 ESLDKWERL (1175.6) 256-264 2 8 1.83 ± 0.06 1.23 ± 0.07 2.49 ± 0.03 1.85 ± 0.08 2.78 ± 0.06 2.07 ± 0.07 
 108 
 












276-291 2 14 2.06 ± 0.04 1.72 ± 0.01 2.94 ± 0.04 2.25 ± 0.06 3.73 ± 0.16 2.69 ± 0.04 
45 IILEGSA (702.40) 293-299 1 6 0.86 ± 0.02 0.75 ± 0.01 0.95 ± 0.02 1.04 ± 0.04 1.09 ± 0.04 1.35 ± 0.03 
46 VLQRRSENEE (1259.63) 301-310 2 9 2.49 ± 0.06 2.40 ± 0.04 2.52 ± 0.05 2.51 ± 0.04 2.45 ± 0.07 2.44 ± 0.03 
47 QRRSENEEF (1194.55) 303-311 2 8 n.a. 2.09 ± 0.06 n.a. 2.16 ± 0.06 n.a. 2.1 ± 0.07 
48 ENEEFVEV (994.44) 307-314 2 7 0.91 ± 0.03 0.54 ± 0.02 0.98 ± 0.03 0.72 ± 0.03 1.10 ± 0.03 0.77 ± 0.03 
49 FVEVGRLGPSDY (1138.67) 311-322 2 10 1.56 ± 0.03 1.49 ± 0.06 2.03 ± 0.04 1.92 ± 0.05 2.43 ± 0.07 1.95 ± 0.08 
50 LMNRPRAAT (1029.56) 329-337 2 7 1.72 ± 0.05 1.24 ± 0.01 2.14 ± 0.03 1.59 ± 0.03 2.53 ± 0.08 1.69 ± 0.03 
51 LMNRPRAATV (1128.63) 329-338 2 8 1.84 ± 0.04 1.14 ± 0.01 2.39 ± 0.03 1.42 ± 0.02 2.80 ± 0.1 1.57 ± 0.05 
52 MNRPRAAT (916.48) 330-337 2 6 1.50 ± 0.05 1.02 ± 0.02 1.82 ± 0.02 1.25 ± 0.03 2.20 ± 0.07 1.35 ± 0.04 
53 MNRPRAATV (1015.55) 330-338 2 7 1.62 ± 0.04 0.92 ± 0.02 1.94 ± 0.02 1.11 ± 0.01 2.45 ± 0.09 1.22 ± 0.04 
54 VVARGPLKC (942.55) 338-346 1 7 1.18 ± 0.05 0.85 ± 0.06 1.44 ± 0.01 1.44 ± 0.06 1.72 ± 0.06 1.79 ± 0.06 
55 VARGPLKC (843.48) 339-346 2 6 1.35 ± 0.04 0.76 ± 0.01 1.58 ± 0.03 1.25 ± 0.03 1.78 ± 0.06 1.56 ± 0.02 
56 ARGPLKC (744.42) 340-346 2 5 1.15 ± 0.07 0.63 ± 0.01 1.36 ± 0.02 1.09 ± 0.03 1.59 ± 0.05 1.38 ± 0.02 
57 VKLDRPRF (1030.61) 347-354 2 6 1.05 ± 0.02 0.69 ± 0.03 1.42 ±  0.02 0.96 ± 0.06 1.53 ± 0.04 0.97 ± 0.05 
58 ERVLGPCSD (975.45) 355-363 2 7 1.89 ± 0.03 1.69 ± 0.05 2.21 ± 0.04 1.92 ± 0.07 2.52 ± 0.09 2.06 ± 0.02 
59 ERVLGPCSDIL (1201.62) 355-365 2 9 2.19 ± 0.01 1.98 ± 0.03 2.72 ± 0.01 2.39 ± 0.07 3.24 ± 0.08 2.65 ± 0.05 
60 ILKRNIQQ (1012.62) 364-371 2 7 2.46 ± 0.04 2.23 ± 0.02 2.83 ± 0.04 3.05 ± 0.10 2.94 ± 0.07 3.21 ± 0.02 
61 ILKRNIQQYNSF (1523.83) 364-375 2 11 3.79 ± 0.04 3.76 ± 0.03 4.43 ± 0.04 4.69 ± 0.10 4.57 ± 0.08 4.82 ± 0.09 
62 KRNIQQY (949.52) 366-372 2 6 2.10 ± 0.03 1.8 ± 0.03 2.31 ± 0.05 2.31 ± 0.04 2.31 ± 0.06 2.43 ± 0.02 
63 KRNIQQYNSF (1297.66) 366-375 2 9 3.36 ± 0.03 3.41 ± 0.04 3.64 ± 0.04 3.85 ± 0.11 3.61 ± 0.04 3.81 0.07 
 z-charge state of the peptide; a Number of maximum exchangeable amides for the peptide. b Average and standard deviation calculated from three 
independent deuterium exchange experiments; n.a - deuterium uptake values not obtained
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3.3.6 Excess cAMP stabilizes PDE8:PKA RIα complex 
In order to monitor how the PDE8:PKA RIα complex hydrolyzes excess cAMP, 
we measured deuterium exchange kinetics of the ternary complex in the presence of 
excess cAMP (330 µM) and compared it to that of RIα under the same conditions, and is 
summarized as a difference plot in Fig. 3.13A. In contrast to the experiments with limiting 
cAMP concentrations, we observed a sustained reduction in exchange over longer time 
points (1-30 min) of deuterium exchange at the PDE8 interaction sites in the complex 
(green boxes in Fig. 3.13A). This indicated that excess cAMP positively contributed to 
the stability of the ternary complex. Further, the magnitude reduction and time-
dependence at the two PDE8AC binding sites corresponding to the two cAMP binding 
sites across the two CNBs reflected a slower dissociation at the PDE8AC interaction site 
flanking the CNB:A site compared to the CNB:B site. Gradual increases in exchange 
across both cAMP binding sites reflect PDE8AC binding to RIα mediates release of cAMP 
as highlighted by the orange box in Fig. 3.13A and mass spectra profiles in Fig. 3.13B. 
These differences are also mapped on to structure of RIα monomer (PDB ID:1RGS, (Su, 
Dostmann et al. 1995) in Fig. 3.13 C, where PDE8-binding regions highlighted in blue 
(peripheral contacts) due to decreased solvent accessibility and the translocation of cAMP 
by coupling of active sites in red depicting increased solvent exchange (catalysis and 
release of ligand). Further, differences between the cAMP binding sites (CNB:A vs 
CNB:B) point towards faster hydrolysis of cAMP at CNB:A. Together, these results 
provide important evidence of a ligand-stabilized channel between RIα and PDE8 that 
operates to actively hydrolyze cAMP-bound to RIα. 
Table 3.2 tabulates the deuterium uptake values at 1, 10 and 30 min for free- and PDE8A-





Table 3.2:  Summary of deuterium uptake values exchanged for peptides spanning full-length RIα, present as free- and PDE8A-bound in the presence of 
excess cAMP at 1, 10 and 30 min deuterium labeling times. 
  
  
      
No. of deuterons 
exchanged after 1 min 
(Mean± SD)b 
No. of deuterons 
exchanged after 10 min 
(Mean± SD)b 
No. of deuterons exchanged 
after 30 min (Mean± SD)b 
S. 
No. 













19-29 2 10 n.a. 3.15 ± 0.07 n.a. 4.18 ± 0.05 n.a. 4.28 ± 0.06 
2 YVQKHNIQA (1100.58) 20-28 2 8 2.44 ± 0.02 2.35 ± 0.09 2.95 ± 0.04 2.87 ± 0.09 3.16 ± 0.1 2.90 ± 0.1 
3 YVQKHNIQAL (1213.67) 20-29 2 9 2.74 ± 0.05 2.50 ± 0.04 3.61 ± 0.02 3.41 ± 0.04 3.74 ± 0.04 3.44 ± 0.05 
4 QALLKDSI (887.52) 27-34 2 7 n.a. 1.05 ± 0.01 n.a. 1.61 ± 0.02 n.a. 2.06 ± 0.04 
5 LKDSIVQL (915.55) 30-37 2 7 0.53 ± 0.03 0.42 ± 0.02 1.32 ± 0.01 1.18 ± 0.03 1.81 ± 0.02 1.74 ± 0.06 




52-63 2 11 n.a. 3.53 ± 0.05 n.a. 4.09 ± 0.07 n.a. 4.38 ± 0.1 
8 EKEEAKQIQNL (1329.7) 57-67 2 10 4.60 ± 0.06 4.36 ± 0.06 4.76 ± 0.02 4.40 ± 0.02 4.11 ± 0.05 4.39 ± 0.03 




79-91 2 7 3.56 ± 0.06 3.92 ± 0.03 3.72 ± 0.02 3.93 ± 0.01 3.73 ± 0.03 3.93 ± 0.04 














112-127 3 14 5.94 ± 0.09 5.49 ± 0.04 6.48 ± 0.02 6.21 ± 0.06 6.57 ± 0.08 6.38 ± 0.06 
15 VRKVIPKD (954.61) 113-120 2 6 2.46 ± 0.05 2.51 ± 0.03 2.64 ± 0.08 2.71 ± 0.01 2.53 ± 0.04 2.73 ± 0.03 
16 LAKAIEKNVL (1098.68) 127-136 2 9 3.08 ± 0.06 2.77 ± 0.00 4.14 ± 0.02 3.94 ± 0.04 4.59 ± 0.1 4.31 ± 0.04 
17 AKAIEKNVL (985.60) 128-136 2 8 2.81 ± 0.04 2.42 ± 0.02 3.52 ± 0.02 3.08 ± 0.03 3.87 ± 0.1 3.50 ± 0.04 












163-173 2 10 1.69 ± 0.05 2.08 ± 0.02 2.11 ± 0.04 2.28 ± 0.01 2.18 ± 0.14 2.43 ± 0.05 
22 YVIDQGEM (954.42) 174-181 2 7 0.72 ± 0.01 0.65 ± 0.02 1.12 ± 0.01 0.92 ± 0.01 1.6 ± 0.07 1.03 ± 0.01 




189-199 1 10 2.66 ± 0.1 2.61 ± 0.01 3.37 ± 0.06 2.85 ± 0.01 4.06 ± 0.01 2.92 ± 0.05 
25 FGELALI (762.44) 199-205 1 6 0.10 ± 0.02 0.16 ± 0.02 0.49 ± 0.08 0.15 ± 0.02 1.7 ± 0.06 0.17 ± 0.02 




203-218 2 14 1.83 ± 0.11 2.04 ± 0.04 3.74 ± 0.02 3.05 ± 0.03 5.26 ± 0.2 3.74 ± 0.1 




205-218 2 12 1.55 ± 0.14 1.6 ± 0.05 2.97 ± 0.09 n.a. 4.52 ± 0.14 2.01 ± 0.17 
30 
IYGTPRAATVKAKTNV
KL  (1931.14) 
205-222 3 16 1.77 ± 0.09 1.59 ± 0.06 3.32 ± 0.08 2.19 ± 0.05 4.97 ± 0.2 2.74 ± 0.08 
 112 
 
31 VKAKTNVKL (1000.65) 214-222 2 8 n.a. 0.86 ± 0.06 n.a. 1.05 ± 0.07 n.a. 1.31 ± 0.1 




223-239 3 16 2.01 ± 0.04 1.73 ± 0.04 3.52 ± 0.06 2.91 ± 0.05 4.69 ± 0.26 3.59 ± 0.10 
34 RRILMGST (933.53) 231-238 2 7 1.85 ± 0.03 1.75 ± 0.02 2.3 ± 0.02 2.22 ± 0.07 2.78 ± 0.06 2.78 ± 0.06 
35 RRILMGSTL (1043.61) 231-239 2 8 1.94 ± 0.04 1.67 ± 0.01 2.93 ± 0.01 2.46 ± 0.04 3.30 ± 0.18 2.93 ± 0.07 
36 LRKRKMYEEF (1399.75) 239-248 2 9 1.54 ± 0.03 1.41 ± 0.02 2.36 ± 0.04 2.09 ± 0.04 2.45 ± 0.13 2.24 ± 0.03 
37 RKRKMYEEF (1286.67) 240-248 3 8 1.74 ± 0.15 1.37 ± 0.02 2.68 ± 0.03 2.01 ± 0.04 2.77 ± 0.13 2.11 ± 0.03 
38 FLSKVSIL (906.56) 248-255 2 7 2.03 ± 0.02 1.97 ± 0.01 2.88 ± 0.02 2.90 ± 0.04 3.22 ± 0.07 3.14 ± 0.05 
39 LSKVSIL (759.49) 249-255 1 6 1.82 ± 0.04 1.64 ± 0.04 2.69 ± 0.03 2.58 ± 0.05 3.04 ± 0.07 2.81 ± 0.05 
40 ESLDKWERL (1175.6) 256-264 2 8 1.58 ± 0.09 1.29 ± 0.04 2.49 ± 0.05 1.88 ± 0.05 3.03 ± 0.1 2.24 ± 0.07 












276-291 2 14 1.48 ± 0.04 1.66 ± 0.01 2.19 ± 0.06 2.18 ± 0.02 3.38 ± 0.17 2.72 ± 0.07 
45 IILEGSA (702.40) 293-299 1 6 0.82 ± 0.01 0.72 ± 0.01 0.99 ± 0.02 0.99 ± 0.01 1.16 ± 0.06 1.38 ± 0.04 
46 VLQRRSENEE (1259.63) 301-310 2 9 2.85 ± 0.15 2.52 ± 0.04 3.03 ± 0.09 2.56 ± 0.02 2.86 ± 0.21 2.56 ± 0.06 
47 QRRSENEEF (1194.55) 303-311 2 8 n.a. 2.17 ± 0.07 n.a. 2.16 ± 0.04 n.a. 2.19 ± 0.07 






311-322 2 10 1.35 ± 0.03 1.44 ± 0.07 1.96 ± 0.04 1.76 ± 0.02 2.37 ± 0.11 1.99 ± 0.04 
50 LMNRPRAAT (1029.56) 329-337 2 7 0.99 ± 0.04 0.93 ± 0.02 1.60 ± 0.02 1.23 ± 0.03 2.53 ± 0.07 1.36 ± 0.03 
51 LMNRPRAATV (1128.63) 329-338 2 8 1.04 ± 0.02 0.82 ± 0.01 1.66 ± 0.02 1.13 ± 0.1 1.57 ± 0.05 1.26 ± 0.12 
52 MNRPRAAT (916.48) 330-337 2 6 0.76 ± 0.05 0.82 ± 0.02 1.29 ± 0.04 0.99 ± 0.02 2.14 ± 0.07 1.11 ± 0.01 
53 MNRPRAATV (1015.55) 330-338 2 7 0.80 ± 0.07 0.80 ± 0.03 1.40 ± 0.03 1.01 ± 0.04 2.21 ± 0.16  1.07 ± 0.02 
54 VVARGPLKC (942.55) 338-346 1 7 0.56 ± 0.02 0.69 ± 0.05 1.05 ± 0.01 1.33 ± 0.05 1.56 ± 0.02 1.78 ± 0.07 
55 VARGPLKC (843.48) 339-346 2 6 0.71 ± 0.05 0.65 ± 0.03 1.17 ± 0.03 1.21 ± 0.02 1.62 ± 0.12 1.62 ± 0.01 
56 ARGPLKC (744.42) 340-346 2 5 0.52 ± 0.05 0.60 ± 0.02 0.96 ± 0.06 1.10 ± 0.01 1.44 ± 0.05 1.49 ± 0.03 
57 VKLDRPRF (1030.61) 347-354 2 6 n.a. 0.69 ± 0.03 n.a. 1.05 ± 0.04 n.a. 1.11 ± 0.03 
58 ERVLGPCSD (975.45) 355-363 2 7 1.70 ± 0.06 1.65 ± 0.01 2.26 ± 0.01 2.04 ± 0.03 2.55 ± 0.16 2.23 ± 0.03 
59 ERVLGPCSDIL (1201.62) 355-365 2 9 2.04 ± 0.02 2.10 ± 0.01 2.56 ± 0.02 2.56 ± 0.04 3.15 ± 0.09 2.95 ± 0.06 




364-375 2 11 3.99 ± 0.06 1.95 ± 0.01 5.16 ± 0.09 4.95 ± 0.06 5.44 ± 0.01 5.27 ± 0.07 
62 KRNIQQY (949.52) 366-372 2 6 2.13 ± 0.08 2.08 ± 0.06 263 ± 0.02 2.58 ± 0.03 2.59 ± 0.10 2.58 ± 0.03 
63 KRNIQQYNSF (1297.66) 366-375 2 9 3.76 ± 0.03 3.57 ± 0.02 4.27 ± 0.03 3.98 ± 0.04 4.26 ± 0.03 4.14 ± 0.06 
z- charge state of the peptide; a Number of maximum exchangeable amides for the peptide. b Average and standard deviation calculated from three 




Figure 3.13: Mapping PDE8:PKA-RIα interactions in presence of excess cAMP. (A) Differences 
in average deuterons exchanged (Y-axis) in PDE8AC:RIα:cAMP relative to RIα:cAMP for each 
pepsin fragment peptide listed from N to C-terminus (X-axis). Peptides spanning continuous 
regions are grouped by brace brackets. Domain organization of RIα is shown. Peptides spanning 
the cAMP binding regions in CNB:A (199-222) and CNB:B (329-338) are highlighted in orange 
and peptides specific to PDE8AC binding in green. Positive differences in deuterium exchange 
indicate increased exchange and negative differences indicate decreased exchange in the 
PDE8AC:RIα in the presence of excess cAMP. Deuterium labeling time for every peptide is 
depicted and colored according to the key. Red dashed line represents a significance threshold of 
±0.5 Da for differences in deuterium exchange and standard deviations are shaded gray. Plots were 
generated using DynamX 2.0 software (Waters, Milford, MA). (B) Stacked mass spectra for RIα 
with excess cAMP and PDE8AC:RIα:cAMP ternary complex after 10 min deuterium labeling are 
shown for peptides highlighted in green (putative PDE-binding sites) and orange (cAMP binding 
pocket). Difference in their masses, i.e., centroid are represented by colored boxes compared to 
undeuterated control (vertical dashed line). (C) Differences in deuteration levels were mapped on 
the structure of monomer of RIα, with regions showing increased deuterium exchange in shades of 
red and decreased deuterium exchange in blue. cAMP is shown in yellow sticks. 
 
 
These time-dependent changes in deuterium uptake by RIα in different states are also 
shown by kinetic plots of peptides from representative regions – PDE8-binding regions 
(158-173), CNB:A site (199-205, 203-222), αB:C helix (223-238), CNB:B site (329- 337) 
and C-terminus region (364-375). Significant uptake at the two cAMP binding pockets is 





Figure 3.14: Time-dependent increase in deuterium uptake for representative regions of RIα. 
Kinetic plots of peptides that show largest differences between different states of RIα, viz., purified 
RIα (●), RIα with excess cAMP (♦), PDE8AC:RIα complex (■) and PDE8AC:RIα complex in the 
presence of excess cAMP (▲). Number of deuterons incorporated (Y-axis) with increase in time 
on (X-axis) where each value is an average of three independent deuterium exchange experiments 
and their standard deviations are also shown. Graphs were plotted using GraphPad Prism 6.0. 
 
 
3.3.7 Enhanced hydrolysis through ‘channeling’ of cAMP from PKA RIα to PDE8 
Importantly, to monitor the time-course kinetics of cAMP hydrolysis by 
PDE8AC:RIα complex, we compared deuterium exchange kinetics of the PDE8AC:RIα 
complex (with limited cAMP) and stable ternary (PDE8AC:RIα:cAMP) complexes (Fig. 
3.15A). The interaction interface of PDE8A and RIα, which was considered above 
showed no differences in deuterium exchange, indicating that the complex stays bound 
throughout the time of the experiment. Further, the RIα dimer-interface and the PKA C-
subunit binding regions (peptides spanning 112-144) show increased exchange at longer 
deuterium labeling times, indicating a more ‘open’ conformation of RIα. The N3A helical 
regions also showed higher deuterium exchange in the presence of excess cAMP. It was 
previously suggested that these regions may play a regulatory role and have functional 
significance (Bruystens, Wu et al.). At shorter labeling times, cAMP binding resulted in 
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decreased deuterium exchange in the two cAMP binding domains (CNB:A and CNB:B, 
green boxes Fig. 3.15A). Based on our results from fluorescence polarization (Fig. 3.3A), 
we conclude that differences in deuterium exchange observed are because of 
PDE8AC:RIα:cAMP ternary complex rapidly hydrolyzing all cAMP molecules to AMP 
to generate a ligand-free end-state complex (Krishnamurthy, Moorthy et al. 2014). 
 Peptides spanning the cAMP binding pockets showed large differences in 
deuterium exchange, where at shorter labeling times decreased exchange was observed 
and at longer labeling times increased deuterium exchange was observed in PDE8AC:RIα 
complex in the presence of excess cAMP. Upon closer examination, peptides covering 
the cAMP pocket in CNB:A in the ternary complex exhibited characteristic bimodal 
distributions of the mass spectral isotopic envelope (highlighted in Fig. 3.15B i). Bimodal 
distributions in HDXMS are indicative of conformational heterogeneity giving an 
ensemble of multiple conformations of protein or peptides in solution (Wang, Morgan et 
al. 2012). In this case, we observed two distinct conformations - a higher exchanging 
cAMP-free (green envelope) and lower exchanging cAMP-bound conformations 
(highlighted by blue envelope, Fig. 3.15B). With increasing deuteration times, the 
bimodal characteristic is not observable and the unimodal increased deuterium exchange 
population likely reflects release of ligand. The transition of RIα from the cAMP-bound 
to cAMP-free conformations in real time is mapped on its structure, Fig. 3.15C and 
summarizes protein-wide increases in deuterium exchange associated with cAMP 
hydrolysis by the PDE8AC:RIα complex. These differences in deuterium uptake at CNB 
regions in the complex at different time points suggests translocation of excess cAMP to 
PDE8AC via RIα by ternary complexation. Interestingly, examination of relative 
intensities of the different mass distribution envelopes corresponding to cAMP-bound and 
cAMP-free states revealed that peptides spanning the CNB:A site showed faster decrease 
of bound state compared to equivalent peptide from CNB:B site. This is consistent with 
asymmetric kinetics of PDE8-mediated hydrolysis of bound cAMP and indicated faster 
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hydrolysis from CNB:A site in the PDE8:RIα complex. The distinct time-dependent 
HDXMS kinetics for the PDE8AC:RIα complex in the presence of an excess of cAMP 
through an associated stabilization, is suggestive of a channeling mechanism for cAMP 
hydrolysis by the PDE8AC:RIα complex.  
 
Figure 3.15: Capturing cAMP dissociation and turnover in RIα by the PDE8:PKA-RIα complex. 
(A) Differences in average deuterons exchanged (Y-axis) between PDE8AC:RIα:cAMP and 
PDE8AC:RIα for peptides of RIα as listed from N to C-terminus (X-axis). Peptides spanning 
contiguous regions grouped by brace brackets and the domain organization is shown. Negative 
differences indicate decreased deuterium exchange, while positive differences denote increased 
deuterium exchange in the ternary complex. The two domains CNB:A and CNB:B are shown in 
orange boxes. Each deuterium labeling time for every peptide is depicted and colored according to 
the key. Red dashed line represents a significance threshold of ± 0.5 Da for differences in deuterium 
exchange and standard deviations are shaded gray. (B) Cyclic nucleotide-binding domains CNB:A 
and CNB:B are indicated by stacked mass spectra of representative peptides, spanning residues 
203-218 (panel i) and 329-338 (panel ii), respectively. Each panel consists of spectra from 
PDE8AC:RIα:cAMP (left) and from PDE8AC:RIα (right) states at three different deuterium 
labeling times as labeled. Spectra for undeuterated controls are also shown. Extent of deuterium 
uptake for each spectrum is represented by a double-headed arrow, while reference point in 
undeuterated is shown as a vertical dashed line. (C) Surface representation of the crystal structure 
of RIα, with regions showing significant differences (>0.5 Da) in deuterium exchange at three 
times (1, 10 and 60 min) in the ternary complex are mapped according to panel A. Regions showing 
decreased exchange are in shades of green and regions with increased exchange are in shades of 




3.3.8 HDXMS results for cAMP hydrolysis by free PDE8A 
To study the conformational changes in the catalytic domain of PDE8A upon 
cAMP binding, HDXMS experiments for free PDE8A (3.5 µM) and incubation with 
cAMP (330 µM) were carried out for different labeling times. A total of 71 pepsin digest 
fragments, covering ~ 82% of the catalytic domain of PDE8A sequence were analyzed 
for this study (Fig. 3.16). 
 
Figure 3.16: Sequence coverage of PDE8A for experiments with cAMP. Primary sequence of a 
catalytic domain of PDE8A is depicted. The orange boxes indicate all peptide fragments spanning 
regions of the primary sequence obtained from our analysis for describing the effects of cAMP on 
PDE8A using HDXMS.  Approximately 82% sequence coverage was observed. The numbers 
shown here (1-337) correspond to the primary amino acid sequence of deletion construct of PDE8A 
(472-829). 
 
PDE8A catalyzes the hydrolysis of cAMP in its active site. HDXMS results for 
free PDE8A reacting with cAMP, showed differences in deuterium exchange in only three 
regions associated with cAMP binding or hydrolysis, as highlighted by purple outlines on 
the difference plot in Fig. 3.17. The catalytic site (590-614) showed no considerable 
 X  N  I  I  T  P  I  S  L  D  D  V  P  P  R  I  A  R  A  M  E  N  E  E  Y  W  D  F  D  I  F  E  L  E  A  A  T  H  N  R  P  L  I  Y  L  G  L  X  X  F 
 5  10  15  20  25  30  35  40  45  50 
 A  R  F  G  I  C  E  X  X  X  X  X  X  X  X  L  R  S  W  L  Q  I  I  E  A  N  Y  H  S  S  N  P  Y  H  N  S  T  H  S  A  D  V  L  H  A  T  A  Y  F  L 
 55  60  65  70  75  80  85  90  95  100 
 S  K  E  R  I  K  E  T  L  D  P  I  D  E  X  X  A  L  I  A  A  T  I  H  D  V  D  H  P  G  R  T  N  S  F  L  C  N  A  G  S  E  L  A  I  L  Y  N  D  T 
 105  110  115  120  125  130  135  140  145  150 
 A  V  L  E  S  H  H  A  A  L  A  F  Q  L  T  T  G  D  D  K  C  N  I  F  K  N  M  E  R  N  D  Y  R  T  L  R  Q  G  I  I  D  M  X  L  A  T  E  M  T  K 
 155  160  165  170  175  180  185  190  195  200 
 H  F  E  H  V  N  K  F  V  N  S  I  N  K  P  L  A  T  L  E  E  N  G  E  T  D  K  N  Q  E  V  I  N  T  M  L  R  T  P  E  N  R  T  L  I  K  R  M  L  I 
 205  210  215  220  225  230  235  240  245  250 
 K  C  A  D  V  S  N  P  C  R  P  L  Q  Y  C  I  E  W  A  A  R  I  S  E  E  Y  F  S  Q  T  D  E  E  K  Q  Q  G  L  P  V  V  M  P  V  F  D  R  N  T  C 
 255  260  265  270  275  280  285  290  295  300 
 S  I  P  K  S  Q  I  S  F  I  D  Y  F  I  T  D  M  F  D  A  W  D  A  F  V  D  L  P  D  L  M  Q  H  L  D  N  N  F  K  Y  W  K  G  L  D  E  M  K  L  R 
 305  310  315  320  325  330  335  340  345  350 
 N  L  R  P  P  P  E 
 355 
Total: 81.8% Coverage, 2.85 Redundancy
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differences at lower deuterium labeling times, but a slight increase in exchange at the end 
of the time-course of the experiment (blue plot, 100 min). This is consistent with the fact 
that active site of PDE8 is coordinated with water molecules and is solvent accessible 
throughout. Peptides spanning the surface of PDE8 (665-705), where two helices are 
connected with a kink (H12-HE1 helices) showed an initial decrease in deuterium 
exchange, corresponding to their reorientation. Importantly, peptides spanning the 
substrate recognition and substrate binding sites (738-780) showed decreased deuterium 
exchange at shorter deuterium labeling times, indicating binding of cAMP to these 
regions. With increase in deuterium labeling time, these set of residues showed no 
differences in deuterium exchange, indicating a complete cAMP turnover by PDE8A. 
 
Figure 3.17: Effects of cAMP on PDE8A probed by HDXMS. Difference plot showing 
differences in deuterium exchange (Y-axis) between PDE8AC and PDE8AC with 330 µM cAMP, 
with pepsin digest fragments for the catalytic domain of PDE8A listed from N-to-C- terminus on 
X-axis. Positive changes denote decreased deuterium exchange while negative changes denote 
increased exchange in PDE8AC in the presence of excess cAMP. Peptides spanning the catalytic 
site (590-614), the H12 helix (665-685), substrate binding and recognition sites (738-780) are 
outlined by purple boxes. Red dashed line represents a significance threshold of ±0.5 Da for 
differences in deuterium exchange. Plots were generated using DynamX 2.0 software (Waters, 
MA). 
3.3.9 Rapid hydrolysis of cAMP by PDE8A, bound to RIα as a ternary complex 
Parallel mapping of the PDE8AC surface of the PDE8AC:RIα complex and the 
associated conformational changes during its interaction with RIα in the absence and 
presence of excess cAMP was also carried out by HDXMS, to obtain a complementary 
interface on PDE8A for RIα interactions. Saturating concentrations of RIα were added to 
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PDE8 in absence or presence of cAMP and a total of 67 peptides were obtained 
corresponding to ~87% sequence of PDE8AC (Fig. 3.18). 
 
Figure 3.18: Sequence coverage of PDE8A: Primary sequence of a catalytic fragment of PDE8A 
is shown. The blue boxes indicate all peptide fragments spanning regions of the primary sequence 
obtained from our analysis for monitoring the conformational changes in PDE8A present as 
complexes with cAMP and RIα using HDXMS.  Approximately 87% sequence coverage was 
observed. The numbers shown here (1-337) correspond to the primary amino acid sequence of 
deletion construct of PDE8A (472-829). 
 
Residues of PDE8A catalytic domain associated with interaction and catalysis of 
cAMP by PDE8AC:RIα complex showed significant changes in deuterium exchange as 
shown by difference plot in Fig. 3.19A. The catalytic site (604-639, highlighted by yellow 
box) showed increased exchange with time in the ternary complex of PDE8AC:RIα:cAMP 
as compared to binary complex of PDE8AC:RIα (limited cAMP), indicating rapid 
hydrolysis of cAMP by the ternary complex. Two peptides (724-736 and 740-747, Fig. 
3.19), mediate stacking interactions with the adenine ring of cAMP (purple box), while a 
third peptide (748-764) is part of cAMP recognition (M-loop, pink box). After initial 
complexation cAMP gets translocated to the catalytic site of PDE8AC, as evident by the 
decreased deuterium uptake at these corresponding peptides when comparing 




Figure 3.19: Capturing cAMP hydrolysis 
by the PDE8:PKA-RIα complex. (A) Plot 
of average differences in deuterium uptake 
(Y-axis) between PDE8AC:RIα:cAMP  
relative to PDE8AC:RIα, with residue 
numbers for pepsin fragment peptides of 
PDE8A catalytic domain listed from N to 
C-terminus (X-axis). Positive changes 
denote increased deuterium exchange 
while negative changes denote decreased 
exchange in PDE8AC:RIα complex in the 
presence of excess cAMP. Peptides 
spanning the catalytic site of PDE8A are 
highlighted in yellow, substrate binding 
sites in purple and PDE substrate 
recognition site peptides by pink boxes. 
Three peptides interacting with cAMP are 
magnified in inset. Red dashed line 
represents a significance threshold of ±0.5 
Da for differences in deuterium exchange 
and standard deviations are shaded gray.  
Plots were generated using DynamX 2.0 
software (Waters, MA). In the inset, 
peptides spanning 724-736 (i), 740-747 (ii) 
and 748-764 (iii) are marked. (B) Stacked 
spectral plots for the three peptides (i, ii 
and iii) are shown for PDE8AC:RIα 
complex without and with cAMP as indicated for different deuterium labeling times. Shift in centroid values are represented by orange (0.5 min) and blue (60 min) boxes. 
Spectral plots were obtained from DynamX 2.0 software (Waters, MA). 
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Table 3.3 Deuterium uptake values at 1, 10 and 30 min deuterium labeling times for peptides spanning the catalytic domain of PDE8A and RIα-bound PDE8 
in limited cAMP conditions. 
 
      
No. of deuterons exchanged 
after 1 min (Mean± SD)b 
No. of deuterons exchanged 
after 10 min (Mean± SD)b 
No. of deuterons exchanged 
after 30 min (Mean± SD)b 












1 IITPISL (756.48) 475-481 1 5 2.38 ± 0.03 2.29 ± 0.02 2.42 ± 0.09 2.30 ± 0.07 2.42 ± 0.09 2.36 ± 0.01 
2 DDVPPRIARA (1109.61) 482-491 2 7 3.48 ± 0.04 3.27 ± 0.04 4.10 ± 0.05 3.67 ± 0.04 4.1 ± 0.01 3.80 ± 0.01 
3 DDVPPRIARAME (1369.69) 482-493 2 9 3.46 ± 0.01 3.76 ± 0.06 4.41 ± 0.1 4.53 ± 0.05 4.61 ± 0.04 4.70 ± 0.02 
4 ELEAATHNRPLIY (1523.79) 504-516 2 11 1.52 ± 0.01 1.16 ± 0.01 1.99 ± 0.06 1.65 ± 0.06 2.25 ± 0.05 2.08 ± 0.05 
5 ELEAATHNRPLIYL (1639.88) 504-517 2 12 1.16 ± 0.06 0.72 ± 0.02 1.72 ± 0.1 1.27 ± 0.06 2.01 ± 0.02 1.67 ± 0.01 
6 LEAATHNRPLIY (1397.75) 505-516 3 10 1.29 ± 0.02 1.05 ± 0.01 1.62 ± 0.07 1.45 ± 0.05 1.86 ± 0.03 1.78 ± 0.05 
7 LEAATHNRPLIYL (1510.84) 505-517 2 11 0.93 ± 0.04 0.62 ± 0.01 1.42 ± 0.07 1.08 ± 0.05 1.69 ± 0.01 1.41 ± 0.01 
8 AATHNRPLIYL (1268.71) 506-517 2 9 0.76 ± 0.02 0.51 ± 0.02 1.13 ± 0.04 0.88 ± 0.03 1.33 ± 0.02 1.09 ± 0.01 
9 ATHNRPLIY (1084.59) 507-516 2 7 0.69 ± 0.04 0.57 ± 0.01 0.99 ± 0.04 0.86 ± 0.03 1.19 ± 0.04 1.11 ± 0.03 




520-543 3 23 n.a. 6.18 ± 0.06 n.a. 6.30 ± 0.1 n.a. 6.51 ± 0.01 
12 ICEFLHCSESTLRSW (1810.82) 527-541 2 14 1.74 ± 0.05 1.76 ± 0.03 2.58 ± 0.02 2.62 ± 0.02 2.84 ± 0.1 2.97 ± 0.01 






















552-569 3 16 1.74 ± 0.1 1.74 ± 0.04 2.65 ± 0.05 2.76 ± 0.03 2.94 ± 0.09 3.13 ± 0.01 
19 FLSKERIKE (1149.66) 570-579 2 8 1.55 0.01 1.40 0.01 1.66 0.01 1.64 0.02 1.71 0.04 1.78 0.04 
20 FLSKERIKETLDPIDE (1933.02) 571-586 2 14 2.88 ± 0.06 2.59 ± 0.02 3.34 ± 0.03 3.07 ± 0.04 3.48 ± 0.02 3.36 ± 0.07 








591-607 2 15 2.88 ± 0.04 2.79 ± 0.02 3.15 ± 0.03 2.99 ± 0.04 3.19 ± 0.07 3.04 ± 0.10 
24 ATIHDVDHPGRTNS (1519.72) 593-606 2 12 2.25 ± 0.04 2.57 ± 0.02 2.48 ± 0.06 2.58 ± 0.04 2.56 ± 0.01 2.66 ± 0.06 




623-638 2 15 n.a. 3.01 ± 0.09 n.a. 3.50 ± 0.07 n.a. 3.60 ± 0.03 






634-649 3 15  2.92 ± 0.09  3.75 ± 0.04  4.11 ± 0.01 
29 DDKCNIFK (982.46) 639-647 2 7 2.47 ± 0.04 2.19 ± 0.02 2.71 ± 0.04 2.21 ± 0.02 2.85 ± 0.04 2.29 ± 0.04 
30 KNMERNDYRT (1326.62) 647-656 2 9 5.57 ± 0.12 2.63 ± 0.03 5.72 ± 0.10 2.75 ± 0.03 5.64 ± 0.09 2.69 ± 0.11 
31 RTLRQGIID (1071.62) 655-663 2 8 1.41 ± 0.04 1.37 ± 0.02 1.74 ± 0.06 1.86 ± 0.04 1.84 ± 0.08 1.98 ± 0.12 
32 LRQGIID (814.48) 657-663 1 6 0.88 ± 0.04 0.76 ± 0.01 1.15 ± 0.03 1.02 ± 0.03 1.26 ± 0.03 1.07 ± 0.09 








667-690 3 22 3.88 ± 0.07 4.30 ± 0.06 4.99 ± 0.08 5.49 ± 0.05 5.28 ± 0.10 5.96 ± 0.05 








670-691 3 20 4.03 ± 0.07 4.37 ± 0.04 4.96 ± 0.06 5.39 ± 0.06 5.12 ± 0.04 5.77 ± 0.05 
39 TKHFEHVNKFVNS (1586.81) 671-683 2 12 2.08 ± 0.09 2.14 ± 0.02 2.42 ± 0.01 2.52 ± 0.04 2.48 ± 0.10 2.71 ± 0.03 
40 VNSINKPLAT (1056.60) 681-691 2 8 3.08 ± 0.04 3.18 ± 0.03 3.58 ± 0.05 3.66 ± 0.04 3.66 ± 0.01 3.73 ± 0.06 
41 VNSINKPLATL (1169.69) 681-692 2 9 3.29 ± 0.07 3.59 ± 0.04 3.86 ± 0.04 4.11 ± 0.06 3.91 ± 0.02 4.19 ± 0.05 
42 INKPLAT (756.46) 684-690 2 5 2.01 ± 0.02 2.10 ± 0.03 2.20 ± 0.03 2.29 ± 0.02 2.26 ± 0.01 2.32 ± 0.01 










691-707 2 16 5.44 ± 0.01 5.43 ± 0.06 5.57 ± 0.12 5.45 ± 0.06 5.52 ± 0.09 5.46 ± 0.1 
46 MLRTPENRT (1117.58) 707-715 2 7 2.24 ± 0.06 2.36 ± 0.04 2.59 ± 0.04 2.69 ± 0.04 2.60 ± 0.06 2.76 ± 0.03 
47 MLRTPENRTL (1230.66) 707-716 3 8 2.65 ± 0.11 2.10 ± 0.06 3.19 ± 0.03 2.75 ± 0.03 3.27 ± 0.05 2.81 ± 0.11 
48 MLRTPENRTLIKRML (1872.07) 707-721 3 13 1.78 ± 0.11 1.69 ± 0.03 2.41 ± 0.11 2.27 ± 0.05 2.41 ± 0.08 2.34 ± 0.16 
49 LRTPENRTL (1099.62) 708-716 2 7 2.10 ± 0.03 1.99 ± 0.02 2.34 ± 0.01 2.29 ± 0.03 2.38 ± 0.02 2.42 ± 0.01 
50 ADVSNPCRPLQ (1199.58) 725-735 2 8 2.42 ± 0.01 2.40 ± 0.01 2.50 ± 0.01 2.49 ± 0.02 2.52 ± 0.03 2.53 ± 0.01 
51 ADVSNPCRPLQY (1362.65) 725-736 2 9 2.42 ± 0.03 2.46 ± 0.01 2.64 ± 0.05 2.45 ± 0.04 2.77 ± 0.03 2.86 ± 0.01 
52 VSNPCRPLQY (1176.58) 727-736 2 7 0.91 ± 0.07 2.17 ± 0.08 1.54 ± 0.01 2.51 ± 0.01 1.79 ± 0.06 2.73 ± 0.02 
53 EWAARISE (961.47) 739-746 1 7 1.14 ± 0.03 0.96 ± 0.01 1.48 ± 0.04 1.85 ± 0.01 1.78 ± 0.06 1.85 ± 0.01 








749-764 2 14 5.39 ± 0.05 5.36 ± 0.03 5.65 ± 0.05 5.53 ± 0.06 5.70 ± 0.10 5.68 ± 0.01 
57 DEEKQQGLPVVM (1372.68) 753-764 2 10 n.a. 4.24 ± 0.03 n.a. 4.17 ± 0.11 n.a. 4.34 ± 0.01 
58 EKQQGLPVVM (1128.61) 755-764 2 8 3.64 ± 0.03 3.72 ± 0.02 3.74 ± 0.04 3.73 ± 0.04 3.78 ± 0.02 3.73 ± 0.01 
59 FDAWDAF (871.36) 790-796 1 6 0.53 ± 0.04 0.22 ± 0.01 0.69 ± 0.06 0.41 ± 0.04 0.78 ± 0.08 0.41 ± 0.07 
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802-820 3 18 2.93 ± 0.09 0.81 ± 0.09 3.95 ± 0.05 1.06 ± 0.04 4.04 ± 0.07 1.12 ± 0.07 
63 MQHLDNNF (1018.44) 803-810 2 7 0.81 ± 0.09 0.80 ± 0.01 1.06 ± 0.04 0.90 ± 0.03 1.12 ± 0.07 0.94 ± 0.04 
64 FKYWKGLDEM (1316.63) 810-819 2 9 1.71 ± 0.06 1.81 ± 0.01 2.04 ± 0.06 2.05 ± 0.02 2.04 ± 0.12 2.19 ± 0.07 
65 KYWKGLDE (1038.52) 811-818 1 7 1.47 ± 0.08 1.55 ± 0.01 1.70 ± 0.01 1.70 ± 0.02 1.71 ± 0.06 1.78 ± 0.01 
66 MKLRNLRPPPE (1350.77) 819-829 3 7 2.59 ± 0.05 2.66 ± 0.03 2.63 ± 0.08 2.67 ± 0.03 2.60 ± 0.04 2.73 ± 0.01 
z- charge state of the peptide; a Number of maximum exchangeable amides for the peptide. b Average and standard deviation calculated from three 






Table 3.4: Deuterium uptake values at 1, 10 and 30 min deuterium labeling times for peptides spanning the catalytic domain of PDE8A and RIα-bound PDE8 
in the presence of excess cAMP 
 
      
No. of deuterons 
exchanged after 1 min 
(Mean± SD)b 
No. of deuterons 
exchanged after 10 min 
(Mean± SD)b 
No. of deuterons 
exchanged after 30 min 
(Mean± SD)b 















1 IITPISL (756.48) 475-481 1 5 2.43± 0.03 2.39 ± 0.04 2.44 ± 0.02 2.41 ± 0.02 2.48 ± 0.06 2.41 ± 0.05 
2 DDVPPRIARA (1109.61) 482-491 2 7 3.44 ± 0.03 3.24 ± 0.04 4.01 ± 0.07 3.74 ± 0.02 3.96 ± 0.04 3.84 ± 0.02 
3 DDVPPRIARAME (1369.69) 482-493 2 9 3.45 ± 0.02 3.81 ± 0.07 4.34 ± 0.03 4.64 ± 0.02 4.60 ± 0.03 4.72 ± 0.1 
4 ELEAATHNRPLIY (1523.79) 504-516 2 11 1.68 ± 0.03 1.36 ± 0.02 2.02 ± 0.03 1.64 ± 0.03 2.18 ± 0.05 1.95 ± 0.08 
5 ELEAATHNRPLIYL (1639.88) 504-517 2 12 1.33 ± 0.03 0.92 ± 0.03 1.74 ± 0.04 1.22 ± 0.01 1.97 ± 0.06 1.58 ± 0.07 
6 LEAATHNRPLIY (1397.75) 505-516 3 10 1.38 ± 0.01 1.17 ± 0.02 1.66 ± 0.01 1.38 ± 0.02 1.82 ± 0.01 1.65 ± 0.01 
7 LEAATHNRPLIYL (1510.84) 505-517 2 11 1.06 ± 0.02 0.81 ± 0.03 1.43 ± 0.04 0.97 ± 0.01 1.70 ± 0.03 1.31 ± 0.07 
8 AATHNRPLIYL (1268.71) 506-517 2 9 0.84 ± 0.05 0.66 ± 0.02 1.17 ± 0.03 0.82 ± 0.01 1.31 ± 0.05 1.03 ± 0.06 
9 ATHNRPLIY (1084.59) 507-516 2 7 0.83 ± 0.01 0.68 ± 0.03 1.04 ± 0.02 0.84 ± 0.03 1.14 ± 0.05 1.02 ± 0.05 




520-543 3 23 n.a. 5.59 ± 0.04 n.a. 6.18 ± 0.10 n.a. 6.91 ± 0.01 
12 ICEFLHCSESTLRSW (1810.82) 527-541 2 14 1.79 ± 0.05 1.86 ± 0.06 2.58 ± 0.06 2.69 ± 0.02 2.91 ± 0.1 3.06 ± 0.08 






















552-569 3 16 1.77 ± 0.09 1.90 ± 0.09 2.66 ± 0.08 2.84 ± 0.07 3.05 ± 0.1 3.19 ± 0.09 
19 FLSKERIKE (1149.66) 570-579 2 8 1.71 ± 0.04 1.52 ± 0.01 1.80 ± 0.02 1.57 ± 0.03 1.87 ± 0.06 1.63 ± 0.05 
20 FLSKERIKETLDPIDE (1933.02) 571-586 2 14 3.02 ± 0.03 2.87 ± 0.03 3.38 ± 0.02 3.13 ± 0.03 3.54 ± 0.01 3.41 ± 0.08 
21 LSKERIKETLDPIDE (1785.96) 572-586 3 13 3.36 ± 0.04 3.12 ± 0.04 3.63 ± 0.03 3.32 ± 0.05 3.73 ± 0.11 3.53 ± 0.01 




591-607 2 15 3.01 ± 0.03 3.01 ± 0.01 2.18 ± 0.02 2.11 ± 0.04 3.26 ± 0.04 3.18 ± 0.11 
24 ATIHDVDHPGRTNS (1519.72) 593-606 2 12 2.33 ± 0.03 2.39 ± 0.03 2.55 ± 0.02 2.60 ± 0.03 2.64 ± 0.01 2.66 ± 0.09 




623-638 2 15 n.a. 3.17 ± 0.07 n.a. 3.64 ± 0.04 n.a. 3.73 ± 0.08 




634-649 3 15 n.a. 2.90 ± 0.1 n.a. 3.88 ± 0.07 n.a. 4.17 ± 0.08 
29 DDKCNIFK (982.46) 639-647 2 7 2.46 ± 0.02 2.01 ± 0.03 2.73 ± 0.01 2.24 ± 0.02 2.93 ± 0.01 2.28 ± 0.02 
30 KNMERNDYRT (1326.62) 647-656 2 9 5.82 ± 0.06 2.78 ± 0.02 6.02 ± 0.04 2.81 ± 0.05 6.02 ± 0.14 2.88 ± 0.09 
31 RTLRQGIID (1071.62) 655-663 2 8 1.54 ± 0.03 1.53 ± 0.03 1.69 ± 0.08 1.89 ± 0.02 1.94 ± 0.11 2.04 ± 0.04 
32 LRQGIID (814.48) 657-663 1 6 0.92 ± 0.01 0.81 ± 0.01 1.16 ± 0.04 1.06 ± 0.01 1.23 ± 0.02 1.13 ± 0.03 
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667-690 3 22 3.75 ± 0.01 4.24 ± 0.05 4.67 ± 0.08 5.19 ± 0.04 5.05 ± 0.14 5.96 ± 0.05 








670-691 3 20 4.16 ± 0.04 4.53 ± 0.05 5.02 ± 0.03 5.18 ± 0.06 5.15 ± 0.02 5.66 ± 0.17 
39 TKHFEHVNKFVNS (1586.81) 671-683 2 12 2.08 ± 0.03 2.12 ± 0.03 2.23 ± 0.03 2.28 ± 0.03 2.33 ± 0.09 2.52 ± 0.11 
40 VNSINKPLAT (1056.60) 681-691 2 8 3.18 ± 0.03 3.18 ± 0.06 3.70 ± 0.04 3.74 ± 0.02 3.86 ± 0.05 3.77 ± 0.09 
41 VNSINKPLATL (1169.69) 681-692 2 9 3.44 ± 0.03 3.65 ± 0.06 3.96 ± 0.04 4.25 ± 0.02 4.02 ± 0.08 4.29 ± 0.08 
42 INKPLAT (756.46) 684-690 2 5 2.04 ± 0.01 2.11 ± 0.03 2.28 ± 0.02 2.33 ± 0.01 2.29 ± 0.03 2.36 ± 0.03 








691-707 2 16 5.48 ± 0.08 5.63 ± 0.04 5.55 ± 0.07 5.70 ± 0.03 5.61 ± 0.09 5.67 ± 0.08 
46 MLRTPENRT (1117.58) 707-715 2 7 2.29 ± 0.02 2.43 ± 0.05 2.71 ± 0.03 2.84 ± 0.03 2.76 ± 0.09 2.83 ± 0.08 
47 MLRTPENRTL (1230.66) 707-716 3 8 2.94 ± 0.03 2.52 ± 0.04 3.32 ± 0.08 2.86 ± 0.02 3.38 ± 0.10 2.92 ± 0.07 
48 MLRTPENRTLIKRML (1872.07) 707-721 3 13 1.99 ± 0.02 1.93 ± 0.05 2.39 ± 0.11 2.23 ± 0.03 2.50 ± 0.11 2.37 ± 0.06 
49 LRTPENRTL (1099.62) 708-716 2 7 2.15 ± 0.03 2.02 ± 0.01 2.36 ± 0.02 2.35 ± 0.02 2.42 ± 0.03 2.43 ± 0.06 
50 ADVSNPCRPLQ (1199.58) 725-735 2 8 2.41 ± 0.01 2.38 ± 0.01 2.43 ± 0.02 2.44 ± 0.02 2.43 ± 0.01 2.46 ± 0.01 
 130 
 
51 ADVSNPCRPLQY (1362.65) 725-736 2 9 2.42 ± 0.01 2.44 ± 0.02 2.45 ± 0.04 2.50 ± 0.02 2.52 ± 0.01 2.62 ± 0.01 
52 VSNPCRPLQY (1176.58) 727-736 2 7 0.93 ± 0.01 2.35 ± 0.05 1.38 ± 0.01 2.44 ± 0.04 1.59 ± 0.07 2.50 ± 0.09 
53 EWAARISE (961.47) 739-746 1 7 1.22 ± 0.04 0.93 ± 0.01 1.47 ± 0.04 1.53 ± 0.03 1.61 ± 0.03 1.53 ± 0.03 








749-764 2 14 5.58 ± 0.10 5.65 ± 0.04 5.68 ± 0.04 5.71 ± 0.02 5.89 ± 0.04 5.82 ± 0.05 
57 DEEKQQGLPVVM (1372.68) 753-764 2 10 n.a. 4.66 ± 0.05 n.a. 4.27 ± 0.02 n.a. 4.31 ± 0.11 
58 EKQQGLPVVM (1128.61) 755-764 2 8 3.79 ± 0.01 3.76 ± 0.04 3.87 ± 0.01 3.73 ± 0.02 3.87 ± 0.03 3.76 0.03 
59 FDAWDAF (871.36) 790-796 1 6 0.49 ± 0.06 0.31 ± 0.01 0.73 ± 0.07 0.38 ± 0.01 0.77 ± 0.07 0.44 ± 0.02 








802-820 3 18 3.16 ± 0.07 0.94 ± 0.02 3.82 ± 0.12 1.02 ± 0.06 4.03 ± 0.12 1.07 ± 0.08 
63 MQHLDNNF (1018.44) 803-810 2 7 0.94 ± 0.02 0.89 ± 0.04 1.02 ± 0.06 0.86 ± 0.02 1.07 ± 0.08 0.86 ± 0.04 
64 FKYWKGLDEM (1316.63) 810-819 2 9 1.75 ± 0.05 1.86 ± 0.01 1.96 ± 0.03 1.89 ± 0.02 2.11 ± 0.06 2.04 ± 0.08 
65 KYWKGLDE (1038.52) 811-818 1 7 1.36 ± 0.03 1.54 ± 0.01 1.61 ± 0.07 1.66 ± 0.02 1.64 ± 0.06 1.72 ± 0.08 
66 MKLRNLRPPPE (1350.77) 819-829 3 7 2.70 ± 0.06 2.74 ± 0.03 2.67 ± 0.05 2.79 ± 0.01 2.77 ± 0.05 2.75 ± 0.07 
z-charge state of the peptide; a Number of maximum exchangeable amides for the peptide. b Average and standard deviation calculated from three 




Complexation of RIα and PDE8 induce conformational changes leading to translocation 
of cAMP to PDE8 active site as observed by decreased deuterium uptake at the peptides 
when comparing PDE8AC:RIα complex in the  presence and absence of excess cAMP. In 
PDE8AC:RIα:cAMP complex, putative RIα interaction sites (black arrows, Fig. 3.19A) 
exchanged fewer deuterons throughout the labeling times signifying complexation. 
To further validate that these changes observed are effects of complexation with 
RIα in the presence of cAMP, we performed and compared the hydrogen-deuterium 
exchange results of PDE8AC:RIα in the presence of excess cAMP with PDE8AC incubated 
with excess cAMP (Fig. 3.20A). In the presence of cAMP in excess, increased deuterium 
exchange was observed at the catalytic site in PDE8AC:RIα complex than in PDE8AC 
alone, indicating increased dynamics associated with increased catalytic hydrolysis of 
cAMP by the ternary complex. The deuterium uptake values at 1, 10 and 30 min for the 
catalytic domain of PDE8A as a ternary complex and with excess cAMP are tabulated in 
Table 3.4. 
 
Figure 3.20: Mapping the effects of PKA RIα on PDE8A in PDE8:PKA-RIα complex. (A) Plot 
of average differences in deuterium uptake (Y-axis) between PDE8AC:RIα:cAMP  relative to 
PDE8AC:cAMP, with residue numbers for pepsin fragment peptides of PDE8A catalytic domain 
listed from N to C-terminus (X-axis). Positive changes denote increased deuterium exchange while 
negative changes denote decreased exchange in PDE8AC:RIα complex as compared to PDE8Ac 
with excess cAMP. Peptides spanning the catalytic site of PDE8A are highlighted in yellow, 
substrate binding sites in purple and PDE substrate recognition site peptides by pink boxes. Sites 
of interaction with RIα are pointed by the black arrow. Three peptides interacting with cAMP are 





These interaction sites of cAMP and RIα on PDE8A are mapped onto the crystal 
structure of catalytic domain of PDE8A (PDB ID: 3ECM) in Figure 3.21. Active site of 
cAMP hydrolysis is shown in yellow which coordinates the two metal cations (red 
spheres) with the residues of Q-pocket. Interaction interface showing decreased deuterium 
exchange observed in PDE8A upon RIα binding are shown in blue. These regions move 
away from the lid-region and are overlapped by αB:C helix of RIα. The two peptides 
binding to cAMP (728-736, 740-747) and residues spanning M-loop are also indicated.  
 
Figure 3.21: Active site of PDE8A. Cartoon form of crystal structure of catalytic domain of 
PDE8A is shown in cyan, with catalytic site (590-614) in yellow, RIα interaction interface (675-
690) in blue, substrate binding peptides (724-736, 740-747) in purple and set of residues helping 




In this section of my thesis, I have described the mechanism for termination of 
the cAMP-PKA signaling pathway, through ‘channeling’ between the binding sites of 
cAMP-target RIα and the active site of the cAMP hydrolyzing enzyme PDE8A. This has 
important implications for understanding how cAMP signaling output is controlled 
through the termination phase of cAMP signaling by modulating PDE action. More 
importantly, this study highlights a unique mechanism, whereupon the enzymatic activity 
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of PDE8 in the complex, accelerates cAMP hydrolysis. In this context, our model 
highlights a critical biological role of the PDE8:PKA RIα complex in promoting rapid 
cAMP hydrolysis and robustness in response to dynamic levels of cAMP in cAMP-PKA 
signaling pathway. While rapid fluxes in cAMP levels through hormonal modulation of 
adenylyl cyclase is well understood, we describe for the first time how a cAMP receptor, 
PKA RIα enhances cAMP hydrolysis rates through dynamic interactions with a 
phosphodiesterase. In addition to its well-recognized function of hydrolyzing free cAMP 
inside the cell, we show that PDEs directly target cAMP-bound PKA R-subunits in the 
cytosol and catalyze active hydrolysis to 5′-AMP. PDEs are thus exquisitely poised to 
carry out a range of enzymatic functions. Active hydrolysis of cAMP in PDE:PKAR-
subunit complexes appears to be essential to effective regulation of cAMP signaling. 
Moreover, according to a clinical study (Elli, Bordogna et al. 2016), patients with 
acrodysostosis showed hormonal resistance due to mutations in PKA RIα (Y173, T207, 
D267, and F291) and PDE4D. These genetic mutant sites were found to be in the exact 
same regions spanning the interaction interface on both RIα and PDE8, proposed in this 
study. This further enhances the relevance of our study and importance of PDE8A:RIα 
interactions. 
PDE8:PKAR complex is stabilized by ligand binding 
Our fluorescence polarization results showed competitive displacement of 
fluorescent cAMP analogs by cAMP from free RIα, but not PDE8-bound RIα. Higher 
polarization reflects decreased ligand mobility with concomitant increases in the relative 
molecular mass of complex, therefore, the increased polarization observed for fluorescent 
cAMP saturated RIα and PDE8 reaction can only occur as a result of stable complexation. 
Interestingly, the lack of differences in polarization observed in the ternary complexes 
mediated by the two separate fluorescent analogs of cAMP (8-[fluo]-cAMP:RIα:PDE8AC 
or 2′-fluo-cAMP:RIα:PDE8AC) supports a cAMP channeling model wherein the non-
hydrolyzable 8-[fluo]-cAMP promotes complexation, hydrolysis of PDE-susceptible, 2′-
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fluo-cAMP to the product 2′-fluo-AMP, retains the stability of the ternary complex. This 
enhanced stability is contributed by fluorescein moiety which mediates additional 
hydrophobic contacts with aromatic residues lining the opening of the active site of PDE8. 
Thus excess cAMP, RIα and PDE8 are each critical in promoting the termination phase 
of cAMP signaling. 
 
Figure 3.22: Substrate channeling in PDE8A:PKAR complex for termination phase of cAMP 
signaling. PDE8:PKAR complex is shown in structure representation (A) and cartoon illustration 
(B) with the dimer of PDE8AC (PDB ID: 3ECN) in gray and a monomer of PKA RIα (PDB ID: 
4MX3) in blue. The PDE8:PKAR complex is an extension of active-site coupling model, with 
interaction interface determined by HDXMS experiments as described. Cyclic AMP (yellow 
sticks) are shown in both CNB:A and CNB:B domains and its binding surface is indicated in 
yellow. Ligand mediates stabilization of complex, with the catalytic site of PDE8 being in close 
proximity to the cAMP binding pockets of RIα, forming a channel as outlined by cylindrical 
cartoon. Substrate channels between PDE8 and PKAR for cAMP binding at CNB:A (inset A) and 
CNB:B (inset B) sites are zoomed. Key residues involved in cAMP binding to RIα (sticks in blue) 
and PDE8 (sticks in cyan) are marked for channel spanning CNB:A (inset, A). Hydrolysis and 
turnover of cAMP by PDE8:PKAR complex is illustrated in inset B, showing PDE-substrate cAMP 
(yellow sticks) in RIα and PDE-product AMP in PDE8. Channeling of cAMP is indicated by 
double-headed arrows in yellow. Two metal ions (Zn+2 and Mg+2) coordinating the catalytic 




Our HDXMS and fluorescence polarization assays together reveal insights into 
the PDE8:PKA RIα complex by detailing their interface map. Further, they describe how 
the complex is maintained in the presence of a steady-state excess of cAMP through 
protein contacts at the periphery and cemented by the ligand at the core of the channel 
formed between the two active sites of PKA RIα and PDE8. The cAMP binding pockets 
of PKAR at one end and the catalytic site of PDE8 at other end form the channel (Fig. 
3.22A), with PDE8 residues responsible for substrate recognition and hydrolysis lining it 
(Fig. 3.22B). We believe that channeling, described for the first time in cAMP signaling, 
enhances the robustness of the cAMP response. The PDE-PKAR interactions and 
complexation would be further enhanced in the presence of AKAP proteins which would 
likely increase co-localization of these classes of proteins (Lefkimmiatis and Zaccolo 
2014).  
Channeling model for PDE-mediated cAMP dissociation from PKAR 
Detailed understanding of PDE8-mediated cAMP release from R-subunit was 
obtained by monitoring the conformational changes accompanying complexation. 
HDXMS results clearly showed that the ternary complex populated distinct conformations 
through the reaction, allowing us to discriminate the effects of cAMP and PDE8 binding 
to R-subunit. While cAMP binding reduced the solvent accessibility, PDE8 binding 
resulted in increased solvent accessibility in the cAMP binding pockets indicative of 
ligand release. PDE8-mediated cAMP release was observed to be a dynamic process 
initiated by the complexation of cAMP, R-subunit, and PDE8. Central to this dynamic 
interaction is R-subunit, which occludes the phosphodiester bond but presents adenine 
ring of ‘caged substrate’ cAMP to PDE8 and this complexation leads to sequential 
changes illustrated Fig. 3.20A inset. At higher cAMP concentrations, the ternary complex 
stays bound and catalyzes the hydrolysis of cAMP to AMP, leading to the formation of 
cAMP-free R-subunit.  
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On the basis of our HDXMS results, we propose a cAMP channeling model in the 
PDE8:PKA-RIα terminator complex for accelerated cAMP turnover in cAMP signal 
termination. The steps include: 
(1) PDE8 binding to cAMP-bound R-subunit induces conformational changes, 
including the αB:C helix of RIα. This results in the altered conformation of the 
CNB:A capping residue W260, weakening the interactions between aromatic ring 
of tryptophan and the adenine ring of cAMP. Similarly for CNB:B, the capping 
residue Y371 moves away from adenine ring of cAMP and weakens equivalent 
π-stacking interactions. 
(2) PDE8 binding destabilizes the bonds between the cyclic phosphate of cAMP and 
the residues in the cAMP binding pocket (CNB:A and CNB:B). As a result, the 
binding between cAMP and RIα is weakened.  
(3) Conserved hydrophobic residues present on the surface of PDE8, spanning the 
substrate recognition M-loop, present a shell of strong aromatic (π-ring) contacts 
to draw the adenine ring of cAMP away from RIα to PDE8 while still maintaining 
the ternary complex.  
(4) Active site of enzyme PDE8 lined up with positively charged residues attracts 
negatively charged cyclic phosphate of cAMP and promotes active hydrolysis.  
The PDE8:PKA R-subunit (Fig. 3.23, step 1) channel would thus catalyze active cAMP 
hydrolysis without diffusion of any unhydrolyzed cAMP into solution. Processive 
hydrolysis of all cAMP molecules would thus take place through repeated cycles of 
binding of cAMP to R-subunit, channeling and PDE-mediated hydrolysis to AMP (Fig. 
3.23, steps 2-4). We predict that channel formation must occur at both CNB domains with 
a dimer of PDE8 binding to individual monomer of PKA R-subunit. The ‘burst’ and lag 
phase in cAMP hydrolysis observed is reflective of an asymmetric ternary complex with 
two catalytic cores with separate Michaelis constants (KM - cAMP) and turnover rates. 
Evidence for two channel sites has come from PDE inhibitor screens using our 
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fluorescence polarization assay, wherein using cGMP and certain natural extracts we 
identified potential inhibitors some of which facilitated dissociation of fluorescent cAMP 
analogs from both PDE:R-subunit channel sites and others that were specific for only one 
of the two channels (Chapter 6).  
 
Figure 3.23: Processive hydrolysis of cAMP by channeling through PDE8:PKAR complex. A 
dimer of PDE8 (green) recognizes cAMP (red spheres) which is bound to PKA regulatory subunit, 
which is represented as two cAMP binding domains (blue spheres) connected by a helix, leading 
to formation of PDE8:PKAR complex (step 1). The cAMP binding site of PKAR and active site 
of PDE8 (highlighted by two metal cations as black dots) get coupled to form a ‘substrate channel’ 
(red cylinder). During a cAMP flux, excess cAMP is translocated to PDE8 via PKAR through this 
channel (step 2), resulting in activated hydrolysis of cAMP (step 3) and the generated product 5’-
AMP is effluxed out (step 4), until all cAMP molecules get rapidly hydrolyzed by the PDE8:PKAR 
complex. This results in dissociation of the complex (step 5), generating a cAMP-free PKA 




This study highlights rapid hydrolysis of cAMP by enhanced phosphodiesterase 
activity of PDE8A:RIα complex, which has important implications in the understanding 
of how cAMP signaling output is controlled through the termination phase of cAMP 
signaling by modulating PDE action. Our data presents a major advancement, where the 
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PDE8:PKA complex represents a new enzyme core by channeling of cAMP. This ensures 
that the cAMP signalosome’s preferential response would be to rapid fluxes rather than 
steady-state levels of cAMP, enabling adaptation to hormonal input signals. Besides, 
multiple studies have shown maximal PKA activity and in turn fine-regulation of cAMP 
signaling under dynamic levels of cAMP in the cytoplasm, rather than static equilibrium 
(Leiser, Fleischer et al. 1986, Friedrich and Aszódi 1989). The PDE8A:RIα complex, 
therefore, allows the cells to have ‘bistability’, a molecular property where cells are stable 
under two conditions (Teruel and Meyer 2002), here, in low-cAMP state and high-cAMP 
state (Giri, Mutalik et al. 2004, Ozbudak, Thattai et al. 2004).  
 
Figure 3.24: Illustration of substrate channel between PDE8A and PKA RIα. An illustration of 
predicted channel between phosphate-binding cassette of CNB:A domain of RIα (blue shaded area) 
with the chemical structures of the binding amino acid residues highlighted (Gly199, Glu200, 
Ala202, Arg209, Ala210, and Trp 260). Blue dashed lines indicate hydrogen-bonding with the 
atoms highlighted in red. The purple dots and dotted line between adenine ring of cAMP and indole 
ring of Trp260 represent pi-pi stacking interactions. Amino acid residues lining the catalytic pocket 
(F719, A742, Y748, E778, F781, and F785) of PDE8A (green shaded area) and the catalytic 
residues (H556, H596, D597, H600, D726) coordinating the two metal cations (Zn+2, Mg+2) as 
black circles are highlighted by their chemical structures.  Approximate distances of the channel 
(highlighted by gray cylinder), were measured from crystal structures of the two proteins. The 
image illustrates the channel and is not drawn to scale. 
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Our current research findings provide a substrate channeling via receptor-enzyme co-
localization model in second messenger signaling and have widened the avenues of 
understanding the various roles of PKA and PDE8 in regulating cAMP signaling. In a 
signaling pathway, this is the first instance which demonstrates conversion of bound-
substrates (cAMP to AMP) by physical proximity of the donor (R subunit) – acceptor 
(PDE8), without diffusing into the cytoplasm (Bauler, Huber et al. 2010). The channeling 
of cAMP accelerates cAMP hydrolysis without allowing diffusion into the cytoplasm. 
This accelerated turnover by the termination complex would result in generation of 
cAMP-free RIα (Fig. 3.23, step 5) through rapid reduction in cAMP flux, enabling robust 
desensitization of the cAMP signal to quickly reset the cellular milieu for subsequent 
stimulations. Importantly, restricted diffusion of cAMP into the cytoplasm confines the 
signaling response to a specific subset of cytoplasm in a stimulus-dependent manner. Such 
localized signaling response also prevents false elicitation of non-canonical signaling 
pathway associated with second messengers, which are widely distributed and responsible 
for varied stimuli. Lastly, the channel in the PDE8:PKA-RIα (Fig. 3.24) terminator 
complex offers a new target with improved specificity for small molecule disruptors of 








AMP induced conformational 
dynamics in PDE8:PKAR complex: 





In a hormone-stimulated cell, continuous hydrolysis of high concentrations of 
cAMP leads to increased levels of the hydrolyzed product 5′-AMP (henceforth referred to 
as ‘AMP’). Often, such increases in AMP levels are signs of diseased or alarming 
conditions like starvation, ischemia or stress. AMP and its binding protein AMP-activated 
protein kinase (AMPK) act as cellular energy sensor which triggers different pathways 
when the AMP:ATP ratio is increased (Hardie 2011). Indirectly, an increase in AMP 
levels indicates a decrease in ATP levels. Therefore, AMPK activates pathways which 
conserve or produce ATP and negatively regulates ATP-consuming processes. In the 
context of rapid hydrolysis of cAMP by PDEs, an increase in AMP levels must regulate 
the initiation of catabolic pathways and termination of anabolic pathways and therefore 
restoring the AMP:ATP balance in the cell (Hardie 2008). In addition to the regulation by 
signaling pathways, the levels of AMP should be decreased to maintain AMP:ATP 
homoeostasis and prevent constant activation of AMP-related signaling pathways 
(Daniels, O. Brien WG et al. 2013). The breakdown of AMP is mediated by two enzymes 
– AMP deaminase, which catalyzes the conversion of AMP to inosine monophosphate to 
positively regulate the purine nucleotide cycle (Hancock, Brault et al. 2006); and 5′-
nucleotidase, which breaks down the 5′-phosphate group and generates adenosine 
molecules (Zimmermann 1992, Ipata and Balestri 2013). 
One of the ways by which AMP molecules are generated, is by the hydrolysis of 
cAMP by phosphodiesterases. In addition to the passive role of PDEs, including PDE8, 
in catalyzing the hydrolysis of cAMP to 5′-AMP, we have shown that PDE8 actively 
hydrolyzes bound-cAMP from its target protein regulatory subunit of Protein Kinase A 
(PKAR). We observed different effects of limited and excess amounts of cAMP on 
PDE:PKAR complex, wherein excess cAMP or excess AMP thereupon lead to increased 
conformational dynamics at the cAMP binding sites of PKAR. It is highly likely that the 
reaction product AMP plays a role in stabilization of the complex, so that all cAMP 
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molecules get serially hydrolyzed. This potentiates that AMP might have an yet 
undiscovered role in regulation of cAMP-PKA signaling pathway, and mediate crosstalk 
between cAMP and AMP signaling pathways for regulation of ATP:AMP balance in the 
cytoplasm. Through the catalytic subunit (PKAC), activated cAMP-PKA signaling 
pathway negatively regulates AMPK signaling by phosphorylation of AMPK. However, 
hydrolysis of cAMP elevates AMP levels that leads to negative feedback regulation of 
PKA activity. This occurs by the activation of AMPK to indirectly reduce AMP levels, 
underlying its possible role in regulating cAMP-PKA signaling. Previous studies by 
O’Greid and Doskeland have shown that increasing concentrations of nucleotides such as 
cAMP, ADP or AMP reduce PKAC-induced cAMP release from PKAR (Ogreid and 
Doskeland 1983), suggesting towards alternative pathways for cAMP release from PKAR 
to terminate cAMP signal. This further supports that AMP may have a role in cAMP-PKA 
signaling. Moreover, it was also reported that AMPK-mediated activation of PDEs 
decreases cytoplasmic cAMP levels stimulated by glucagon in hepatocytes (Johanns, Lai 
et al. 2016). Together, these results knit a converging role of AMPK and cAMP signaling 
pathways in regulation and metabolic control of cell energetics, as proposed recently 
(Mihaylova and Shaw 2011). 
Lack of understanding and absence of clear evidence related to cAMP and AMPK 
signaling, proposes one to investigate further on a possible role of AMP in cAMP 
signaling pathway and how it mediates activity of PDE8:PKAR complex during cAMP 
turnover. A detailed interaction map of cAMP with RIα is known, where direct contacts 
and indirect associations have been characterized. The 3′, 5′- cyclic phosphate group of 
cAMP engages three hydrogen-bonds with side chains of A202 and R209, while the 2′-
OH of ribose hydrogen bonds with G199 and E200. Hydrolysis of the cyclic phosphate 
by PDEs results in AMP, which differs cAMP only at 5′ and 3′ positions. Therefore, we 
assume that AMP may bind to cAMP binding pocket and to test this, amide hydrogen-
deuterium exchange mass spectrometry was carried out for RIα in the presence of excess 
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AMP. Moreover, it has been shown that very high concentration of AMP (2 mM) causes 
up to 90% dissociation of R:C PKA holoenzyme (Ogreid and Doskeland 1983), thereby 
activating PKA C-subunit. This further suggests that AMP may have a role in cAMP-
PKA signaling. To explore these effects of AMP on cAMP-PKA-PDE8 signaling, in this 
chapter, I investigated if AMP is able to bind to RIα or PDE8A stably, and if it has any 
potential biological role within cAMP-PKA-PDE signaling purview. Here, we applied 
amide hydrogen-deuterium exchange mass spectrometry (HDXMS) for purified RIα in 
the presence of excess AMP and phosphodiesterase PDE8 and observed that PDE8:RIα 
complex is stabilized in the presence of excess AMP. However, with progression of the 
reaction, PDE8 facilitated the dissociation of AMP from RIα by a substrate channeling 
mechanism, similar to that of cAMP unbinding (Krishnamurthy, Moorthy et al. 2014, 
Krishnamurthy, Tulsian et al. 2015), as explained in the previous chapter. Interestingly, 
we also observed that RIα alone could hydrolyze AMP to adenosine and free phosphates. 
Therefore, results from this chapter provide insights into the importance of the product 
AMP in regulation of cAMP signaling pathway, and indirectly links different signaling 
pathways regulated by cAMP and AMP ligands. 
4.2 MATERIALS AND METHODS 
4.2.1 Materials 
Chemically ultra-competent Escherichia coli BL21 (DE3) bacterial strains used for 
protein expression were obtained from Life Technologies (Carlsbad, CA). TALON® 
cobalt resin for his-tagged affinity purification was from ClonTech (Mountain View, CA) 
while BioGel HTP hydroxyapatite beads were from BioRad laboratories (Hercules, CA). 
LC/MS grade acetonitrile, methanol, and water were from Fisher Scientific (Waltham, 
MA); and trifluoroacetic acid (TFA), sequence analysis grade from Fluka BioChemika 
(Buchs, Switzerland). Deuterium oxide was from Cambridge Isotope Laboratories 
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(Tewksbury, MA). All other reagents and chemicals were research grade or higher and 
obtained from Sigma-Aldrich (St. Louis, MO). 
4.2.2 Expression and purification of proteins 
Full-length construct of R-subunit (RIα) was purified as described in previous 
chapters. In short, full length-dimeric RIα was purified via metal affinity chromatography 
(6x histidine-tagged) using TALON® cobalt resin, according to manufacturer’s 
instructions. Eluted RIα was subsequently applied to size-exclusion chromatography 
using HiLoad 16/60 superdexTM 200 prep grade with lysis buffer (20 mM Tris pH 7.5, 
100 mM NaCl, 5 mM β-ME) on AKTATM FPLC system (GE Healthcare, Marlborough, 
MA). The quality of the purified RIα was confirmed using denaturing SDS-PAG 
electrophoresis and quantified by Bradford colorimetric assay. Catalytic domain of 
PDE8A1 (residues 472-829) was cloned into pETDuet-1 plasmid and purified via 
unfolding (6x histidine-tagged purification) and refolding (Biogel HTP hydroxyapatite 
beads) process, as described in previous chapters. 
4.2.3 Enzyme Assay for RIα and AMP 
To monitor if RIα was able to hydrolyse any AMP, we carried out an enzymatic 
assay to quantify free phosphates using colorimetric BioMol malachite green kit 
(BioAssay systems, Hayward, CA). Purified RIα (1 µM) was incubated with different 
concentrations of ultrapure AMP solution (0.5, 1, 2, and 5 mM) at room temperature for 
varied time periods (0.25, 0.5, 1, 2, 4, 6 and 8 h). After stipulated time, the reaction was 
terminated using malachite green reagent and the absorbance was detected at 620 nm 
wavelength, using Infinite® 200 Pro (Tecan Group Ltd., Switzerland) multimode 
microplate reader. Each value represents an average of three measurements and the 
standard errors are also shown. Graphs were plotted by fitting the values for linear 
regression equation for product vs time plots and Michaelis-Menten equation for kinetic 
analysis using GraphPad Prism 6.0 (San Diego, CA). 
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4.2.4 Amide hydrogen-deuterium exchange mass spectrometry 
To monitor the effects of AMP on RIα and PDE8AC, deuterium labeling 
experiments were performed in 30 µl reaction volumes with D2O at a final concentration 
of 90%. HDXMS experiments were carried out for RIα and PDE8AC free proteins 
separately, without AMP and with AMP (3 mM). Next, HDXMS was performed as two 
different sample sets: (i) PDE8AC:RIα in 3:1 molar ratio to map changes on RIα and (ii) 
PDE8AC:RIα in 1:3 molar ratio to monitor changes on PDE8A. Complexation and 
deuterium exchange reactions were simultaneously initiated by addition of the 
components and deuterium buffer (99% D2O, 20 mM Tris pH 7.5, 50 mM NaCl, 5 mM 
MgCl2, 20 µM ZnSO4, 5 mM β-ME). 
Each exchange reaction was done in triplicates at 298 K for 1, 10 and 30 min 
labeling times followed by quenching to pHread ~ 2.5 using chilled 0.1% TFA quench 
solution. Samples were then subjected to digestion and identification by UPLC-MS as 
explained in chapter 1. 
4.3 RESULTS 
4.3.1 AMP binding stabilizes PDE8A:RIα complex 
Effect of limited and excess concentrations of cAMP on the conformational 
dynamics of PDE8A:RIα protein-protein complex and enzymatic turnover described 
previously showed that the complex facilitated accelerated hydrolysis of cAMP to 5′-
AMP, and the AMP formed mediated concentration-dependent dynamics in RIα, 
especially at the cAMP binding regions. To probe the effects of AMP on the complex and 
monitor the associated stabilization of PDE8A:RIα complex, we carried out hydrogen-
deuterium exchange mass spectrometry for PDE8A:RIα complex in the presence and 
absence of excess AMP (3 mM) at three deuterium labeling time points- 1, 10 and 30 min. 
A total of 59 peptides equivalent to 83% of primary sequence were analyzed (Fig. 4.1).  
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HDXMS results showed significant differences in deuterium exchange in most 
regions of PDE8A:RIα complex in the presence of excess AMP as shown in Fig. 4.2A. In 
the ternary complex, initial decrease in deuterium exchange was observed in peptides 
spanning phosphate-binding cassettes of both CNB domains, indicative of ligand (AMP) 
binding (green boxes, Fig. 4.2A). With time the trend reversed, where increased deuterium 
exchange was observed in these regions, as shown by deuterium uptake plots (Fig. 4.2B 
iii) and CNB:B (Fig. 4.2B iv). This inversion (Fig. 4.2B iii, iv), relative decrease at initial 
labeling times followed by relative increase at these same regions, indicate AMP binds to 
RIα in the complex initially, and with time PDE8A induces conformational changes in 
RIα, facilitating AMP dissociation. 
 
Figure 4.1: Primary sequence coverage of RIα in HDXMS experiments with excess AMP. The 
primary sequence of full-length RIα. Green boxes indicate all peptide fragments spanning regions 
of the primary sequence obtained from HDXMS experiments of RIα with AMP.  Approximately 
83% sequence coverage was observed. Amino acids labeled as ‘X’ are residues which were not 
identified in the initial protein database search engine. 
 
Further, peptides spanning ‘capping residues’ for both domains (W260, and 
Y371), also showed increased deuterium uptake, suggestive of PDE8A-mediated AMP 
release from RIα. Peptides spanning the potential PDE8-binding sites on RIα showed 
time-dependent changes in deuterium exchange (Fig. 4.2B ii) suggesting that the complex 
 X  A  S  G  T  T  A  S  E  E  E  R  S  L  R  E  C  E  L  Y  V  Q  K  H  N  I  Q  A  L  L  K  D  S  I  V  Q  L  C  T  A  R  P  E  R  X  X  X  X  L  R  E  Y  F  E  K  L  E  K  E  E  A  K  Q  I  Q 
 5  10  15  20  25  30  35  40  45  50  55  60  65 
 N  L  Q  K  A  G  S  R  A  D  S  R  E  D  E  I  S  P  P  P  P  N  P  V  V  K  G  R  R  R  R  G  A  I  S  A  E  V  Y  T  E  E  D  A  A  S  Y  V  R  K  V  I  P  K  D  Y  K  T  M  A  A  L  A  K  A 
 70  75  80  85  90  95  100  105  110  115  120  125  130 
 I  E  K  N  V  L  F  S  H  L  D  D  N  E  R  S  D  I  F  D  A  M  F  P  V  S  F  I  A  G  E  T  V  I  Q  Q  G  D  E  G  D  N  F  Y  V  I  D  Q  G  E  M  D  V  Y  V  N  N  E  W  A  T  S  V  G  E 
 135  140  145  150  155  160  165  170  175  180  185  190  195 
 G  G  S  F  G  E  L  A  L  I  Y  G  T  P  R  A  A  T  V  K  A  K  T  N  V  K  L  W  G  I  D  R  D  S  Y  R  R  I  L  M  G  S  T  L  R  K  R  K  M  Y  E  E  F  L  S  K  V  S  I  L  E  S  L  D  K 
 200  205  210  215  220  225  230  235  240  245  250  255  260 
 W  E  R  L  T  V  A  D  A  L  E  P  V  Q  F  E  D  G  Q  K  I  V  V  Q  G  E  P  G  D  E  F  X  I  I  L  E  G  S  A  A  V  L  Q  R  R  S  E  N  E  E  F  V  E  V  G  R  L  G  P  S  D  Y  X  X  X 
 265  270  275  280  285  290  295  300  305  310  315  320  325 
 X  X  X  L  M  N  R  P  R  A  A  T  V  V  A  R  G  P  L  K  C  V  K  L  D  R  P  R  F  E  R  V  L  G  P  C  S  D  I  L  K  R  N  I  Q  Q  Y  N  S  F  V  S  L  S  V 
 330  335  340  345  350  355  360  365  370  375  380 
Total: 82.4%  Coverage, 1.98 Redundancy
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dissociates when most AMP gets released from the binding pockets of RIα. Importantly, 
peptides from dimerization/docking domain and PKA C-subunit binding regions of RIα 
(Fig. 4.2B i) showed progressively increased deuterium exchange in PDE8AC:RIα in the 
presence of excess AMP, suggesting allosteric changes in these peptides due to initial 
AMP binding and subsequent PDE8A-mediated AMP-release. It is probable that AMP 
binding followed by PDE8-mediated unbinding propagates allosteric changes across these 
peptides that changes the conformation of RIα similar to cAMP-free conformation (Su, 
Dostmann et al. 1995). The deuterium uptake values are listed in Table 4.1. 
 
Figure 4.2: Effects of AMP on PDE8A:RIα complex. A. Difference plot of differences in 
deuterium uptake (Y-axis) between PDE8AC:RIα:AMP and PDE8AC:RIα for each pepsin fragment 
of RIα listed from N- to C- terminus. Peptides overlapping continuous regions are grouped and the 
domain organization of RIα is shown. Positive differences indicate increased exchange while 
negative differences indicate decreased deuterium uptake in PDE8AC:RIα complex in presence of 
excess AMP. Peptides spanning cAMP binding sites are highlighted by green box. Each deuterium 
labeling time for every peptide is depicted and colored according to the key. Red dashed line 
indicates a significant difference of ± 0.5 Da used, and standard deviations are in gray. (B) Kinetic 
plots showing relative deuterium uptake with time in four regions of RIα. Plots of representative 
peptides from PKA C-subunit binding site (112-126), PDE8-binding site (158-173), CNB:A (203-
218) and CNB:B (329-337) are shown. Each plot shows number of deuterons exchanged by 
PDE8AC:RIα (□), PDE8AC: RIα:AMP (■). Each value is an average of three independent 
deuterium exchange experiments and their standard deviations are also shown. The plots were 
generated using GraphPad Prism 6.0 (San Diego, CA).  
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Table 4.1 Deuterium uptake values at 1, 10 and 30 min for full-length RIα, bound to PDE8A in the presence and absence of excess AMP. 
          PDE8A:RIα PDE8A:RIα:AMP 
       1 min  10 min 30 min 1 min  10 min 30 min 
S.N
o. 










11-22 2 11 0.96 ± 0.11 1.41 ± 0.13 2.00 ± 0.12 0.65 ± 0.02 1.13 ± 0.03 1.65 ± 0.09 
2 YVQKHNIQAL (1213.67) 20-29 2 9 2.49 ± 0.20 3.34 ± 0.07 3.41 ± 0.07 2.42 ± 0.06 3.46 ± 0.12 3.68 ± 0.02 




























112-127 3 14 5.41 ± 0.09 6.00 ± 0.08 6.21 ± 0.05 5.64 ± 0.11 7.17 ± 0.05 7.68 ± 0.00 








113-127 2 13 5.05 ± 0.09 5.49 ± 0.08 5.73 ± 0.11 4.87 ± 0.20 6.08 ± 0.17 7.02 ± 0.19 
16 LAKAIEKNVL (1098.68) 127-136 2 9 3.01 ± 0.07 3.84 ± 0.07 4.15 ± 0.08 3.18 ± 0.03 4.09 ± 0.04 4.96 ± 0.02 
17 AKAIEKNVL (985.60) 128-136 2 8 2.65 ± 0.10 3.21 ± 0.10 3.50 ± 0.12 2.73 ± 0.02 3.25 ± 0.02 3.83 ± 0.02 
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18 AIEKNVL (786.47) 130-136 1 6 1.81 ± 0.07 2.20 ± 0.06 2.27 ± 0.05 1.84 ± 0.01 2.25 ± 0.06 2.58 ± 0.03 




137-149 3 12 1.28 ± 0.02 1.47 ± 0.02 1.68 ± 0.04 1.36 ± 0.02 1.54 ± 0.01 1.74 ± 0.01 
21 DDNERSDIF (1110.47) 141-149 2 8 1.05 ± 0.10 1.29 ± 0.11 1.46 ± 0.10 1.14 ± 0.06 1.46 ± 0.02 1.64 ± 0.02 












174-183 1 9 0.85 ± 0.08 1.19 ± 0.08 1.75 ± 0.18 0.52 ± 0.06 0.97 ± 0.06 1.55 ± 0.04 
















206-222 2 15 3.09 ± 0.21 3.21 ± 0.17 4.06 ± 0.18 1.67 ± 0.06 3.62 ± 0.04 6.16 ± 0.10 
31 VKAKTNVKL (1000.65) 214-222 2 8   ±   ±   ±   0.60 ± 0.02 1.01 ± 0.05 1.98 ± 0.04 
32 WGIDRDSY (1011.45) 223-230 2 7 1.04 ± 0.03 1.21 ± 0.01 1.36 ± 0.04 0.49 ± 0.03 0.88 ± 0.01 1.20 ± 0.01 
33 RRILMGSTL (1046.61) 231-239 2 8 2.19 ± 0.04 2.71 ± 0.03 3.05 ± 0.05 1.58 ± 0.03 2.39 ± 0.02 3.06 ± 0.02 
34 RKRKMYEEF (1286.67) 240-248 3 8 2.03 ± 0.02 2.32 ± 0.06 2.30 ± 0.06 1.65 ± 0.05 2.72 ± 0.02 3.11 ± 0.01 
35 FLSKVSIL (906.57) 248-255 2 7 1.92 ± 0.02 2.71 ± 0.01 2.88 ± 0.05 1.93 ± 0.03 2.75 ± 0.02 3.26 ± 0.01 
36 LSKVSIL (759.49) 249-255 2 6 1.74 ± 0.03 2.53 ± 0.04 2.70 ± 0.01 1.63 ± 0.02 2.35 ± 0.03 2.83 ± 0.01 
37 ESLDKWERL (1175.60) 256-264 2 8 1.83 ± 0.02 2.51 ± 0.02 2.79 ± 0.05 1.48 ± 0.02 2.21 ± 0.02 3.06 ± 0.01 
38 TVADALE (718.36) 265-271 1 6 1.06 ± 0.04 2.07 ± 0.02 2.45 ± 0.07 0.39 ± 0.02 1.47 ± 0.03 2.51 ± 0.02 
39 DALEPVQF (918.45) 268-275 1 6 1.10 ± 0.08 1.64 ± 0.04 1.77 ± 0.07 0.88 ± 0.01 1.33 ± 0.02 1.86 ± 0.01 
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276-291 2 14 2.06 ± 0.04 2.76 ± 0.04 3.72 ± 0.18 1.47 ± 0.02 2.33 ± 0.06 3.54 ± 0.03 




300-310 2 10 n.a.    n.a.    n.a.     2.33 ± 0.04 2.58 ± 0.03 2.74 ± 0.09 








311-322 2 10 1.55 ± 0.02 2.01 ± 0.03 2.41 ± 0.07 1.20 ± 0.02 1.80 ± 0.01 2.23 ± 0.02 




329-338 2 8 1.84 ± 0.05 2.39 ± 0.03 3.07 ± 0.12 0.81 ± 0.03 1.74 ± 0.01 2.76 ± 0.07 
49 MNRPRAAT (916.48) 33-337 2 6 1.50 ± 0.05 1.82 ± 0.02 2.20 ± 0.07 0.79 ± 0.02 1.53 ± 0.04 2.32 ± 0.03 
50 VVARGPLKC (942.55) 338-346 2 7 1.37 ± 0.04 1.66 ± 0.02 1.94 ± 0.06 0.40 ± 0.05 0.81 ± 0.05 1.37 ± 0.04 
51 VARGPLKC (843.48) 339-346 2 6 1.35 ± 0.04 1.58 ± 0.03 1.78 ± 0.06 0.33 ± 0.04 0.74 ± 0.03 1.27 ± 0.04 
52 ARGPLKC (744.41) 340-346 2 5 1.07 ± 0.08 1.29 ± 0.04 1.52 ± 0.06 0.33 ± 0.02 0.67 ± 0.03 1.17 ± 0.02 
53 VKLDRPRF (1030.61) 347-354 2 6 1.05 ± 0.01 1.42 ± 0.01 1.53 ± 0.03 0.44 ± 0.02 0.97 ± 0.01 1.25 ± 0.01 
54 ERVLGPCSD (975.45) 355-363 1 7 1.96 ± 0.04 2.32 ± 0.03 2.64 ± 0.05 1.70 ± 0.04 2.36 ± 0.01 2.89 ± 0.02 
55 ERVLGPCSDIL (1201.62) 355-365 2 9 2.22 ± 0.02 2.72 ± 0.01 3.26 ± 0.09 2.02 ± 0.03 2.76 ± 0.02 3.47 ± 0.01 
56 ILKRNIQQ (1012.62) 364-371 2 7 2.46 ± 0.04 2.83 ± 0.04 2.94 ± 0.07 2.06 ± 0.04 3.19 ± 0.03 3.65 ± 0.04 




364-375 2 11 3.79 ± 0.04 4.44 ± 0.04 4.57 ± 0.08 3.95 ± 0.07 5.20 ± 0.01 5.70 ± 0.01 
59 KRNIQQYNSF (1297.66) 366-375 2 9 3.36 ± 0.03 3.64 ± 0.04 3.78 ± 0.03 4.13 ± 0.05 4.72 ± 0.04 4.82 ± 0.03 





4.3.2 AMP binds to PKA R-subunit in cAMP binding pocket  
While we observed AMP-mediated stabilization of PDE8:RIα complex, no 
previous study has shown binding of AMP to RIα. Hence, we next aimed to determine the 
binding kinetics of AMP and monitor the conformational dynamics of AMP-bound RIα. 
To ensure complete saturation, purified RIα was incubated with 3 mM of AMP for 3 h 
prior to HDXMS experiments at labeling times of 1, 10 and 30 min. AMP binding resulted 
in significant differences in deuterium exchange compared to free RIα, as summarized as 
difference plot in Fig. 4.3A.  
AMP binding lead to an initial decrease in deuterium exchange in peptides 
spanning the two cyclic-nucleotide binding sites (highlighted in green boxes, Fig. 4.3A) 
and an overall increase in deuterium uptake in most other regions of RIα. Interestingly, 
regions spanning the dimerization/docking interface, pseudosubstrate binding site, PKA 
C-subunit binding site showed increased deuterium uptake with time in AMP-bound RIα. 
These observations were contrary to the effects known for cAMP binding to RIα, which 
is known to cause decreased deuterium exchange at these sites. Peptides spanning the 
cAMP binding pockets (CNB:A and CNB:B) showed decrease in deuterium uptake with 
time for AMP-incubated RIα, owing to successful occupancy of AMP in these regions. 
The differences in deuterium uptake profile between the two CNB domains is similar to 
the changes observed previously for cAMP-saturated RIα, where CNB:A undergoes fast 
exchange kinetics (hence more number of deuterons) than the CNB:B site (Ogreid and 
Doskeland 1981). These differences are better inferred by the mass spectral envelopes for 
two representative peptides spanning CNB:A (205-222) and CNB:B (329-338) as shown 
in Fig. 4.3B and deuterium uptake plots in Fig. 4.4. The inter-domain linker (αB:C helix) 
transmits communication between the two CNB domains and undergoes a kinked-helical 
conformation change upon ligand binding (Su, Dostmann et al. 1995). Consistently, in 




Figure 4.3: AMP-binding induces dynamic changes in RIα. (A) Differences in average number 
of deuterons (Y-axis) exchanged by RIα relative to AMP-saturated RIα for each pepsin fragment 
listed from N- to C- terminus. Peptides overlapping continuous regions are grouped and the domain 
organization of RIα is indicated. Positive differences indicate decreased exchange, while points in 
negative scale indicate increased deuterium uptake in RIα upon AMP binding. Peptides spanning 
the cAMP binding pocket of CNB domains are highlighted in green. Each deuterium labeling time 
for every peptide is depicted and colored according to the key. Red dashed line indicates a 
significant difference of ± 0.5 Da and standard deviations are in gray. (B) Stacked mass spectral 
plots for peptides from cAMP binding pockets from CNB:A (205-222) and CNB:B (329-339) at 
different labeling times for RIα (left) and RIα:AMP (right) with the deuterium uptake values 
indicated and the centroids shown by triangles. 
 
 
covering (residues 223-230, Fig. 4.4) the inter-domain linker. Hence, these results suggest 
that AMP binds to RIα at cAMP binding loci. Importantly, these results show that AMP-
saturated RIα exhibits partial profiles belonging to two different conformations: cAMP-
bound (decreased exchange at CNB sites) and cAMP-free (increased-exchange at 
pseudosubstrate and PKA C-subunit binding sites) conformations. Binding of AMP to 
RIα and the corresponding dynamic changes across the protein are consistent with the 
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known information that RIα undergoes multiple transitions and exists as a conformational 
ensemble in solution (Akimoto, McNicholl et al. 2015, Nussinov and Tsai 2015).   
These differences in AMP-saturated RIα and RIα can also be seen by kinetic plots in Fig. 
4.5 and the deuterium uptake values are listed in Table 4.2. 
 
 
Figure 4.4: Relative uptake plots showing binding of AMP to RIα. Significant differences in 
deuterium exchange in RIα upon AMP binding are mapped onto crystal structure of cAMP-bound 
RIα. Regions showing decreased exchange in deuterium differences are in blue and regions with 
increased exchange are in salmon. Important regions are marked and their kinetic plots showing 






Table 4.2: Deuterium uptake values for peptides spanning full-length RIα in the presence and absence of excess AMP at different deuterium labeling times.  
     Deuterium uptake in RIα Deuterium uptake in RIα:AMP 
     1 min  10 min 30 min 1 min  10 min 30 min 
S.N
o. 




11-22 2 11 0.79 ± 0.04 1.22 ± 0.04 1.37 ± 0.03 0.70 ± 0.01 1.14 ± 0.03 1.56 ± 0.05 
2 YVQKHNIQAL (1213.67) 20-29 2 9 2.95 ± 0.04 3.82 ± 0.06 3.83 ± 0.05 2.55 ± 0.03 3.59 ± 0.08 3.83 ± 0.02 
3 QALLKDSI (887.52) 27-34 2 7 1.03 ± 0.05 1.48 ± 0.11 1.93 ± 0.04 0.88 ± 0.04 1.28 ± 0.05 1.59 ± 0.07 
































112-127 3 14 6.09 ± 0.20 7.28 ± 0.14 7.68 ± 0.10 5.52 ± 0.01 6.93 ± 0.11 7.55 ± 0.11 










113-127 2 13 5.34 ± 0.24 6.53 ± 0.26 6.93 ± 0.17 4.81 ± 0.18 6.15 ± 0.18 6.90 ± 0.26 
16 LAKAIEKNVL (1098.68) 127-136 2 9 3.31 ± 0.09 4.17 ± 0.10 4.96 ± 0.05 3.11 ± 0.02 3.86 ± 0.05 4.55 ± 0.08 
17 AKAIEKNVL (985.60) 128-136 2 8 2.77 ± 0.05 3.25 ± 0.07 3.80 ± 0.05 2.70 ± 0.03 3.05 ± 0.05 3.50 ± 0.06 
18 AIEKNVL (786.47) 130-136 1 6 2.00 ± 0.03 2.37 ± 0.05 2.72 ± 0.02 1.88 ± 0.01 2.23 ± 0.05 2.50 ± 0.05 




137-149 3 12 1.68 ± 0.04 1.78 ± 0.03 1.94 ± 0.02 1.49 ± 0.02 1.78 ± 0.04 1.92 ± 0.05 
21 DDNERSDIF (1110.47) 141-149 2 8 1.25 ± 0.04 1.39 ± 0.03 1.55 ± 0.03 1.10 ± 0.01 1.34 ± 0.03 1.45 ± 0.03 












174-183 1 9 0.69 ± 0.04 0.82 ± 0.03 0.95 ± 0.02 0.61 ± 0.01 0.79 ± 0.01 0.86 ± 0.01 
















206-222 2 15 1.64 ± 0.08 2.68 ± 0.16 3.73 ± 0.14 1.48 ± 0.07 2.21 ± 0.07 3.05 ± 0.10 
31 VKAKTNVKL (1000.65) 214-222 2 8 0.77 ± 0.03 1.07 ± 0.05 1.46 ± 0.03 0.76 ± 0.03 0.90 ± 0.02 1.16 ± 0.02 
32 WGIDRDSY (1011.45) 223-230 2 7 0.56 ± 0.03 0.84 ± 0.03 1.00 ± 0.01 0.46 ± 0.01 0.73 ± 0.02 0.94 ± 0.04 
33 RRILMGSTL (1046.61) 231-239 2 8 1.80 ± 0.01 2.62 ± 0.09 3.20 ± 0.03 1.52 ± 0.02 2.25 ± 0.06 2.77 ± 0.08 
34 RKRKMYEEF (1286.67) 240-248 3 8 1.74 ± 0.09 2.73 ± 0.10 3.13 ± 0.04 1.48 ± 0.02 2.33 ± 0.06 2.83 ± 0.06 
35 FLSKVSIL (906.57) 248-255 2 7 2.15 ± 0.06 2.95 ± 0.09 3.35 ± 0.05 1.93 ± 0.01 2.68 ± 0.06 3.26 ± 0.07 
36 LSKVSIL (759.49) 249-255 2 6 1.77 ± 0.06 2.53 ± 0.08 2.90 ± 0.04 1.60 ± 0.01 2.22 ± 0.05 2.76 ± 0.06 
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37 ESLDKWERL (1175.60) 256-264 2 8 1.56 ± 0.06 2.20 ± 0.08 2.59 ± 0.03 1.44 ± 0.02 1.91 ± 0.04 2.37 ± 0.05 
38 TVADALE (718.36) 265-271 1 6 0.42 ± 0.04 1.25 ± 0.07 1.75 ± 0.02 0.29 ± 0.01 0.85 ± 0.03 1.33 ± 0.03 
39 DALEPVQF (918.45) 268-275 1 6 0.88 ± 0.04 1.40 ± 0.05 1.66 ± 0.02 0.82 ± 0.01 1.23 ± 0.02 1.51 ± 0.02 




276-291 2 14 1.56 ± 0.05 2.04 ± 0.09 2.61 ± 0.04 1.50 ± 0.02 1.81 ± 0.04 2.23 ± 0.06 




300-310 2 10 3.00 ± 0.06 3.18 ± 0.04 3.17 ± 0.06 2.85 ± 0.01 3.16 ± 0.05 3.19 ± 0.03 








311-322 2 10 1.31 ± 0.04 1.83 ± 0.05 2.02 ± 0.02 1.22 ± 0.01 1.76 ± 0.03 1.98 ± 0.03 




329-338 2 8 0.84 ± 0.04 1.32 ± 0.04 1.63 ± 0.04 0.73 ± 0.03 1.06 ± 0.05 1.38 ± 0.05 
49 MNRPRAAT (916.48) 33-337 2 6 0.66 ± 0.01 1.08 ± 0.06 1.42 ± 0.04 0.60 ± 0.03 0.93 ± 0.03 1.24 ± 0.02 
50 VVARGPLKC (942.55) 338-346 2 7 0.40 ± 0.05 0.99 ± 0.06 1.62 ± 0.03 0.36 ± 0.03 0.76 ± 0.03 1.26 ± 0.04 
51 VARGPLKC (843.48) 339-346 2 6 0.35 ± 0.04 0.92 ± 0.06 1.46 ± 0.03 0.29 ± 0.03 0.65 ± 0.03 1.08 ± 0.04 
52 ARGPLKC (744.41) 340-346 2 5 0.32 ± 0.02 0.82 ± 0.05 1.32 ± 0.03 0.29 ± 0.02 0.62 ± 0.03 1.01 ± 0.02 
53 VKLDRPRF (1030.61) 347-354 2 6 0.53 ± 0.04 1.00 ± 0.03 1.05 ± 0.01 0.38 ± 0.01 0.87 ± 0.03 1.00 ± 0.02 
54 ERVLGPCSD (975.45) 355-363 1 7 1.87 ± 0.10 2.30 ± 0.05 2.49 ± 0.04 1.56 ± 0.01 2.15 ± 0.04 2.34 ± 0.05 
55 ERVLGPCSDIL (1201.62) 355-365 2 9 2.29 ± 0.10 2.79 ± 0.08 3.07 ± 0.08 1.97 ± 0.00 2.57 ± 0.06 2.86 ± 0.08 
56 ILKRNIQQ (1012.62) 364-371 2 7 2.34 ± 0.24 3.52 ± 0.12 3.81 ± 0.04 1.88 ± 0.03 3.07 ± 0.07 3.61 ± 0.06 




364-375 2 11 4.68 ± 0.24 5.76 ± 0.14 6.05 ± 0.08 3.93 ± 0.02 5.42 ± 0.10 5.96 ± 0.10 
59 KRNIQQYNSF (1297.66) 366-375 2 9 4.33 ± 0.06 4.73 ± 0.08 4.84 ± 0.08 3.78 ± 0.02 4.57 ± 0.06 4.87 ± 0.01 
z= charge state; MEA = Maximum exchangeable amides; Dex ± SD: Average of three measurements with their standard deviations; n.a = values not available
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4.3.3 RIα shows slow 5′- nucleotidase activity to degrade AMP 
In the above section we observed that AMP binds to RIα and induces 
conformational changes across most parts of the protein. Consequently, we hypothesized 
whether AMP played a passive role and gets diffused out during cAMP turnover or does 
it play a regulatory role in signaling or complex formation. Although AMP levels in the 
cytoplasm are very low and minute changes in its levels triggers an alarm across the cell, 
it is essential to understand how large amounts of AMP produced (hydrolysis of large flux 
of cAMP) is removed without mimicking a stressed condition in the cell. We therefore set 
out to check if RIα could degrade 5′-AMP to adenosine, ultimately leading to reduction 
in AMP levels. The 5′-nucleotidase activity was monitored by incubating RIα (1 µM) with 
different concentrations of AMP (0.5, 1, 2, 5 mM) at different reaction times.  
 
 
Figure 4.5: RIα hydrolyzes AMP to adenosine and free phosphate. (A) Enzymatic activity 
of RIα (1 µM) is measured by quantifying the amount of free phosphate (µM) detected at 
different concentrations of AMP substrate, 0.5 mM (●), 1 mM (◼), 2 mM (▲) and 5 mM (▼) 
as a function of time (0.25, 0.5, 1, 2, 4, 6, and 8 h) is plotted. Each value is an average of three 
independent measurements, with their standard errors shown. The values were fit to linear 
regression curve to obtain the rate of product formation. (B) Different velocities of reaction 
(µM/h) were plotted as a function of substrate AMP (mM) concentration using Michaelis-
Menten equation. The graphs were plotted using GraphPad Prism 6.0 (San Diego, CA).  
 
The amount of AMP hydrolyzed was then quantified using a colorimetric 
phosphate detection assay, as described in methods section. At low AMP concentrations 
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and at short time-scales, we did not observe any phosphate formation by AMP hydrolysis. 
However, at concentrations >1 mM for longer incubation times (> 1 h), free phosphates 
were detected, indicating that RIα was capable of hydrolyzing AMP (Fig. 4.5A). 
Importantly, appropriate controls of buffer and AMP alone (at different concentrations) 
were also carried out to measure intrinsic dissociation of AMP, showed no free phosphates 
during the assay. At higher concentrations of AMP, the nucleotidase activity was much 
more pronounced (red plots, Fig. 4.5A). This is the first instance showing RIα possesses 
enzymatic characteristics in catalyzing degradation of AMP, with the rate of reaction 
calculated as Vmax = 3 µM/h and KM = 0.8 mM (Fig. 4.5B). 
4.3.4 Bimodal signatures signify PDE8 facilitated AMP release from RIα 
Dissociation of cAMP from R-subunits is essential for inactivation of PKA C-
subunit, and we have previously reported an active role of PDE8A in facilitating cAMP 
release and hydrolysis. However, binding of the cAMP-product AMP to PDE8A:RIα 
complex and subsequent stabilization, would prevent from the generation of ligand-free 
RIα. Now, the question arises whether AMP plays a passive role and is diffused out during 
cAMP turnover or is it involved in regulation of signaling. Therefore, we next explored if 
PDE8AC could remove AMP-bound to RIα using HDXMS, as described in methods.  
Complex formation of PDE8AC with AMP-saturated RIα induced changes only 
in the phosphate binding cassettes of CNB domains, as observed by progressively 
increased deuterium uptake with time (Fig. 4.6A). Closer inspection of the mass spectra 
showed characteristic bimodal isotopic distribution of mass spectra for peptides spanning 
CNB:A and CNB:B binding pocket (Fig. 4.6B) in PDE8AC:RIα:AMP ternary complex. 
These may be attributed to – (a) low-exchanging population (AMP-bound conformation) 
similar to the distribution seen for AMP-bound RIα (right panels, Fig. 4.6B i, ii) and (b) 
high-exchanging population (AMP-free conformation) similar to the distribution profile 
observed for PDE8AC:RIα binary complex (left panels, Fig. 4.6B i, ii). These increased 
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differences were observed for both cyclic nucleotide binding sites, indicating that 
PDE8AC binding induced changes in RIα that facilitated the release of AMP from both 
the binding pockets. Protein-wide increased deuterium exchange in PDE8AC:AMP:RIα 
complex, therefore suggests that PDE8AC facilitates the release of AMP from RIα. This 
result proposes a model similar to PDE8AC:cAMP:RIα, i.e., AMP binds in the cAMP 
binding pockets initially, which later gets sequestered into the channel formed between 
RIα and PDE8AC complexation and resulting in ligand-free, high-dynamic conformation 
of RIα.  
 
Figure 4.6: Bimodal signatures in PDE8A:RIα:AMP complex show AMP release from RIα. (A) 
Differences in number of deuterons (Y-axis) exchanged by PDE8AC:RIα:AMP relative to AMP-
saturated RIα for each pepsin fragment listed from N- to C- terminus. Peptides overlapping 
continuous regions are grouped and the domain organization of RIα is indicated. Positive 
differences indicate increased exchange and negative differences indicate decreased deuterium 
uptake in ternary complex RIα upon AMP binding. Peptides spanning the cAMP binding pocket 
of CNB domains are highlighted in green. Each deuterium labeling time for every peptide is 
depicted and colored according to the key. Red dashed line indicates a difference of ± 0.5Da 
considered significant and standard deviations are in gray. (B) Stacked mass spectral plots for 
representative peptides from cAMP binding pockets from CNB:A (residues 205-218) and CNB:B 
(329-338) at different labeling times with each panel consisting of spectra for PDE8AC:RIα (left), 
PDE8AC:RIα:AMP (center) and RIα:AMP (right). The centroids are indicated by red triangles, 
compared to undeuterated control. Bimodal profiles for PDE8AC:RIα:AMP can be seen, blue and 
orange curves. Plots were generated from DynamX software 3.0 (Waters, Milford, MA). 
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4.3.5 PDE8:RIα complex sequesters AMP from PKA R-subunit to PDE8 
To determine the mechanism of dissociation of AMP from PDE8A:RIα complex, 
real-time monitoring of AMP release from RIα by PDE8A was performed by comparing 
the deuterium exchange kinetics of PDE8AC:RIα complex in the presence and absence of 
AMP (Fig. 4.8A) and significant differences are mapped onto the crystal structure of the 
catalytic fragment of PDE8A (Fig. 4.8B). About 74% of PDE8AC sequence was covered 
by 77 peptides analyzed and quantified (Fig. 4.7). Deuterium uptake values for different 
peptides of PDE8AC at different deuterium exchange times for PDE8A:RIα and 
PDE8A:RIα:AMP are listed in Table 4.3. 
 
Figure 4.7: Primary sequence coverage of PDE8A from HDXMS experiments with excess AMP. 
The primary sequence of a deletion construct of the catalytic domain of mammalian PDE8A is 
shown with the purple boxes indicating all peptide fragments spanning regions of the primary 
sequence obtained from HDXMS experiments of PDE8AC with AMP.  Approximately 74% 
sequence coverage was observed. The numbers shown here (1-337) correspond to the primary 





Table 4.3: Deuterium uptake values at 1, 10 and 30 min for catalytic domains of PDE8A bound to RIα, in the presence and absence of AMP. 
     Deuterium uptake in PDE8A:RIα   Deuterium uptake in PDE8A:RIα:AMP 
     1 min 10 min 30 min  1 min 10 min 30 min 
S.No. Peptide sequence (MH+) Residues 
ME
A z Dex   SD Dex   SD Dex   SD 




479-497 16 3 2.05 ± 0.12 2.83 ± 0.14 3.32 ± 0.14  1.93 ± 0.17 3.37 ± 0.12 4.08 ± 0.24 
2 DDVPPRIARA (1109.60) 482-491 7 2 3.38 ± 0.12 3.89 ± 0.12 3.91 ± 0.12  2.97 ± 0.10 4.26 ± 0.03 4.32 ± 0.01 








482-496 12 2 4.20 ± 0.23 5.36 ± 0.16 5.50 ± 0.14  3.85 ± 0.17 6.92 ± 0.48 7.08 ± 0.46 




504-517 12 2 0.86 ± 0.07 1.07 ± 0.07 1.42 ± 0.11  0.20 ± 0.06 0.37 ± 0.05 0.59 ± 0.05 
8 LEAATHNRPLIY (1397.75) 505-516 10 3 1.07 ± 0.05 1.22 ± 0.05 1.51 ± 0.10  0.21 ± 0.04 0.32 ± 0.04 0.50 ± 0.03 








505-521 15 3 0.69 ± 0.11 0.89 ± 0.11 1.20 ± 0.12  0.16 ± 0.03 0.33 ± 0.03 0.57 ± 0.03 
12 AATHNRPLIY (1155.63) 506-517 8 2 0.85 ± 0.12 1.00 ± 0.12 1.08 ± 0.09  0.33 ± 0.02 0.36 ± 0.02 0.53 ± 0.02 
13 ATHNRPLIY (1084.59) 507-516 7 2 0.58 ± 0.07 0.70 ± 0.07 0.89 ± 0.08  0.06 ± 0.11 0.10 ± 0.10 0.20 ± 0.11 
14 ATHNRPLIYL (1197.67) 507-517 8 2 0.46 ± 0.07 0.55 ± 0.07 0.75 ± 0.08  0.06 ± 0.01 0.10 ± 0.01 0.16 ± 0.02 






























569-586 15 2 2.65 ± 0.17 2.89 ± 0.20 3.13 ± 0.22  2.33 ± 0.06 2.99 ± 0.03 3.41 ± 0.02 
23 FLSKERIKE (1149.66) 571-579 8 2 1.55 ± 0.03 1.68 ± 0.04 1.74 ± 0.05  n/a     n/a     n/a     




571-586 14 2 2.86 ± 0.18 3.08 ± 0.18 3.24 ± 0.20  2.39 ± 0.07 2.95 ± 0.04 3.44 ± 0.05 




572-586 13 2 2.76 ± 0.24 2.97 ± 0.24 3.12 ± 0.28  2.28 ± 0.04 2.87 ± 0.02 3.30 ± 0.02 


























632-644 12 2 3.45 ± 0.13 3.73 ± 0.13 3.77 ± 0.09  1.99 ± 0.18 3.20 ± 0.06 3.94 ± 0.07 
35 KNMERNDYRT (1326.62) 647-656 9 2 3.06 ± 0.08 3.95 ± 0.01 3.98 ± 0.05  5.10 ± 0.03 5.50 ± 0.10 5.72 ± 0.09 
36 YRTLRQGIID (1234.69) 654-663 9 2 1.68 ± 0.05 2.14 ± 0.07 2.31 ± 0.10  0.70 ± 0.05 0.90 ± 0.04 1.24 ± 0.04 
37 YRTLRQGIIDM (1365.73) 654-664 10 2 1.17 ± 0.06 1.73 ± 0.07 2.05 ± 0.17  0.63 ± 0.02 0.94 ± 0.03 1.26 ± 0.03 
38 RTLRQGIID (1071.62) 655-663 8 2 1.50 ± 0.04 1.89 ± 0.05 2.04 ± 0.08  0.27 ± 0.01 0.55 ± 0.01 0.90 ± 0.01 












666-691 23 3 4.74 ± 0.80 5.90 ± 0.61 6.22 ± 0.34  4.62 ± 0.13 6.91 ± 0.08 8.07 ± 0.13 
















671-683 12 2 2.10 ± 0.09 2.28 ± 0.11 2.37 ± 0.13  0.94 ± 0.03 1.58 ± 0.03 2.04 ± 0.05 
48 VNSINKPLAT (1056.60) 681-691 8 2 2.97 ± 0.46 3.61 ± 0.46 3.74 ± 0.46  2.35 ± 0.08 3.66 ± 0.05 4.16 ± 0.03 
49 INKPLAT (756.41) 684-690 5 1 2.01 ± 0.12 2.27 ± 0.11 2.29 ± 0.11  1.80 ± 0.04 2.39 ± 0.02 2.43 ± 0.01 








691-707 16 2 5.62 ± 0.39 5.62 ± 0.41 5.59 ± 0.40  6.93 ± 0.05 7.10 ± 0.04 7.08 ± 0.02 
53 MLRTPENRTL (1230.66) 707-716 8 2 2.36 ± 0.07 2.68 ± 0.09 2.77 ± 0.11  1.60 ± 0.06 2.94 ± 0.04 3.33 ± 0.04 










707-724 16 2 1.65 ± 0.12 2.07 ± 0.12 2.21 ± 0.17  1.02 ± 0.06 1.86 ± 0.03 2.16 ± 0.02 




708-724 15 2 1.16 ± 0.21 1.38 ± 0.14 1.77 ± 0.32  0.68 ± 0.04 1.19 ± 0.05 1.41 ± 0.08 
59 IKRMLIKCAD (1190.75) 718-726 9 3 1.61 ± 0.07 1.56 ± 0.07 1.52 ± 0.07  0.46 ± 0.03 0.46 ± 0.03 0.45 ± 0.05 
60 ADVSNPCRPLQ (1362.64) 724-735 8 2 2.55 ± 0.06 2.59 ± 0.05 2.57 ± 0.05  1.88 ± 0.03 2.04 ± 0.01 2.12 ± 0.02 




724-737 10 2 2.60 ± 0.03 2.70 ± 0.02 2.83 ± 0.04  1.87 ± 0.03 2.04 ± 0.01 2.18 ± 0.02 
63 EWAARISE (961.47) 739-746 7 2 1.23 ± 0.01 1.55 ± 0.04 1.77 ± 0.07  0.12 ± 0.01 0.14 ± 0.01 0.16 ± 0.01 
64 WAARISE (832.43) 740-747 6 2 0.98 ± 0.08 1.25 ± 0.07 1.49 ± 0.08  0.06 ± 0.03 0.08 ± 0.03 0.12 ± 0.03 




747-764 16 2 5.69 ± 0.25 5.64 ± 0.23 5.62 ± 0.24  6.08 ± 0.10 7.14 ± 0.04 7.31 ± 0.05 




748-764 15 2 5.59 ± 0.14 5.50 ± 0.12 5.52 ± 0.09  5.74 ± 0.09 6.69 ± 0.02 6.80 ± 0.02 
69 DEEKQQGLPVVM (1372.67) 753-764 10 2 4.49 ± 0.13 4.41 ± 0.12 4.43 ± 0.14  4.74 ± 0.09 5.28 ± 0.05 5.32 ± 0.05 
70 EKQQGLPVVM (1128.61) 755-764 8 2 4.01 ± 0.09 3.98 ± 0.09 4.03 ± 0.06  4.02 ± 0.05 4.40 ± 0.02 4.40 ± 0.04 
71 KQQGLPVVM (999.56) 756-764 7 2 3.50 ± 0.16 3.48 ± 0.16 3.48 ± 0.16  3.50 ± 0.04 3.80 ± 0.02 3.81 ± 0.01 




803-818 15 2 1.79 ± 0.07 2.23 ± 0.11 2.61 ± 0.22  1.40 ± 0.05 1.98 ± 0.03 2.24 ± 0.02 
74 FKYWKGLDE (1185.59) 810-818 8 2 1.74 ± 0.16 1.94 ± 0.17 2.02 ± 0.16  1.39 ± 0.11 1.59 ± 0.03 1.73 ± 0.02 
75 KYWKGLDEM (1169.56) 811-819 8 2 1.81 ± 0.05 1.84 ± 0.07 1.87 ± 0.04  1.75 ± 0.04 2.23 ± 0.02 2.25 ± 0.03 
76 MKLRNLRPPPE (1350.76) 819-829 7 3 2.61 ± 0.15 2.60 ± 0.12 2.55 ± 0.13   3.51 ± 0.03 3.52 ± 0.04 3.49 ± 0.03 
z= charge state; MEA = Maximum exchangeable amides; Dex ± SD: Average of three measurements with their standard deviations; n.a = values not available
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AMP binding showed considerable effects in deuterium exchange kinetics of 
PDE8A (Fig. 4.8), as monitored by AMP release from RIα by PDE8A. Decreased 
deuterium exchange was observed in sets of residues that interact with ligand M-site and 
core pocket (residues 542-564), and bind to cAMP/AMP (residues 740-747) in 
PDE8A:RIα:AMP complex (right panels, Fig. 4.8B).  
 
Figure 4.8: HDXMS results show sequestering of from RIα to PDE8A via complexation. (A) 
Difference plots, plotting difference in deuterium exchange (Y-axis) of PDE8C:RIα:AMP relative 
to PDE8AC:RIα with residue numbers for each pepsin digest of catalytic domain of PDE8A listed 
from N to C-terminus (X-axis). Positive scale indicates higher deuterium uptake, while points in 
negative scale indicate lower deuterium uptake by PDE8AC in the PDE8C:RIα:AMP complex. 
Deuterium labeling time for every peptide is depicted and colored according to the key. Significant 
difference of ±0.5 Da is represented by a red dashed line and standard deviations are in gray. (B) 
Significant differences between the two complex states of PDE8A are mapped onto the structure 
of PDE8AC. PDE8AC monomers are differentiated as P (left) and P’ (right) and the N and C-termini 
of the protein are labeled accordingly. A cAMP analog (IBMX) is in cyan spheres; Zn+2 and Mg+2 
cations as pink spheres. Structure on left highlights regions of PDE8AC showing increased 
exchange in the ternary complex; structure on right highlights peptides with decreased exchange. 
Mass spectra of four representative peptides with residues 666-689, 747-763, 542-564 and 739-
746 are shown. Each panel is comprised of mass spectra from undeuterated control on top (i), 
PDE8AC:RIα complex in middle (ii), and PDE8AC:RIα:AMP at bottom (iii), after 10 min of 
deuterium labeling time. The centroids are also shown by triangles. Spectral plots are obtained 
from DynamX 3.0 software (Waters, MA). 
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These regions showed bigger shifts to the negative scale in the ternary complex, indicating 
AMP dissociated from RIα is sequestered to PDE8AC. Further, these regions in showed 
decreased deuterium exchange in PDE8A:RIα:AMP complex, as compared to PDE8 with 
excess AMP, suggesting that AMP binds to PDE8A:RIα complex, but not free PDE8A. 
Through extensive studies on other members of PDE superfamily, it has been shown that 
the binding residues/site for cAMP and AMP in the catalytic core are similar but 
orientations are slightly different (Huai, Colicelli et al. 2003). 
Interestingly, residues in M-loop region (747-764) showed increased deuterium 
exchange in the presence of AMP in the complex. We have previously shown that PDE8A 
undergoes conformational changes, which causes conformational changes in M-loop and 
lid-regions and enable complexation. PDE8AC sites of interaction with RIα (multiple 
peptides spanning residues 665-690) exchanged more number of deuterons than the 
PDE8AC:RIα:AMP complex, traversing from being ordered (at 1 min) to becoming 
dynamic (at 30 min). The increases in uptake (shifts in centroid) in these two regions after 
10 min deuterium labeling time are also represented by their stacked spectral plots, panels 
on the left and are marked on the structure of PDE8AC on left, Fig. 4.8B. These results 
clearly show the stabilization of PDE8AC:RIα complex in the presence of AMP, and 
corroborate to the binding of AMP released from RIα and translocated to PDE8AC via 
direct interactions. Our data thus points towards ‘channeling’ of AMP from RIα in 
PDE8AC:RIα complexation, via active-site coupling mechanism (Bauler, Huber et al. 
2010, Krishnamurthy, Moorthy et al. 2014).  
4.3.6 PDE8A:RIα complex traps AMP in the channel 
We next set out to characterize the effects of AMP on PDE8A, present either 
alone or as PDE8AC:RIα complex. To monitor this, saturating concentrations of RIα (4.5 
µM) incubated with AMP (3 mM) was added to PDE8AC (1.5 µM) and hydrogen-
deuterium exchange was performed. Differences in deuterium exchange between 
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PDE8AC:RIα:AMP complex and PDE8AC with excess AMP showed protein-wide 
decrease in deuterium exchange was observed for PDE8AC present in ternary complex 
(Fig. 4.9A). Four important regions spanning RIα interaction and AMP binding sites to 
PDE8AC are highlighted, and relative uptake plots are represented in Fig. 4.9B. In regions 
spanning the interaction interface (residues 679-689) between PDE8AC and RIα, decrease 
in deuterium uptake was observed, indicating the formation of a stable complex of RIα, 
PDE8AC, and AMP.  
Most importantly, no significant differences were observed in the catalytic site 
(residues 590-607), where PDE8AC:RIα:AMP ternary complex appeared to be more 
ordered only during shorter labeling times. This is important result as AMP, a product of 
hydrolysis, does not engage the catalytic residues and hence no differences in deuterium 
exchange. Peptides spanning substrate binding residues (740-747) that mediate 
hydrophobic contacts with adenine ring of AMP showed decreased deuterium exchange 
in the ternary complex compared to PDE8AC:AMP. This suggests that AMP binds to 
PDE8AC:RIα complex but not free PDE8AC. Peptides spanning substrate recognition M-
loop (residues 748-764) initially showed minor decreases in deuterium exchange, but with 
time increased deuterium the exchange was observed in this region. Complex formation 
between PDE8AC and RIα induces conformational rearrangements in the M-loop and lid 
region, which move away and are solvent accessible. Consequently, the decreased 
deuterium exchange in the complex suggests that AMP dissociated from RIα binds to 
PDE8AC in complex and stays bound, while AMP enters and exits PDE8AC without stably 
binding to it.  
Deuterium uptake values for PDE8AC:AMP and PDE8AC:RIα:AMP at various labeling 




Figure 4.9: Determining effect of AMP on PDE8 dynamics using HDXMS. A. Difference plot 
of differences in deuterium uptake (Y-axis) at different times between PDE8AC RIα:AMP and 
PDE8AC with excess AMP, for each pepsin fragment of the catalytic domain of PDE8A listed from 
N- to C- terminus, with overlapping peptides, grouped. Positive magnitude differences indicate 
increased exchange in PDE8AC:RIα:AMP ternary complex compared to PDE8AC with excess 
AMP, negative magnitude differences indicate decreased deuterium uptake. Peptides spanning 
important regions of interaction and binding are highlighted by dashed boxes as marked. Each 
deuterium labeling time for every peptide is depicted and colored according to the key. Red dashed 
line indicates a significant difference of ± 0.5 Da and the standard deviations are in gray. Plots 
were generated from DynamX software 3.0 (Waters, Milford, MA). (B) Relative deuterium uptake 
plots for representative peptides from four regions – H-loop (590-607), RIα binding site (671-683), 
substrate binding (740-747) and substrate recognition (748-764) are shown. Each plot shows 
number of deuterons exchanged by free PDE8AC (○), PDE8AC with excess AMP (●), PDE8AC:RIα 
(□), and PDE8AC:RIα:AMP (■). Each value is an average of three independent deuterium 
exchange experiments and their standard deviations are also shown. The plots were generated using 






Table 4.4: Deuterium uptake values for catalytic domain of PDE8A, in the presence and absence of excess AMP at different deuterium labeling times 
     Deuterium uptake in PDE8A  
Deuterium uptake in 
PDE8A:AMP 
     1 min 10 min 30 min  1 min 10 min 
S.N
o. 
Peptide sequence (MH+) Residues 
ME
A 




479-497 16 3 2.05 ± 0.12 2.83 ± 0.14 3.32 ± 0.14  1.93 ± 0.17 4.1 ± 0.12 
2 DDVPPRIARA (1109.60) 482-491 7 2 3.26 ± 0.12 3.66 ± 0.12 3.69 ± 0.12  3.66 ± 0.10 5.2 ± 0.03 
3 DDVPPRIARAME (1369.69) 482-493 9 2 3.76 ± 0.05 4.53 ± 0.08 4.69 ± 0.09  4.47 ± 0.15 5.6 ± 0.04 




482-496 12 2 3.98 ± 0.23 5.01 ± 0.16 5.17 ± 0.14  4.61 ± 0.17 1.4 ± 0.48 
6 ELEAATHNRPLIY (1526.79) 504-516 11 2 0.32 ± 0.13 0.37 ± 0.27 0.39 ± 0.19  0.95 ± 0.01 1.3 ± 0.01 
7 ELEAATHNRPLIYL (1639.88) 504-517 12 2 1.16 ± 0.07 1.66 ± 0.07 2.02 ± 0.11  0.8 ± 0.06 1.9 ± 0.05 
8 LEAATHNRPLIY (1397.75) 505-516 10 3 0.73 ± 0.05 1.32 ± 0.05 1.44 ± 0.10  1.62 ± 0.04 1.1 ± 0.04 
9 LEAATHNRPLIYL (1639.88) 505-517 11 3 1.03 ± 0.06 1.44 ± 0.04 1.67 ± 0.08  0.79 ± 0.03 1 ± 0.03 




505-521 15 3 0.77 ± 0.11 1.29 ± 0.11 1.43 ± 0.12  0.82 ± 0.03 0.9 ± 0.03 
12 AATHNRPLIY (1155.63) 506-517 8 2 0.61 ± 0.12 1.30 ± 0.12 1.4 ± 0.09  0.62 ± 0.02 0.8 ± 0.02 
13 ATHNRPLIY (1084.59) 507-516 7 2 0.74 ± 0.07 1.02 ± 0.07 1.18 ± 0.08  0.5 ± 0.11 1.2 ± 0.10 
14 ATHNRPLIYL (1197.67) 507-517 8 2 0.57 ± 0.07 0.86 ± 0.07 1.04 ± 0.08  0.72 ± 0.01 1.6 ± 0.01 






























569-586 15 2 2.46 ± 0.17 3.06 ± 0.20 3.38 ± 0.22  1.54 ± 0.06 2.6 ± 0.03 
23 FLSKERIKE (1149.66) 571-579 8 2 1.42 ± 0.03 1.65 ± 0.04 1.71 ± 0.05  2.17   3.4   
24 FLSKERIKETLD (1478.82) 571-582 11 2 2.59 ± 0.03 3.07 ± 0.07 3.37 ± 0.25  2.89 ± 0.44 2.6 ± 0.44 
25 FLSKERIKETLDPIDE (1933.02) 571-586 14 2 2.04 ± 0.18 2.40 ± 0.18 2.46 ± 0.20  2.25 ± 0.07 3.2 ± 0.04 
26 LSKERIKETLD (1331.75) 572-582 10 2 2.74 ± 0.11 3.21 ± 0.13 3.39 ± 0.14  2.82 ± 0.04 2 ± 0.02 
27 LSKERIKETLDPIDE (1933.02) 572-586 13 2 2.05 ± 0.24 2.23 ± 0.24 2.29 ± 0.28  1.79 ± 0.04 2.4 ± 0.02 




















593-607 14 3 2.63 ± 0.16 2.75 ± 0.15 2.69 ± 0.10  3.09 ± 0.09 2.3 ± 0.03 
34 LAFQLTTGDDKCN (1425.66) 632-644 12 2 1.38 ± 0.13 1.94 ± 0.13 2.11 ± 0.09  1.3 ± 0.18 1.7 ± 0.06 
35 KNMERNDYRT (1326.62) 647-656 9 2 1.04 ± 0.08 1.70 ± 0.01 1.94 ± 0.05  1.06 ± 0.03 1.7 ± 0.10 
36 YRTLRQGIID (1234.69) 654-663 9 2 1.37 ± 0.05 1.86 ± 0.07 2.07 ± 0.10  1.17 ± 0.05 0.9 ± 0.04 
 171 
 
37 YRTLRQGIIDM (1365.73) 654-664 10 2 0.76 ± 0.06 1.02 ± 0.07 1.07 ± 0.17  0.64 ± 0.02 7.6 ± 0.03 
38 RTLRQGIID (1071.62) 655-663 8 2 4.66 ± 0.04 6.20 ± 0.05 6.9 ± 0.08  5.67 ± 0.01 6.3 ± 0.01 












666-691 23 3 4.68 ± 0.80 2.41 ± 0.61 6.47 ± 0.34  5.44 ± 0.13 6.1 ± 0.08 
43 MTKHFEHVNKF (1417.70) 670-680 10 2 1.28 ± 0.16 5.16 ± 0.16 1.56 ± 0.17  1.14 ± 0.02 6.9 ± 0.02 








670-691 20 3 4.37 ± 0.22 3.66 ± 0.37 5.78 ± 0.47  5.52 ± 0.11 2.5 ± 0.06 
47 TKHFEHVNKFVNS (1586.80) 671-683 12 2 2.14 ± 0.09 2.26 ± 0.11 2.62 ± 0.13  1.8 ± 0.03 3.9 ± 0.03 
48 VNSINKPLAT (1056.60) 681-691 8 2 3.15 ± 0.46 3.66 ± 0.46 3.74 ± 0.46  3.68 ± 0.08 6 ± 0.05 
49 INKPLAT (756.41) 684-690 5 1 2.10 ± 0.12 2.26 ± 0.11 2.27 ± 0.11  2.42 ± 0.04 6.4 ± 0.02 








691-707 16 2 5.44 ± 0.39 5.45 ± 0.41 5.46 ± 0.40  6.53 ± 0.05 2.4 ± 0.04 
53 MLRTPENRTL (1230.66) 707-716 8 2 2.35 ± 0.07 2.75 ± 0.09 2.92 ± 0.11  2.62 ± 0.06 1.8 ± 0.04 










707-724 16 2 1.42 ± 0.12 1.53 ± 0.12 2.68 ± 0.17  1.31 ± 0.06 0.7 ± 0.03 




708-724 15 2 2.46 ± 0.21 2.69 ± 0.14 1.67 ± 0.32  0.93 ± 0.04 2.7 ± 0.05 
59 IKRMLIKCAD (1190.75) 718-726 9 3 2.59 ± 0.07 2.83 ± 0.07 1.55 ± 0.07  0.7 ± 0.03 2.6 ± 0.03 
60 ADVSNPCRPLQ (1362.64) 724-735 8 2 2.40 ± 0.06 2.49 ± 0.05 2.53 ± 0.05  2.3 ± 0.03 1.1 ± 0.01 
61 ADVSNPCRPLQY (1362.65) 724-736 9 2 2.46 ± 0.06 2.69 ± 0.07 2.68 ± 0.08  2.43 ± 0.02 1 ± 0.01 
62 ADVSNPCRPLQYC (1465.65) 724-737 10 2 2.59 ± 0.03 2.83 ± 0.02 2.96 ± 0.04  2.52 ± 0.03 1.2 ± 0.01 
63 EWAARISE (961.47) 739-746 7 2 1.00 ± 0.01 1.45 ± 0.04 1.67 ± 0.07  0.69 ± 0.01 6.3 ± 0.01 
64 WAARISE (832.43) 740-747 6 2 0.81 ± 0.08 1.22 ± 0.07 1.41 ± 0.08  0.68 ± 0.03 1.7 ± 0.03 




747-764 16 2 5.11 ± 0.25 5.18 ± 0.23 5.22 ± 0.24  6.46 ± 0.10 5.1 ± 0.04 




748-764 15 2 5.15 ± 0.14 5.06 ± 0.12 5.27 ± 0.09  6.16 ± 0.09 3.7 ± 0.02 
69 DEEKQQGLPVVM (1372.67) 753-764 10 2 4.24 ± 0.13 4.22 ± 0.12 4.35 ± 0.14  5.15 ± 0.09 2.4 ± 0.05 
70 EKQQGLPVVM (1128.61) 755-764 8 2 3.81 ± 0.09 3.73 ± 0.09 3.9 ± 0.06  4.3 ± 0.05 2.9 ± 0.02 
71 KQQGLPVVM (999.56) 756-764 7 2 3.33 ± 0.16 3.35 ± 0.16 3.38 ± 0.16  3.72 ± 0.04 2.1 ± 0.02 




803-818 15 2 2.57 ± 0.07 2.59 ± 0.11 2.76 ± 0.22  2.33 ± 0.05 2.8 ± 0.03 
74 FKYWKGLDE (1185.59) 810-818 8 2 2.07 ± 0.16 2.09 ± 0.17 2.02 ± 0.16  1.91 ± 0.11 2.2 ± 0.03 
75 KYWKGLDEM (1169.56) 811-819 8 2 1.81 ± 0.05 1.84 ± 0.07 1.87 ± 0.04  1.52 ± 0.04 2.23 ± 0.02 
76 MKLRNLRPPPE (1350.76) 819-829 7 3 2.61 ± 0.15 2.60 ± 0.12 2.55 ± 0.13  2.8 ± 0.03 3.52 ± 0.04 
77 KLRNLRPPPE (1219.27) 820-829 6 2 2.06 ± 0.08  ±  1.99 ± 0.09  2.75 ± 0.08 2.72 ± 0.06 
z= charge state; MEA = Maximum exchangeable amides; Dex ± SD: Average of three measurements with their standard deviations; n.a = values not available
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4.3.7 Distinct effects of AMP and cAMP on PDE8:RIα complex 
 Phosphodiesterase (PDE8) mediates direct interactions with PKA R-subunit and 
facilitates active hydrolysis of bound cAMP and forms the product 5′-AMP. In order to 
investigate the release of AMP from the ternary end-state complex of PDE8AC:RIα:AMP, 
we first set out to determine the effect of excess AMP on the complex by monitoring their 
conformational dynamics using HDXMS. This would generate cAMP-free RIα, priming 
it to bind to PKA C-subunit and hence complete the cAMP signal termination. We 
compared the conformational dynamics of R-subunit between the end-states of 
PDE8AC:RIα:AMP (‘terminator complex’) and PDE8AC:RIα:cAMP (end-state complex). 
The HDXMS results are summarized in Fig. 4.10 as a difference plot.  
 
Figure 4.10 Comparison of deuterium uptake in end-states of PDE8AC:RIα:cAMP and 
PDE8AC:RIα:AMP complexes. Difference plot of differences in deuterium uptake (Y-axis) at 
different times between PDE8AC:RIα:cAMP and PDE8AC:RIα:AMP for each pepsin fragment of 
RIα listed from N- to C- terminus. Peptides overlapping continuous regions are grouped and the 
domain organization is indicated. Positive differences indicate increased exchange in 
PDE8AC:RIα:cAMP terminator complex, negative differences indicate increased deuterium uptake 
in PDE8AC:RIα:AMP end-state complex. Peptides spanning PKA C-subunit binding region 
(yellow), PDE8A binding regions (blue), and cAMP binding pocket of CNB domains (green) are 
highlighted. Each deuterium labeling time for every peptide is depicted and colored according to 
key. Red dashed line indicates a significant difference of ± 0.5 Da used as threshold, and standard 





We observed time-dependent significant increased deuterium exchange in 
PDE8AC:RIα:AMP complex in most regions, signifying a dynamic and partially 
disordered state of R-subunit. We first examined the differences at the interaction 
interface of PDE8AC:RIα (blue boxes, Fig. 4.10) and observed increased deuterium 
uptake with time in the end-state complex. This suggests that initial stabilization of the 
complex due to ligand-binding, and as reaction progresses, the complex gets dissociated. 
This dissociation disrupts the interaction interface to be freely accessible by the 
solvent. Next, the ligand binding pockets of CNB:A and CNB:B domains (green boxes) 
showed time-dependent increased exchange in PDE8AC:RIα:AMP complex. Initially, 
both CNB:A and CNB:B sites showed decreased deuterium exchange, indicating ligand 
binding. But with increase in time, PDE8AC mediated ligand dissociation results in an 
increased deuterium exchange. Dissociation of ligand makes the binding pockets more 
accessible to solvent. While dissociation of cAMP and AMP should allow similar solvent 
accessibility to empty cAMP binding pockets, we observed one deuteron increased 
exchange in PDE8AC:RIα:AMP complex. This indicates that AMP binds to RIα 
differently from cAMP, having an additional hydrogen-bond with phosphate binding 
cassette (Fig. 4.10). Furthermore, these differences point toward a novel stable 
conformation of RIα. 
Similar changes were observed at the αXN helix region, which spans the 
pseudosubstrate site and PKA C-subunit binding motif, highlighted in yellow, Fig. 4.9. 
At shorter labeling times (1 min), these regions showed decreased deuterium exchange in 
AMP-bound PDE8AC:RIα complex, indicating reduced dynamics of the helical region. 
But at longer labeling times, an inversion of deuterium exchange was seen, with these 
regions showing increase in deuterium exchange, when compared to cAMP-bound 
terminator complex. This region is distal to both the CNB domains, suggesting that 
dissociation of ligand induced allosteric changes to the αXN helix. Enhanced dynamics in 
these regions suggests towards open conformation that allows PKA C-binding. Together, 
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these results clearly show PDE8A-mediated active hydrolysis and release of ligand from 
both the binding pockets of RIα generates a cAMP-free conformation to readily bind PKA 
C-subunit and thus rendering it inactive.  
4.4 DISCUSSION 
In this chapter of my thesis, I have characterized the end-state complex of RIα with 
PDE8A in presence and absence of AMP, by understanding the conformational dynamics 
of the proteins using amide hydrogen-deuterium exchange mass spectrometry technique. 
From these results, it is evident that cAMP hydrolyzed product AMP binds to RIα in the 
same loci as cAMP, but enhances the overall inherent dynamics of RIα, pointing towards 
a novel conformation. In the current data, I have uncovered a novel role of AMP in binding 
to RIα, formation of a stable complex of RIα and PDE8A with AMP, and subsequent 
changes for making RIα ligand-free, all of which are essential for PKA holoenzyme 
formation and cAMP-PKA signal termination.  
From previous chapters, it was clear that PDE8A actively hydrolyses all cAMP 
molecules bound to RIα, and also serially hydrolyses surrounding cAMP molecules, by 
forming an active PDE8A:RIα terminator complex. This causes a drastic increase in AMP 
levels surrounding the complex in vitro or surrounding the macromolecular assemblies in 
the particular cAMP microdomain. Further, it was also evident that AMP exit from the 
‘terminator complex’ occurs via channeling back to RIα. Therefore, these findings 
necessitated to determine the role of AMP and identify the release mechanism. The 
HDXMS results clearly show that AMP binds to RIα in cAMP binding loci, albeit with 
alteration in hydrogen bonding and other accompanying interactions (Fig. 4.10). In 
particular, the phosphate binding cassette, the hinge and the capping residues, all pointed 




Figure 4.11: Illustration of cAMP and AMP binding in CNB:A site. (On left) A framework of 
hydrogen bonds (blue dashed lines) between cAMP and residues of cAMP binding site in CNB:A 
domain (G199, E200, A202, R209, A210) and hydrophobic interaction (orange line) with capping 
residue (W260) is shown. (On right) Probable binding contacts between the AMP (product) and 
residues in CNB:A site, as inferred from our HDXMS results and known literature. Besides known 
contacts (for cAMP) the 3′ and 5′ positions (highlighted by green spheres) may form additional 
contacts in cAMP binding site. Image was constructed using ChemBio Draw v1.5. 
 
Activation of RIα by cooperative binding of cAMP to the two CNB sites and the 
accompanying allosteric changes provided a guide in understanding AMP-induced 
dynamics in RIα. Just like cAMP, AMP binding induces allosteric changes across the 
αB:C helix, which undergoes rigid conformational changes and mediates long-range 
communication between the two CNB domains. These results warrant further 
characterization of AMP and its effects on RIα and PDE8A.  
In the presence of excess cAMP, PDE8A:RIα complex plays an active role in 
cAMP turnover. At longer labeling times, the presence of excess AMP enhanced the 
dynamics of cAMP binding loci in RIα, suggesting a very dynamic and disordered 
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conformation. When the effects of AMP binding to PDE8AC:RIα complex were probed, 
we observed initial binding of AMP to RIα (decreased exchange), followed by PDE8A 
mediated release (increased exchange). Moreover, the mass spectra showed a bimodal 
distribution of low-exchanging and high-exchanging conformations. These changes were 
observed in both CNB domains, and hence indicate that AMP bound to RIα gets 
dissociated by PDE8AC interaction. In addition, the ligand dissociation disrupts multiple 
hydrogen bonding networks, R209 and R333 in particular, which in turn induce allosteric 
changes across other regions of RIα (Su, Dostmann et al. 1995, Kim, Xuong et al. 2005). 
Most importantly, increased solvent accessibility in the αXN helix, pseudosubstrate site, 
and the PKA C-subunit binding motif suggest that ligand-free RIα now populates an 
ensemble of conformations. It has been previously shown by NMR and computational 
approaches that these are dynamic regions and PKA C-subunit selects the right 
conformation as a ‘fit’ (conformational selection model) (Das, Esposito et al. 2007, 
Akimoto, McNicholl et al. 2015, Nussinov and Tsai 2015). 
Simultaneously, effects of AMP on PDE8A was also monitored by HDXMS, 
which showed that AMP binds to free- and RIα-bound PDE8A similarly. Consequently, 
in the ternary complex of PDE8A:RIα:AMP, the AMP dissociated from RIα was observed 
to be translocated to the active site of PDE8A, just like cAMP translocation. This was 
further supported by the decreased dynamics observed at substrate binding regions and 
core Q pocket in the ternary complex state. These decreases were transient, but not 
significant in PDE8A with excess AMP state. Hence, AMP binds with higher affinity to 
RIα-bound PDE8A than free PDE8A. The AMP translocation therefore probably occurs 
via the active-site coupling model and AMP sequestering by substrate channeling.  
Conclusive evidence of PDE8A mediated ligand dissociation from RIα was 
obtained from results in this chapter, suggesting that PDE8 facilitates generation of 
ligand-free RIα. This is the first instance, where we report successful AMP binding to 
RIα. The transition of RIα from cAMP/AMP-bound form to ligand-free form, therefore, 
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allows reassociation of PKA holoenzyme and highlights the essential role of PDE8A:RIα 
complex in termination phase of cAMP-PKA signaling, and a potential biological role of 
AMP. It is well known that AMP acts as a sensor for cellular ATP levels, and increased 
AMP levels in cells would trigger multiple pathways to maintain the AMP:ATP ratio in 
the cytoplasm. Certain studies have reported cAMP-induced activation of AMP-related 
signaling pathways, and data from the aforementioned results support this novel idea. The 
independent cascades of cAMP-PKA signaling and AMP-AMPK signaling are shown 
here to interact functionally and thereby facilitating fine-tuned regulation of AMP:ATP 
ratios in cells. Importantly, it is of interest that PDE8A ensure dissociation of ligand 
(cAMP or AMP) from PKA R-subunit, highlighting an important role of PDE8-PKA 
interactions. These interactions could be manifested by the N-terminal domain of PDE8A, 
which is known to sense small fluctuations in nucleotides in cytoplasm. Further, these 
open new paradigms for regulation of cAMP-PDE signaling pathways by identification 
of PDE8A interacting partners that may have a role in post-translational modification of 
PDE8A or the unidentified role of N-terminal receiver domain of PDE8. This study 
widens avenues of protein-protein interactions, cross-talk between signaling pathways 






Parallels between two model systems in 
understanding the mechanism of PDE-




Second messenger signaling or cAMP-PKA signaling pathway is highly 
conserved across all species and present in all organisms (Berman, Ten Eyck et al. 2005, 
Das, Esposito et al. 2007). While in prokaryotes cAMP (Rickemberg 1974) exerts the 
functions primarily via binding to Catabolite activator protein (CAP), the main cAMP-
receptor in higher eukaryotes is cAMP-dependent protein kinase A (PKA) (Weber, Takio 
et al. 1982). Although the receptors are different, the effects are similar, where cAMP 
signaling triggers a sophisticated and highly regulated downstream signaling pathway 
involved in cell growth and development. A specific example of this coordination is the 
unicellular social amoebae Dictyostelium discoideum, where cAMP plays a dual role – 
externally as a chemoattractant, and internally as a signaling second messenger (Harwood, 
Hopper et al. 1992, Reymond, Schaap et al. 1995). Importantly, the intracellular cAMP 
signaling is associated with binding of cAMP molecules to PKA leading to activation of 
C-subunit and regulation by R-subunit. Active C-subunit regulates many different 
processes in Dictyostelium cells, including the development and morphogenesis where 
uncontrolled C-subunit activity showed premature differentiation of pre-stalk and pre-
spore cells forming multicellular aggregates of the slime mould (Loomis 1998).  
 Interestingly, during the evolutionary course, Dictyostelium were an early off-
shoot from the lineage that evolved to mammals (McCarroll, Olsen et al. 1983, Conti and 
Beavo 2007). Many Dictyostelium proteins share a high sequence homology with 
mammalian proteins. In the context of cAMP-PKA signaling, most regulatory processes 
and the components also share homology, like adenylyl cyclase, PKA catalytic and 
regulatory subunits and phosphodiesterases (Mutzel, Lacombe et al. 1987, Loomis and 
Smith 1990, Bader, Kortholt et al. 2007). Differences in their cellularity and adaptation to 
changing environments is reflected by the complexity of their signaling networks and their 
regulation. While mammalian PKA R-subunit is a dimer with dimerization/docking 
domain and four cAMP binding sites in total (Potter and Taylor 1979), D. discoideum 
 181 
 
PKA R-subunit occurs as a monomer and lacks the dimerization domain (Leichtling, 
Majerfeld et al. 1982, Mutzel, Lacombe et al. 1987). Further, the mammalian 
phosphodiesterase PDE8A has receiver, PAS, and catalytic domains; and its homolog 
from slime mould, phosphodiesterase RegA, has receiver and catalytic domains, both 
having conserved sequences (Bader, Kortholt et al. 2007, Conti and Beavo 2007) as shown 
in Appendix A-3. These similarities and differences between mammalian and slime mould 
cAMP-PKA systems offer these as good model systems to understand the cAMP-PKA 
signaling in detail. Previously, many studies have been performed using D. discoideum 
model system, and have helped in understanding the molecular network of mammalian 
PKA characterisation.  
Although similar, the cAMP-PKA signaling of social amoeba and mammals are 
quite different in terms of their regulation and the kinetics of the interactions. While both 
cAMP binding sites of mammalian PKA R-subunit have very high affinity to cAMP (KD 
~ nM range), the two cAMP binding domains of PKA R-subunit from D. discoideum have 
very different affinities to cAMP. Moreover, it was shown that mammalian R-subunit 
could bind to and activate RegA (Shaulsky, Fuller et al. 1998, Moorthy, Gao et al. 2011) 
highlighting a role of phosphodiesterases in termination phase of cAMP-PKA signaling. 
RegA mediated dissociation of cAMP from RIα was shown to be a two-step mechanism 
(Krishnamurthy, Moorthy et al. 2013) while that of PDE8-mediated dissociation of cAMP 
from RIα via an active-site coupling mechanism (Krishnamurthy, Moorthy et al. 2014).  
To gain further insights on the specifics of molecular mechanism of the activity 
of phosphodiesterases, I performed experiments with both the model systems – 
mammalian (RIα and PDE8A) and slime mould (RD and RegA). Based on the results from 
previous chapters, I summarize the similarities and differences observed for PDE8A:RIα 
and RegA:RD complexes, and their role in termination phase of cAMP-PKA signaling. It 
was observed that mammalian and Dictyostelium systems operate through slightly 
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different processes, ultimately leading to cAMP dissociation from the PKA R-subunit and 
thereby inactivation of PKA C-subunit.  
5.2 RESULTS 
5.2.1 PDE8A:RIα complex is more stable than RegA:RD complex 
 To probe the association and dissociation of phosphodiesterase with PKAR 
subunits, we firstly compared fluorescence polarization data that is discussed in detail in 
the previous chapters. Two fluorescent analogs of cAMP were used, a phosphodiesterase 
resistant analog 8-[fluo]-cAMP, which allowed us to probe the inactive initiation complex 
and its stability, and a phosphodiesterase hydrolysable analog- 2′-fluo-cAMP, that reports 
catalytic active complex and reaction progression. When PKA R-subunits (RIα and RD) 
saturated with 8-[fluo]-cAMP were treated with PDE8A and RegA respectively (at two 
different time-points of reactions t = 0 min blue plots, and t = 20 min red plots) increased 
polarization was observed for both the model systems (Fig. 5.1 A, B), signifying 
interaction and stable complexation of respective phosphodiesterases with PKA R-
subunits over the time-course of the experiment (100 min). The bulky fluorescein moiety 
of 8-fluo-cAMP tethers PDEs to PKA R-subunits by forming strong hydrophobic 
interactions, in addition to the peripheral protein-protein contacts, and thus leading to a 
stable complex formation.  
However, when the respective phosphodiesterases were added to 2′-fluo-cAMP 
saturated RIα and RD, different polarization results were observed. Increased polarization 
for the mammalian PDE8A:RIα complex in presence of PDE-hydrolysable cAMP analog 
(Fig. 5.1C), but gradual decrease in polarization was observed for RegA-treated 2′-fluo-
cAMP:RD (orange and red plots, Fig. 5.1D). This suggests that PDE8A and RegA interact 
and mediate different end-states with their respective R-subunits. To further monitor this 
RegA-mediated dissociation of 2′-fluo-cAMP from RD, real-time reactions were 
performed to detect competitive association or dissociation of fluorescent cAMP with 
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unlabelled cAMP (Fig. 5.1E, F). Firstly, addition of excess cAMP could displace out the 
fluorescent ligand from R-subunits as observed from initial drop in FP (red plots, Fig. 
5.1E, F). Although addition of PDE8A and RegA after 20 min to these reactions showed 
increased polarization, the duration of polarization increase was different; where an rapid 
complexation of PDE8A:RIα (< 2 min) and progressive complexation between RegA and 
2′-fluo-cAMP saturated RD (~25 min). These differences suggest that the excess cAMP is 
hydrolysed at different rates by the two phosphodiesterases and reassociation of 
fluorescent ligand to RegA:RD complex occurs once all cAMP is hydrolysed. 
Next, we set out to test the stability of the complex formed in presence of 
fluorescent ligand, by addition of excess cAMP (100-fold) at time t = 20 min. Contrasting 
results were observed for 2′-fluo-cAMP:RIα:PDE8A and 2′-fluo-cAMP:RD:RegA 
complexes. In accordance with previous observation, the PDE8A:RIα complex was stably 
bound and the addition of natural substrate cAMP did not result in dissociation of the 
complex (lilac plot, Fig. 5.1E). On the other hand, when excess cAMP was added to 2′-
fluo-cAMP:RD:RegA, instant drop in FP was detected, indicating complete displacement 
of fluorescent ligand from RegA:RD complex. However, with time progression, 
continuous increase in polarization was observed (lilac plot, Fig. 5.1F) after the initial 
decrease. This drop followed by gradual increase in FP values can only be explained by 
hydrolysis of cAMP molecules by the complex RegA:RD, followed by simultaneous 
competitive reassociation of displaced fluorescent ligand. Further, the rate of 
reassociation is slower compared to previous reaction (red plot, Fig. 5.1F), probably due 
to the occurrence of two events together – cAMP hydrolysis and 2′-fluo-cAMP binding. 
Importantly, these different observations for PDE8A:RIα and RegA:RD complexes clearly 




Figure 5.1: Fluorescence polarization 
results showing different stabilities of 
PDE:PKAR complexes. Fluorescence 
polarization graphs plotting polarization 
(mP) as a function of time (X-axis) for 
different reaction conditions. Plots in the 
top panel (A, C, E) are from PDE8A:RIα 
complex while bottom panels are from 
RegA:RD experiments with fluorescent 
cAMP analogs. (A, B) To full-length PKA 
R-subunit RIα (top) and RD (bottom) 
saturated with 8-[fluo]-cAMP (●), 
phosphodiesterase PDE8A and RegA were 
added at 0 min (■) or 20 min (▲), 
respectively. (C, D) PKA R-subunits RIα 
(top) and RD (bottom) saturated with PDE-
hydrolysable analog 2′-fluo-cAMP (●), 
phosphodiesterase PDE8A and RegA were 
added at 0 min (▲) and 20 min (♦) 
respectively. (E, F) To PKA R-subunits 
saturated with 2′-fluo-cAMP RIα (top) and 
RD (bottom), cAMP was added at 0 min 
followed by phosphodiesterase (PDE8A 
and RegA) at 20 min (■); and 
phosphodiesterase (PDE8A and RegA) 
added at 0 min, followed by cAMP at 20 min (♦). Time plots of polarization were generated using GraphPad Prism 6.0 (San Diego, CA). Each point represents an average value 
obtained from triplicate measurements from two independent experiments. Error bars are too small to be readily visible in some plots.
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5.2.2 Different interaction interfaces of PDE8A:RIα and RegA:RD complexes 
 To probe these interactions between PDE8A with RIα and RegA with RD, I next 
compared their conformational dynamics in the presence and absence of ligand. 
Conformational changes of PDE8A on RIα and RegA on RD were compared and are 
shown in Fig. 5.2A and Fig. 5.2B, respectively. We observed different sites of interaction 
interface for the two complexes. As discussed in chapter 3, PDE8A bound to RIα stably 
in the peripheral regions of both cAMP binding pockets (highlighted by green boxes, 
showing decreased deuterium exchange) with the coupling of their active sites and having 
allosteric effects to the inter-domain linker. The interaction interface (discussed in chapter 
2) of RegA with RD was different, where decreased deuterium exchange was observed 
only at CNB:B site, indicating that RegA bound to RD only at the second cAMP binding 
pocket (CNB:B, residues 266-279). Bimodal spectra at lower time points and binomial 
spectra at longer labeling times indicated that RegA binding reduced the conformational 
heterogeneity of apo RD, making it completely disordered (increased deuterium exchange 
at 30-100 min). Further, an initial decrease in exchange was observed in the RegA:RD 
complex at the peripheral regions (green box, Fig. 5.2B), but not at N-terminal cAMP 
binding site (CNB:A). A significant allosteric relay was transmitted across the linker 
connecting the two domains with CNB:A (residues 138-150) showing structural 
alterations at longer deuterium labeling times. 
Furthermore, similar differences of deuterium exchange were seen upon 
phosphodiesterase interaction with PKA R-subunit in the presence of excess ligand (data 
from chapters 2 and 3). Based on these differences, we conclude that PDE8A interacts 
with both domains of RIα and forms a stable complex with it in the presence of low and 
high concentrations of cAMP, while RegA forms a transient complex with RD at the 
CNB:B site in the absence of cAMP, and a stable complex in the presence of excess 
cAMP. Importantly, both complex formations are proceeded by conformational changes 
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across the R-subunits with important allosteric regulation of the inter-domain connecting 
αB:C linker (McNicholl, Das et al. 2010). 
 
Figure 5.2: Comparison of interaction interface of PDE:PKAR complexes from mammals and 
slime mold. Differences in average number of deuterons exchange for PDE:PKAR complex 
relative to PKAR is shown with the peptic digest fragments of PKAR subunit listed from N- to C-
terminus. Positive differences indicate increased deuterium exchange while negative differences 
indicate decreased deuterium exchange in PDE:PKAR complex as compared to the unbound 
PKAR. The two cAMP binding sites are highlighted by orange box while the PDE-binding region 
by green box. Top panel (A) shows results for mammalian PDE8A:RIα complex while bottom 
panel (B) shows comparison for slime mould RegA:RD complex. Evidently, PDE binding to RIα 
or RD is seen to have different effects and binds differently. Deuterium exchange times for every 
peptide are depicted and colored according to key. Red dashed line represents a significance 
threshold of ±0.5 Da for differences in deuterium exchange and standard deviations are shaded 
gray. Plots were generated using DynamX 2.0 software (Waters, Milford, MA). 
 
5.2.3 Accelerated cAMP hydrolysis by PDE:PKAR complex 
 The fluorescence polarization results indicate different kinetics of 
phosphodiesterase association and subsequent cAMP hydrolysis by PDE:PKAR 
complexes. To gain further insights into these rates and durations of PDE-mediated cAMP 
dissociation from PKA R-subunit, deuterium uptake at the cAMP binding pockets 
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(CNB:A and CNB:B) with increase in reaction time (deuterium labeling time) was 
analysed (Fig. 5.3). No inherent dissociation of cAMP was observed from either of the 
CNB domains of both PKA R-subunits (closed diamond and closed circle plots, Fig. 5.3). 
As shown, addition of phosphodiesterases had differential effects on RIα (top panels) and 
RD (bottom panels). For both cAMP binding pockets (CNB:A and CNB:B) of RIα, direct 
interactions with PDE8A led to initial decrease in deuterium exchange in the complex 
with excess cAMP (closed triangles, Fig. 5.3 A, B). By 5 min of deuterium labeling, these 
differences abolished as PDE8A facilitated cAMP release. With longer incubation, 
PDE8A mediated complete cAMP removal as seen by increased deuterium exchange 
compared to RIα (open diamond plots, Fig. 5.3 A, B), resulting in much higher solvent 
accessibility. A delayed but fast response of RegA on RD was observed for 
RegA:RD:cAMP complex, where cAMP dissociation was observed to be initiated around 
10 min, and complete dissociation was observed by 30 min of deuterium labeling reaction 
(closed squares, Fig. 5.3B, D).  
 Different effects of PDE8A and RegA were seen on RIα and RD respectively, 
while PDE8A enhanced the conformational dynamics of RIα, RegA just mediated cAMP 
release, as RegA-treated and apo RD showed similar levels of deuteration. By comparing 
their deuterium-exchange kinetics, it can be clearly observed that PDE8A initiates release 
of cAMP earlier, with the gradual increase in deuterium uptake across 5-30 min time scale. 
These continuous release and not sharp increase in deuterium, signifies the inter-domain 
and inter-dimer cooperativity of the four cAMP binding sites of RIα (Ogreid and 
Doskeland 1983, Ogreid, Ekanger et al. 1989). On the other hand, RD exists as a monomer 
and lacks inter-dimer effects (Leichtling, Majerfeld et al. 1982, De Gunzburg, Part et al. 
1984), and hence interaction with RegA showed a sharp increase in deuterium uptake 
from 10 min – 30 min. These results, in conjunction with fluorescence polarization results 
(Fig. 5.1 C-F) clearly suggest that the mammalian PDE8:PKA RIα system responds to 




Figure 5.3: Monitoring PDE-mediated release from the two CNB domains of PKA R-subunit. 
Kinetic plots showing absolute number of deuterons exchanged with time by the representative 
peptides spanning cAMP binding pockets. (A, B) Plots of deuterium uptake for mammalian RIα 
(◊) in different forms, cAMP-saturated RIα (♦), PDE8A:RIα (∆) and PDE8A:RIα:cAMP (∆) for 
CNB:A (residues 203-222) and CNB:B (residues 329-337) domains. (C, D) Plots of deuterium 
uptake for mammalian RD (○), cAMP-saturated RD (●),RegA:RD (□) and RegA:RD:cAMP (■) for 
CNB:A (residues 138-150) and CNB:B (residues 266-274) domains. Semi-log plots, with time on 
X-axis as log10 base scale and relative deuterium uptake on Y-axis in linear scale were plotted 
using GraphPad Prism 6.0 (San Diego, CA). 
 
 
These different rates of cAMP hydrolysis by PDE:PKA complexes can be 
attributed to the complexity of the two biological systems. In mammals, 
compartmentalization of cAMP signaling is observed, where cAMP flux is bordered by 
phosphodiesterases, and these cAMP microdomains are centred around AKAP:PKA:PDE 
signalosomes (Dodge-Kafka, Bauman et al. 2008, Ahmad, Murata et al. 2015). The 
hormone-specific spatio-temporal arrangement of each cAMP microdomain to particular 
stimulus requires a robust and sensitive regulatory mechanism in higher eukaryotes 
(Lomas and Zaccolo 2014, McCormick and Baillie 2014). Hence, a faster rate of cAMP 
turnover and stable PDE8A:RIα complexation was observed. On the other hand, slime 
mould Dictyostelium discoideum is a unicellular organism and lacks this complexity of 
cAMP compartmentalization (Bagorda, Das et al. 2009). Expression of RegA (regA 
mRNA) was detected only after a certain time of sensitization of the cAMP-PKA 
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signaling. Furthermore, many studies have reported the adaptation of D. discoideum cells 
to waves of cAMP levels, and shown that the cells treated with micromolar concentrations 
of cAMP extinguished the stimuli by 10 minutes (Dinauer, Steck et al. 1980, Halloy, 
Lauzeral et al. 1998). Due to this lack of compartmentalization and simplicity of signaling 
modules, a different cAMP turnover rate was observed for RegA:RD:cAMP complex. The 
cAMP release after 10 min was consistent with the previously observed duration of 
adaptation of D. discoideum. 
5.2.4 Similar effect but different mechanisms 
 Taken in conjunction, the above results show ligand-mediated stable interactions 
between phosphodiesterases and PKA R-subunits. This complexation is accompanied by 
various conformational changes across both proteins, including direct and allosteric 
effects. Coordinated interactions facilitate cAMP release from the cAMP-binding pockets 
of R-subunit to the catalytic site of phosphodiesterase, making R-subunit cAMP-free and 
priming it for reassociation with PKA C-subunit. For both the model systems - 
PDE8A:RIα complex and RegA:RD complex, phosphodiesterase-induced cAMP 
unbinding was observed, however, the mechanism of release and hydrolysis, and the time 
taken to achieve this was found to be different.  As described above, PDE8A-mediated 
dissociation of cAMP from RIα was faster than RegA-mediated dissociation from RD. 
These differences can be attributed to their interaction sites, where PDE8A was observed 
to bind to both domains of RIα, RegA binds only to CNB:B domain. Through allosteric 
communication via the inter-domain linker, RegA facilitates cAMP dissociation from the 
CNB:A site. Further, great differences between the two cAMP binding sites, especially 
their affinities to cAMP binding (2 nM vs 1 µM) suggests their kinetic disparity.  
  The fluorescence polarization results and HDXMS results taken together suggest 
that PDE8A-mediated cAMP dissociation and hydrolysis occurs via a channeling 
mechanism, where the cAMP-binding sites of RIα are coupled to the active site of PDE8 
forming inter-protein substrate channel. Accompanying conformational changes in 
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PDE8A:RIα complex weakens the interactions between cAMP and the residues in cAMP 
binding pocket. Loosely bound cAMP is steered to the hydrophobic residues lining the 
pocket of PDE8A, ultimately leading to translocation of cAMP directly to active site of 
PDE8A. Importantly, we did not observe any complex dissociation throughout these chain 
of events. The catalytic site of PDE8A hydrolyses cAMP to 5′-AMP. These two processes 
of cAMP dissociation and hydrolysis are coupled with PDE8A:RIα complex acting as a 
‘composite enzyme core’. Further, excess of cAMP was serially hydrolysed by the 
complex, as inferred from the increased rate of cAMP hydrolysis. On the other hand, 
RegA- facilitated cAMP dissociation and hydrolysis from RD was observed to be a two-
step mechanism. Fluorescence polarization results from 8-[fluo]-cAMP analog suggest 
stable complexation of RegA and RD, but results from the 2′-fluo-cAMP analog 
association-dissociation curve suggest that RegA facilitates cAMP dissociation from RD 
(first step) followed by cAMP hydrolysis (second step). Direct interactions facilitate 
translocation of cAMP from RD to RegA via substrate channeling mechanism, as 
described for PDE8A:RIα interaction. However, the hydrolysis of cAMP by RegA occurs 
after their dissociation.  
Firstly, gradual decrease in FP for 2′-fluo-cAMP saturated RD upon addition of 
RegA was observed, indicating dissociation of 2′-fluo-cAMP from RD, followed by 
hydrolysis to 2′-fluo-AMP separately. If the dissociation and hydrolysis were linked, 
decreased FP would not be observed, as observed for 2′-fluo-cAMP:RIα:PDE8A reaction. 
As a rapidly tumbling unbound fluorophore has lower polarization than a bound-
fluorophore, RegA-mediated 2′-fluo-cAMP dissociation and hydrolysis are uncoupled, 
with immediate exit of hydrolysed fluorescent 2′-fluo-AMP. Secondly, gradual 
reassociation of displaced 2′-fluo-cAMP analog to RegA:RD complex was observed. In 
the two-step model, RegA-mediated dissociation and hydrolysis of all cAMP happens 
initially, which then allows the reassociation of 2′-fluo-cAMP. Compared to PDE8A:RIα 
reaction, where no competitive displacement of fluorescent cAMP by unlabelled cAMP 
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was observed, competitive displacement and slow reassociation suggest that these two 
processes appear to be uncoupled for RegA:RD interaction.  
Furthermore, comparison of HDXMS results between end-states of PDE8A:RIα 
and RegA:RD (Fig. 5.4), also support these observations. Time-dependent concurrent 
changes were observed in PDE8A substrate binding and catalytic residues, along with 
decreased deuterium exchange at the interaction interface (Fig. 5.4A).  
 
Figure 5.4: Comparison of deuterium exchange kinetics of PDE present as a complex with 
PKAR in the presence and absence of excess cAMP. Differences in deuterium exchange for 
PDE:PKAR complex in presence of excess cAMP relative to absence of cAMP is plotted with 
pepsin digests of respective phosphodiesterases listed from N- to C-terminus. Points in positive 
scale denote increased exchange while points in negative scale denote decreased exchange in the 
ternary complex of PDE:PKA in presence of excess cAMP. Top panel (A) indicates results for 
catalytic domain of mammalian PDE8A, present as a complex, while bottom panel (B) shows 
results for full-length RegA from D. discoideum. Deuterium exchange times for every peptide are 
depicted and colored according to key. Red dashed line represents a significance threshold of ±0.5 
Da for differences in deuterium exchange and standard deviations are shaded gray. Plots were 





Simultaneous changes in RIα and PDE8A and their stable complexation even at 
longer deuterium labeling times, signify the dissociation and hydrolysis as a coupled 
process. Meanwhile, in the RegA:RD complex increased deuterium exchange in peptides 
spanning cAMP binding sites (CNB:A and CNB:B) was observed only after 10 min. 
In RegA:RD complex in the presence of excess cAMP, increased differences in 
deuterium exchange was seen throughout RegA at shorter labeling times (0.5 – 5 min), 
compared to RegA:RD complex without cAMP (Fig. 5.4B), indicating its dynamic and 
open conformation. Decreased deuterium exchange in RegA:RD:cAMP complex was 
observed at 10 min of labeling times, and no differences were observed by the end of 
reaction. These differences between PDE8A:RIα and RegA:RD complexes, therefore 
suggests that RegA-mediated cAMP removal from RD appears to be a two-step process. 
Moreover, release of cAMP from the CNB:A site in RegA:RD interactions occurs via 
allosteric relay and not by direct interactions with RegA, further validating the two-step 
model. 
5.3 DISCUSSION 
 The two complexes, PDE8A:RIα and RegA:RD, may differ in the mechanism of 
release of cAMP but their overall effect is similar. Direct interactions lead to 
conformational changes in both proteins of PDE:PKAR complex. Regions spanning the 
interaction interface show solvent protection, signifying complexation. These mediate 
allosteric changes across the inter-domain linker connecting the β-subdomains of cAMP 
binding pockets. Unfolding of the inter-domain linker and subsequent conformational 
dynamics in cAMP binding residues dislodge cAMP from binding pocket. Consequently, 
enhanced dynamics of regions spanning the αXN and pseudo-substrate sites is observed, 
indicating an open-conformation that readily binds to PKA C-subunit. Increased solvent 
accessibility at cAMP binding pockets, capping residues and N-terminal regions of PKA 
R-subunit therefore point towards a cAMP-free conformation.  
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 While the previous chapters focussed on the molecular details and mechanism of 
cAMP release during the interactions between phosphodiesterases and PKA regulatory 
subunit, this chapter identifies the differences between the two model systems used for 
the study. Together, PDE-facilitates dissociation of cAMP from its bound receptor PKAR 
by substrate channeling mechanism, resulting in a dynamic and open conformation of 
PKAR. The cAMP-free R-subunit can readily reassociate with PKA C-subunit and 







Identifying potential inhibitor drugs  
of PDE:PKAR complex by 




Cyclic nucleotide phosphodiesterases (PDEs) catalyze the hydrolysis of 
cAMP/cGMP to AMP/GMP respectively, and therefore reduce their levels inside 
cytoplasm. PDEs play an essential role in numerous cellular processes such as cardiac 
contraction/relaxation, cystic fibrosis, β-adrenoreceptor signaling, learning and memory, 
glycogenolysis and in inflammatory pathways (Conti and Beavo 2007, Ahmad, Murata et 
al. 2015). As they control the levels of second messengers inside cells which regulate such 
processes, PDEs have been important drug targets. Many inhibitors have been discovered, 
and many are being discovered, which block the catalytic activity of PDEs and hence 
increase levels of cAMP/cGMP for treatment of various diseases, cardiac ischemia and 
failure, erectile dysfunction, chronic obstructive pulmonary disease, to name a few (Jeon, 
Heo et al. 2005, Maurice, Ke et al. 2014). Some of these drugs are widespread in clinical 
use and have resulted in effective treatment. Prolonged medications and advancement in 
research has shown non-specificity and cross-reactivity of some of these drug inhibitors. 
Given the complexity of numerous isoforms of PDEs and the similarities in their catalytic 
domains, production of an efficient and specific drug has been fruitless.  
Further, PDEs have also been shown to regulate the compartmentalization of cyclic 
nucleotides that provide signal specificity inside cells. In such cAMP microdomains, PDEs 
are known to associate to other proteins and form large macro-molecular complexes called 
signalosomes (McSorley, Stefan et al. 2006, Wilson, Elbatarny et al. 2008, Houslay 2010, 
Maurice, Wilson et al. 2014). Disruption of activity of these compartment-specific PDE 
signaling modules have been indicated as potential therapeutic targets (Lefkimmiatis and 
Zaccolo 2014, Fields, Koschinski et al. 2015). With increased understanding of the detailed 
roles of PDEs in different signaling and metabolic processes and the functional impact of 
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controlling cAMP levels, a great pharmaceutical interest lies in discovery of small molecule 
therapeutics and drugs that target specific isoforms. 
PDEs are a superfamily of enzymes comprises of 11 PDE families, categorized 
based on their selectivity to cAMP or cGMP and their mode of regulation. In particular, 
degradation of cAMP is catalyzed by the dual-specificity PDEs (1, 2, 3, 10, and 11), but 
more efficiently by PDE4, PDE7 and PDE8 (Thompson 1991, Conti and Beavo 2007). As 
discussed before, each phosphodiesterase has unique N-terminal domain and conserved 
catalytic domain. The cAMP-specific phosphodiesterase, PDE8, is unique in having 
bacteria-like N-terminal domain with receiver domain (acting as response regulator), a Per-
Arnt-Sim (PAS) domain, and the conserved catalytic domain of eukaryotes (Beavo 1995, 
Wang, Yan et al. 2008, Brown, Lee et al. 2012, Ahmad, Murata et al. 2015). Two isoforms 
of PDE8 are known PDE8A and PDE8B, with each having its own splice variant and 
different tissue distributions. In general, PDE8 is distributed throughout the body, but 
abundantly in genital organs (ovary/testis), followed by spleen and liver (Conti and Beavo 
2007, Petersen, Kristensen et al. 2015). Consequently, PDE8 regulates critical metabolic 
processes, such as adrenal steroidogenesis, lymphocyte chemotaxis, and more recently in 
inhibition of HIV replication (Vang, Ben-Sasson et al. 2010, Bol, Booiman et al. 2011, 
Dong, Claffey et al. 2015, Golkowski, Shimizu-Albergine et al. 2015). While most PDEs 
are inhibited by IBMX, PDE8 is IBMX-insensitive and currently only two PDE8 inhibiting 
drugs are known – dipyridamole (general PDE-inhibitor) and PF-04957325 (PDE8-specific 
inhibitor) (Vang, Ben-Sasson et al. 2010). Regulation of critical cellular processes, 
biological responses in different cAMP microdomains, and receiver-PAS domains in N-
terminal make PDE8 and important drug target.  
On the other hand, we showed an active role of PDE8 in governing dynamic cAMP 
levels through direct interactions with regulatory subunit of PKA (PKAR), the primary 
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target of cAMP (Krishnamurthy, Moorthy et al. 2014). An accelerated turnover of cAMP 
by PDE8:PKAR facilitates cAMP signal termination, and thus plays an important role in 
regulating the cAMP-related processes. The regulatory subunit is known to impart 
specificity to cAMP signaling and also responsible in health and disease. A stable 
complexation between PDE:PKAR in the presence of excess cAMP (like in cytoplasm), 
offers itself as a composite drug target for discovery of novel and potent inhibitors. As an 
application of the observations and results discussed in previous chapters, we tested the 
possibility of PDE:PKAR complex as a drug target using fluorescence polarization 
spectroscopic assay. Fluorescence polarization technique depends on the use of small 
fluorescent molecules (ligands/peptides) reporters of protein-ligand and protein-protein 
interactions in solution (Rossi and Taylor 2011). The polarization intensity recorded is 
inversely proportional to the molecular mass of ligand-receptor association, where free 
ligand shows low polarization and bound-ligand shows higher polarization. Association-
dissociation kinetics can be monitored by competitive displacement of tracer-ligands by 
test molecules. This method has been widely applied as a high-throughput screen to identify 
inhibitors from a large library (Huang, Zhang et al. 2002). However, these rely on activity 
of PDEs and requires numerous steps of incubation and optimization. In this section, we 
present a semi-quantitative method to identify inhibitors, PDE-specific and PDE:PKAR 
specific, using the PDE:PKAR complex as a FP probe.  
6.2 MATERIALS & METHODS 
6.2.1 Materials 
Chemically ultra-competent Escherichia coli BL 21 (DE3) bacterial strains used 
for protein expression were obtained from Life Technologies (Carlsbad, CA). TALON® 
cobalt resin for his-tagged affinity purification was from ClonTech (Mountain View, CA). 
Fluorescent analog of cAMP: 2′-fluo-AHC-cAMP was acquired from Biolog Life Science 
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Institute (Bremen, Germany). IBMX and cAMP were from Sigma-Aldrich (St. Louis, MO). 
A library of 12 different unknown compounds (plant extracts) dissolved in 4% DMSO, 
were generous gift from Dept. of Pharmacy, NUS. 
6.2.2 Expression and purification of proteins 
To develop the utility of FP assay as a drug screening tool based on PDE:PKAR 
complex as the target, the proteins were first purified by recombinant expression and 
purification methods in vitro. Both, phosphodiesterase enzyme PDE (cAMP-specific) and 
the ligand-receptor PKA Regulatory subunit were purified by affinity chromatography and 
their concentrations were determined using colorimetric assay. Purity of the proteins was 
checked by SDS-PAG electrophoresis to calculate any non-specific binding of ligand, if 
any. Activity of PDE was tested by BioMol malachite green phosphodiesterase assay 
(BioAssay systems, Hayward, CA). Buffer used for assay was 50 mM Tris pH 7.5, 100 
mM NaCl, 5 mM MgCl2 and 20 µM ZnSO4. 
6.2.3 Inhibitors/Plant Extracts* 
 A set of 12 different extracts were a generous gift from Dept. of Pharmacy, 
National University of Singapore. These were isolated from two different plants using 
different extraction procedures with the buffers varying in their composition (Table 6.1). 
We named these extracts as VT1-9 and SM1-3. A known PDE inhibitor IBMX, and 
competitive displacing PDE substrates cAMP and cGMP were used as appropriate controls. 
These extracts serve as lead compounds to identify the potential of natural 
products/molecules from plants as inhibitors of PDE activity. A brief protocol for 
extraction of the compounds from two different plants is as follows: 
 




Table 6.1: Extraction method and solvents used for various plant extracts 
Extract Extraction Method and Solvent Used 
SM1 Soxhlet | water 
SM2 Soxhlet | 70% ethanol 
SM3 Ultrasonication | water 
VT1 Soxhlet | water 
VT2 Soxhlet | 70% ethanol 
VT3 Soxhlet | 70% methanol 
VT4 Maceration | water 
VT5 Maceration | 70% ethanol 
VT6 Maceration | 70% methanol 
VT7 Ultrasonication | water 
VT8 Ultrasonication | 70% ethanol 
VT9 Ultrasonication | 70% methanol 
 
a. SM 
(i) Ultrasonication: The extraction was performed using an ultra-sonicator (Branson 5510, 
France) at room temperature (298 K) for three cycles, with each cycle lasting for 15 
minutes. After each cycle, the solvent was decanted and replaced with the same volume of 
fresh solvent. Following which, the extracts were filtered through Whatmann’s filter paper 
(Grade1, 11 µm, England). 
(ii) Soxhlet Extraction: The extraction for each solvent was performed for 6 hours. 
b. VT 
(i) Ultrasonication: The extraction was performed using an ultrasonicator (Branson 5510, 
France) at room temperature (298K) for three cycles, with each cycle lasting for 20 
minutes. After each cycle, the solvent was decanted and replaced with the same volume of 
fresh solvent. Following which, the extracts were filtered through Whatmann’s filter paper 
(Grade1, 11 µm, England). 
(ii) Soxhlet Extraction: The extraction for each solvent was performed for 8 hours. 
(iii) Maceration: The plant material was soaked in the respective solvents for three days 
at room temperature (25-28°C) before decantation of the solvent. The same volume of fresh 
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solvent was then added to replace the decanted solvent. This process was repeated three 
times, giving rise to a total maceration time of 9 days. 
For both SM and VT extracts, the solvent was subsequently removed using rotary 
evaporator (Laboroto 4003, Heidolph, Germany) and the extracts were stored at room 
temperature, protected from light. 
6.2.4 Screening by fluorescence polarization spectroscopy 
Fluorescence polarization was carried out using fluorescent cAMP analog 2′-fluo-
AHC-cAMP which can be hydrolyzed by PDEs. Purified cAMP-receptor, PKA regulatory 
subunit (PKAR) was incubated with the PDE-susceptible fluorescent cAMP analog 2′-fluo-
AHC-cAMP (2 mM) for 24 h for complete saturation. Unbound fluorescent ligands were 
then washed by gel filtration chromatography. The FP assays were done using 96-well 
opaque black plates from Greiner Bio-One (Germany). Polarization of samples were 
detected using BioTek Synergy 4 multimode plate reader (BioTek, Winooski, VT) 
programmed in FP mode, with excitation λex = 485 nm and emission λem =524 nm 
wavelength, bandwidth ± 20 nm and instrument G-factor being 0.87.  
To PKAR (2.5 µM) saturated with 2′-fluo-AHC-cAMP, henceforth referred to as 
‘2′-fluo-cAMP:PKAR’, aliquoted in different wells, purified 2.5 µM PDE (1:1 ratio of 
PDE:PKAR) was added to all wells except the controls. FP measurements were carried out 
for initial 20 min, followed by addition of 10 µl of each of the extract to the ‘pre-formed’ 
complex. In addition, ligands at final concentrations - 100 µM cAMP, 100 µM cGMP and 
20 µM IBMX were also added in separate reaction wells. Appropriate controls were also 
carried out, no inhibitors in the reaction, and only PDE or only 2′-fluo-cAMP:PKAR. After 
addition at 20 min, FP measurements were recorded for another 80 min, with total assay 
time set to 100 min and each FP reading was detected at every 2 min interval. A total 
volume of 75 µl was maintained in each reaction and was carried out in technical duplicates 
 201 
 
and biological duplicates and average of four measurements were used to plot graphs using 
GraphPad Prism 6.0 (San Diego, CA). 
6.3 RESULTS 
6.3.1 PDE:PKAR complex as a tool for fluorescence polarization 
 To develop the PDE:PKAR complex as a rapid fluorescence polarization tool for 
screening inhibitors, firstly cAMP receptor PKA regulatory subunit was saturated with 
PDE-susceptible fluorescent cAMP sensor, which allows us to monitor both activity (or 
inhibition) of the PDE:PKAR complex and kinetics of competitive displacement by other 
small molecules or potential inhibitors. Polarization of 2′-fluo-cAMP:PKAR was 
monitored over a time of 100 min to probe intrinsic dissociation of the fluorescent ligands 
from the receptor. Neither a decrease nor an increase in FP was observed, indicating the 
fluorescent cAMP sensor bound to PKAR with high affinity (Fig. 6.1).  
 
 
Figure 6.1: Competitive displacement of fluorescent cAMP analog by natural substrates: using 
PDE:PKAR complex as a tool for fluorescence polarization. Graph showing the polarization 
intensities (mP units) with increase in time of reaction (min) for 2.5 µM PKAR saturated with 2′-
fluo-cAMP (x) and 2′-fluo-cAMP:PKAR complexed with 2.5 µM PDE at 0 min (●). To this pre-
formed complex, 100 mM cAMP (▲) or 100 mM cGMP (○) were added after time t = 20 min 
leading to drop in polarization. 100 mM cAMP was added to 2′-fluo-cAMP:PKAR complex at time 
t = 0 min, followed by 2.5 µM PDE at 20 min (★). An average of two measurements from two 
different experiments was used to plot the graph with their standard errors shown. The graph was 





When equimolar concentrations of PDE was added to 2′-fluo-cAMP:PKAR, we observed 
no dissociation of fluorescent ligand, but observed increased polarization indicating stable 
complexation of 2′-fluo-cAMP:PKAR and PDE (dark blue plot, Fig. 6.1).  
After the initial increase in FP, the values remained constant throughout the time-
scale of the experiment. Next, when excess of natural substrates/ligands like cAMP or 
cGMP (50-fold) were added, we observed an instant drop in polarization. While cAMP 
(green triangle plot, Fig. 6.1) addition resulted in complete displacement, addition of cGMP 
resulted in partial displacement, as observed in Fig. 6.1 (purple circle plot). These 
differences could be attributed to the selective affinities of phosphodiesterase and cyclic-
nucleotide binding domains of PKAR. Different studies have shown that phosphodiesterase 
have 200-fold selectivity to cAMP over cGMP. For PKAR, the CNB:A domain binds 
cAMP 400 times stronger to cAMP than cGMP, while CNB:B is only 100 times selective. 
Therefore, upon addition of 50-fold cGMP, we detected approximately 50% drop in 
polarization compared to addition of cAMP, indicating that cGMP competitively displaced 
fluorescent ligand from only one site. No decrease in polarization was detected upon 
addition of 20 µM IBMX.  
Accordingly, these results indicate that 2′-fluo-cAMP:PKAR:PDE complex lead 
to hydrolysis of 2′-fluo-cAMP, and the presence of excess substrate cAMP could displace 
out the fluorescent ligand. This pointed two things – (i) PDE:PKAR complex was stapled 
in presence of 2′-fluo-cAMP and even after hydrolysis to 2′-fluo-AMP, and (ii) in the 
presence of surrounding ligands, the 2′-fluo-cAMP/2′-fluo-AMP could be displaced out. 
Interestingly, with increase in time, polarization of cAMP displaced 2′-fluo-
cAMP:PKAR:PDE reaction gradually increased. PDE:PKAR complex hydrolyzed all 
cAMP molecules and the bulkier 2′-fluo-AMP (present in lower concentrations than 
cAMP) re-associated with the PDE:PKAR complex albeit slowly, and hence increasing the 
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FP values. Importantly, this result highlighted the catalytic activity and sensitivity of the 
PDE:PKAR complex to minute concentrations of competitive inhibitors/binders in the 
vicinity.  
To further test this, cAMP (100 µM) was added to 2′-fluo-cAMP:PKAR initially 
(at time t = 0 min) to displace out the fluorescent cAMP. We observed an immediate 
decrease in polarization, suggestive of competitive displacement (red stars plot, Fig. 6.1). 
This was followed by addition of 2.5 µM PDE at time t = 20 min. Consistent to our 
expectations, gradual increase in FP was observed with time, indicating that PDE:PKAR 
complex serially hydrolyzed excess cAMP, which allowed 2′-fluo-cAMP to reassociate 
and form 2′-fluo-cAMP:PKAR:PDE (or 2′-fluo-AMP:PKAR:PDE) complex. More 
importantly, the rise in FP was similar to that observed for 2′-fluo-cAMP:PKAR:PDE 
complex, indicating complete binding at both cAMP binding sites. An essential outcome 
from this observation is that PDE:PKAR complex was capable of sensing and binding to 
relatively less concentrations of ligand, where 2′-fluo-cAMP was 50-fold less than cAMP. 
These results, therefore lends PDE:PKAR complex in monitoring the effects of substrates 
or ligands on the phosphodiesterase enzymatic activity. Thus, PDE:PKAR complex in the 
presence of 2′-fluo-cAMP acts as a sensitive fluorescent polarization tool to understand 
competitive protein-ligand interactions.  
6.3.2 Screening of natural compounds as potential PDE-inhibitors 
 Using the 2′-fluo-cAMP:PKAR:PDE complex as a fluorescence polarization tool, 
we tested ability of natural extracts from known medicinal plants to act as potential PDE-
inhibitors. We tested different plant extracts by adding 10 µl of these to the 2′-fluo-
cAMP:PKAR:PDE complex at time t = 20 min, as described in methods section. 
Preliminary studies showed that of the 12 extracts tested, six plant extracts showed 
decreased polarization (VT3, VT4, VT5, VT6, SM2, and SM3), while other six plant 
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extracts did not result in any FP change. Decreased fluorescence polarization indicates 
competitive displacement of fluorescent cAMP bound to PKAR:PDE complex by the 
natural compounds from plant extracts.  
Closer inspection showed differences in the relative decrease in polarization 
between the various plant extracts, indicating that these compounds had dissimilar 
inhibitory effects. The potency or ability of these compounds as potential inhibitors in 
decreasing order is VT5>SM3>SM2>VT3>VT4>VT6, where extract VT5 showed 
complete and rapid displacement of fluorescent cAMP analog and extract VT6 had least 
effects. Interestingly, when lower amounts (5 µl) of two plant extracts, SM3 and VT6, 
(randomly selected) showed dose-dependent effects on competitive displacement. While 
addition of 5 µl each of VT6 and SM3 extracts resulted in decreased polarization, the SM3 
extract showed significant decrease in polarization, greater than that observed for VT4 or 
VT6 extracts, but similar to VT3 extract. This shows that these different extracts bind to 





Figure 6.2: Fluorescence Polarization screening of different plant extracts as potential inhibitors 
of PDE activity. Polarization (mP) changes of 2′-fluo-cAMP:PKAR:PDE complex (●) by addition 
of different plant extracts (VT1, VT2, VT3, VT4, VT5, VT6, VT7, VT8, VT9, SM1, SM2 and SM3), 
tested for a total reaction time of 100 min. As reference, 100 mM cAMP was added to separate 
reaction of 2-fluo-cAMP:PKAR:PDE complex at 20 min (▲) and is indicated in each plot. Each 
graph shows the addition of 10 µl (▼) of respective plant extract (labeled on top of each graph) at 
20 min. Separately, 5 µl (♦) of extracts from VT6 and SM3, were added at 20 min and is represented 
in respective plots. An average of two measurements from two different experiments was used to 
plot the graph with their standard errors shown. The graph was plotted using GraphPad Prism 6.0 
(San Diego, CA). 
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6.3.3 Extract VT5 is more potent than cAMP in displacing 2′-fluo-cAMP from 
PDE:PKAR complex  
Comparison of the effects of these plant extracts with cAMP showed interesting 
differences. Addition of the 6 extracts mentioned, had different quantitative effects on 
decrease in polarization. Extracts from VT5 had maximum effects while extracts from VT6 
had least. Compared to competitive displacement of fluorescent cAMP by cAMP, the 
decreased polarization observed in the order of decreasing potency is as follows:   
VT5>cAMP=SM3a>SM2>VT3=SM3b>VT4>VT6a=cGMP>VT6b, where a = 10 µl of 
extract and b = 5 µl of extract. Evidently, this suggests that extract VT5 was most potent 
and capable of binding to PDE:PKAR complex with affinity similar to cAMP (i.e, ~ nM 
range), and unlike cAMP, polarization values for VT5 extract did not increase back. 
Additionally, for each extract, the polarization values did not increase back, as seen for 
PDE-substrate cAMP, indicating that these extracts indeed had inhibitory effects on the 
enzymatic activity of PDE, rather than mere competitive displacement. Therefore, these 
preliminary results only suggest that the plant extracts tested displaced fluorescent cAMP 
with different affinities, and have to be further tested for determining their pharmacological 






Figure 6.3: Comparison of decrease in polarization as an effect of potential inhibitors with effect 
of cAMP on PDE:PKAR complex. Change in polarization by competitive displacement of 
fluorescent cAMP analog by six different plant extracts is shown. To 2.5 µM 2-fluo-cAMP:PKAR 
with 2.5 µM PDE added (●), 100 mM cAMP (▲), 100 mM cGMP (Ө), or 10 µl each of VT6 (★), 
VT4 (●), VT3 (♦), SM2 (▼), SM3 (■) and VT5 (■), or 5 µl each of VT6 (★) and SM3 (∇) were 
added after time t = 20 min. Fluorescence polarization measurements were carried out for 100 min 
total and an average of two measurements from two different experiments was used to plot the graph 
with their standard errors shown. The graph was plotted using GraphPad Prism 6.0 (San Diego, CA). 
 
6.4 DISCUSSION 
 In this chapter, I have tested the PDE:PKAR complex as a composite drug target 
for modulating the phosphodiesterase activity and thereby cAMP levels inside cells. While 
previous chapters concluded that PDE:PKAR complex responds to dynamic changes in 
cAMP levels and facilitates cAMP signal termination, in this chapter we show one possible 
implication of PDE:PKAR complex as fluorescence polarization probe. This FP probe 
therefore offers the opportunity for selectively targeting specific PDEs or PDE:PKAR 
complexes for treatment in specific disease states and lead to detailed understanding of 
PDE-mediated cAMP compartmentalization and signal regulation. 
 From a set of 12 different plant extracts, we could not only distinguish the 
capability of this probe to report on inhibitory activity of compounds, but also provide 
semi-quantitative and qualitative information on their affinities of binding and the required 
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amounts. We have only carried out preliminary studies and observed certain extracts (VT5 
and SM3) to be better at displacing fluorescent cAMP than tight binding cAMP, suggesting 
that these extracts are stronger inhibitors of PDE action. Certain extracts were able to 
displace out cAMP from complex at lower concentrations, while certain extracts could 
displace it from one cAMP binding site. Recent advancements in PDE structure and their 
functional regulation further provides opportunities in probing the effectiveness of these 
compounds and their allosteric/orthosteric effects towards catalytic activity of the enzyme 
(Ke and Wang 2007, Maurice, Ke et al. 2014, Ahmad, Murata et al. 2015, Chandramohan, 
Krishnamurthy et al. 2016). 
While PDEs were shown to passively hydrolyze freely diffusing cAMP in 
cytoplasm, we provided conclusive evidence of PDEs hydrolyzing cAMP bound to its 
receptors. The enzymatic action of PDEs have been targeted largely by small molecule 
inhibitors to improve cell’s condition in disease states. While many drugs are known, only 
few are in clinical use and of them even fewer are potent and isoform-specific. Therefore, 
a need of discovering or synthesizing novel inhibitors to dysregulate PDEs action, both 
active and passive hydrolysis is essential. Here, we show that PDE:PKAR complex acts a 
sensitive and rapid fluorescence polarization tool, and is able to provide insights into lead 
compounds or identify natural products as potential inhibitors. While other known PDE 
screening assays require multiple steps of incubation, dose-dependence and PDE-
concentration dependent repetitive experiments, the PDE:PKAR complex acts as a robust 
fluorescence polarization tool. While we tested 12 extracts, this method can be easily 
multiplexed as for 96-well and 384-well high throughput screening technique. 
Furthermore, the time duration of screening and the costs are greatly reduced. In addition, 
the benefit of PDE:PKAR complex as fluorescence polarization allows to identify other 
small molecule regulators of PKAR signaling.   
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CONCLUSION & FUTURE PROSPECTS 
 
In this work, I have described the mechanistic basis of dissociation of cAMP tightly 
bound to its primary receptor regulatory subunit of PKA, by cAMP-degrading enzyme 
phosphodiesterase. Active role of PDEs in rapid hydrolysis of cAMP to generate cAMP-
free PKA R-subunits is critical for inactivation of PKA C-subunit under physiological 
conditions, and thereby terminate the cAMP-PKA signaling. Inactivation of constitutively 
active PKA C-subunits is essential for optimal cellular functioning, which otherwise has 
been shown to be deleterious in multiple ways. Currently, no study has yet significantly 
characterised the inactivation of C-subunit by binding to its R-subunits. In the cytoplasm, 
high cAMP concentrations prevent the C- and R-subunit reassociation and therefore 
necessitates the identification of feedback mechanisms that control the cAMP levels. The 
current study highlights a novel role of phosphodiesterases and describes the mechanism 
of interaction of two partner proteins that decrease the cAMP flux in a stimulated cell and 
reset it to undergo new cycle of activation and inactivation.  
The aim of my current research was to understand protein-protein and protein-
ligand interactions using a combination of structural, dynamic, and functional approaches, 
and monitor how these interactions regulate cellular signaling pathways. In particular, the 
interest was to understand the termination phase of cAMP-PKA signaling, and I used two 
different model systems in this pursuit. In my thesis, I have provided molecular description 
of ligand-mediated stabilization of PDE:PKA complexes and how this complex operates to 
ensure cAMP levels are diminished, that help in robust desensitization and adaptation of 
cells to waves of cAMP. Significantly, this study introduces ‘molecular channeling’ 
mechanism for cAMP translocation from receptor to hydrolase, a first instance in signaling 
pathways. Most importantly, the regulation of cAMP-PKA-PDE8 signaling in mammalian 
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systems acts on a much finer level, with the system potentially acting as a AMP:ATP 
sensor, wherein a potential biological role of AMP in termination and/or signaling cross-
talk is unravelled. Further, I applied this knowledge and employed the fluorescence 
polarization assay of PDE:PKAR complex, as a tool to screen potential inhibitors for PDEs.  
 Our findings provides a new model in understanding the spatio-temporal regulation 
of signaling pathways and opens up new avenues in biological regulation, and following 
are some future prospects of this study.  
1. Termination phase of cAMP-PKA signaling and role of AMP 
A likely role of induction of PDE by cAMP is that the pathway serves to turn off cAMP 
signals by feedback inhibition, resulting in desensitization of the cells to further hormonal 
stimulation. While our study highlights an active role of PDE in rapid cAMP turnover, 
complexation of PDE with PKAR and in turn with AKAP leads to formation of 
signalosome, which adds to the regulatory mechanisms. An important implication of this 
study is in visualizing cAMP termination inside cells, where receptor-specific FRET 
reporters have been employed to study the cAMP signaling. An expanded view of PKAR 
and PDEs together, in context of sub-cellular localization and spatio-temporal distribution 
in different cell types enables a detailed characterization. Moreover, these studies can be 
targeted in cell lines and animal models and knock out or gene silencing of specific genes 
can be monitored. 
 The mechanisms of cAMP dissociation and hydrolysis proposed in this study need 
to be further validated via different structural and biochemical approaches. A significant 
discovery of AMP-binding to PKA R-subunit and its probable role in C-subunit binding 
underscores an important aspect of cAMP signaling. The cAMP hydrolysis product ‘AMP’ 
has not been studied with regard to cAMP signaling and an extension of our results may 




2. Structure determination of PKAR-PDE complex 
This study identifies the interaction interface of PKAR and PDEs, where a dimer of PDE8A 
is shown to interact with a monomer of PKA RIα. Under sub-stoichiometric ratios of PDE8 
(1:1) minimal effects were observed, while 2:1 ratio of PDE8:PKA RIα manifested stable 
interactions. Optimization of the preliminary cryo-EM studies in this study would help in 
deciphering interactions and give structural snapshots. In addition, X-ray crystallographic 
studies can also be employed for atomic resolution of PDE:PKAR complex to get exact 
points of contact. Besides, ion-mobility mass spectrometry approach can also be used to 
detect stability of the complex in solution. 
3. Mutational analyses of PKA R-subunit and PDEs 
Our amide hydrogen-deuterium exchange mass spectrometry results have highlighted key 
residues that play critical role in mediating PKAR and PDE interactions. Certain clinical 
studies from aberrant PKAR and PDEs in the same patients, have also supported these 
findings. Site-directed mutagenesis of these critical residues would provide important 
information which can either disrupt the complex formation or subdue the enzymatic 
activity and hence alter cAMP hydrolysis. Specifically, R209K and R333K mutations of 
PKA R-subunit severely reduce the affinity of cAMP, mutants from inter-domain linker 
region (W260A) and PDE8-binding regions (D170) can shed light into cooperativity 
between the domains and the related allostery. 
4. Identification or discovery of potential inhibitors 
Phosphodiesterases are an important drug target as they control the levels of cAMP and 
cGMP, which are responsible for a myriad of cellular processes and signaling pathways. 
Many drugs inhibiting the action of PDEs are known and many more are being discovered. 
However, since most PDEs have commonalities in their binding sites, cross-reactivity and 
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non-specificity of drugs has remained a major problem. Most PDEs are involved in 
regulation of many critical processes in different cell types – neuronal (learning and 
memory), cardiac (ischemia, heartbeat, fibrillation), liver, endocrine signaling etc., 
including PDE8 which is critical in genital (spermiogenesis and steroidogenesis) processes. 
In this study, we have established a simple fluorescence polarization assay, using the 
composite PDE:PKA complex as a drug target. In addition, HDXMS also has been 
indispensable tool in drug discovery processes. Therefore, research findings from this study 
provides a platform for drug screening for novel inhibitors. 
5. Implications of substrate channeling in signaling pathways 
In my current research, I have focussed on specific isoforms of PKA R-subunit (RIα) and 
phosphodiesterases (PDE8A1) and provided molecular description and regulatory 
mechanisms in cAMP signaling pathway. However, there are isoforms of PKA R-subunit 
which have been shown to play important role in signal specificity and associated with 
other cAMP-degrading PDEs. Therefore, our outcomes lay a platform in identifying novel 
interaction network for these proteins and importantly, expansion of the substrate 
channeling mechanism. Higher eukaryotes have compartmentalization of cAMP in to 
microdomains, which have shown to be crucial in different cellular locations. We have 
identified substrate channeling in one of such microdomains, and extension/discovery of 
this phenomenon with other PDEs or PKA subunits would deepen our understanding of 
regulation inside cells. Moreover, both phosphodiesterases targeted in this study (PDE8 
and RegA) have receiver domains that may play role in two-component signal transduction. 
While multiple studies have shown the phosphorylation of RegA and its involvement in 
other signaling pathways, similar studies on PDE8 would aid in identifying novel PDE8 
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APPENDIX – A1 
Figure A1: Sequence alignment of isoforms of mammalian PKA R-subunit. Multiple 
Sequence Alignment of the four different isoforms of mammalian PKA R-subunit – RIα 
(UniProtID: P00514), RIβ (UniProtID: Q17QF5), RIIα (UniProtID: P00515), and RIIβ 





APPENDIX – A2 
Mammalian phosphodiesterase (PDE) superfamily comprises of 11 different families based 
on their kinetic properties, substrate signature and their domain organization. While the 
catalytic domain at C-terminus is conserved, each PDE member has unique N-terminus, as 
shown below.  
 
Figure A2: Domain organization of mammalian phosphodiesterases. Depiction of 
domain organization of 11 different members of mammalian phosphodiesterases (PDE) 
having a conserved catalytic domain (light orange) and the different N-terminal domains 
are also represented by different shapes and colors.
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APPENDIX – A3 
Sequence alignment of the primary amino acid sequences of full-length phosphodiesterases 
from mammalian PDE8A1 (Uniprot ID: O60658) and D. discoideum RegA (Q23917) are 
shown in the next page. PDE8A sequence is on top and RegA sequence is at bottom. 
 
Mammalian PDE8A is 829 amino acids long protein with Receiver domain (spanning 
residues 125-212), Per-Arnt-Sim (PAS) domain (spanning residues 213-329) and the 
catalytic domain (spanning residues 479-819). 
 
Lower eukaryote D. discoideum phosphodiesterase RegA has 793 amino acids and 
comprises of Receiver domain (or) response regulatory domain (spanning residues 127-















APPENDIX – A4 
 
Sequence alignment of the primary amino acid sequences of full-length PKA R-subunits 
from mammalian RIα (UniProt ID: P00514) and D. discoideum RD (P05987) are 
represented here, with RIα sequence on top and RD at bottom. 
 
 
Figure A4: Sequence alignment of regulatory subunits from mammalian RIα 




APPENDIX – A5 
To test the performance and elution profiles of size-exclusion chromatography 
columns with time, calibration of the columns was carried out according to manufacturer’s 
instructions, GE Healthcare Life Sciences. 
1. Calibrate Tricorn Superdex 200 10/300 GL column 
Superdex 200 10/300 analytical column was calibrated using low molecular weight 
kit containing proteins listed in table below.  
2. Calibration of HiLoad 16/60 Superdex 200 pg column 
Hiload 16/60 Superdex 200 pg column was calibrated using low molecular weight 
and high molecular weight kits containing proteins listed in table below. 
Contents of Low Molecular Weight Calibration Kit 
Protein Abbreviation Molecular Weight Source 
Aprotinin Apr 6.5 kDa Bovine Lung 
Ribonuclease A  RNase A 13.7 kDa Bovine Pancreas 
Carbonic Anhydrase CA 29 kDa Bovine 
erythrocytes 
Ovalbumin O 44 kDa Hen Egg White 
Conalbumin C 75 kDa Chicken Egg White 
 
Contents of High Molecular Weight Calibration Kit 
Protein Abbreviation Molecular Weight Source 
Ovalbumin O 44 kDa Hen Egg White 
Conalbumin C 75 kDa Chicken Egg White 
Aldolase A 158 kDa Rabbit Muscle 
Ferritin F 440 kDa Horse Spleen 
 
From each protein mentioned, 3 mg/ml of sample was mixed to a final volume of 2 ml and 
injected onto the column and chromatography was carried out using buffer (50 mM Tris 
pH 7.2, 200 mM NaCl). The calibration profiles for the two columns compared to the 
manufacturer’s initial calibration are shown in figure Appendix 5 (next page). The elution 
profiles of the Superdex 200 10/300 GL column was shifted by +1.5 ml and for HiLoad 




Figure A5: Calibration of Size-exclusion chromatography. (A) Tricorn Superdex 200 
10/300 GL column and (B) HiLoad 16/60 Superdex 200 pg column were calibrated with 
calibration kits obtained from GE Healthcare Lifesciences. Compared to standard 
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